CN106390093B - 操作后的皮肤护理系统、组合物及其使用方法 - Google Patents
操作后的皮肤护理系统、组合物及其使用方法 Download PDFInfo
- Publication number
- CN106390093B CN106390093B CN201610585492.4A CN201610585492A CN106390093B CN 106390093 B CN106390093 B CN 106390093B CN 201610585492 A CN201610585492 A CN 201610585492A CN 106390093 B CN106390093 B CN 106390093B
- Authority
- CN
- China
- Prior art keywords
- skin
- composition
- local damage
- acid
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 253
- 238000000034 method Methods 0.000 title abstract description 23
- 230000000474 nursing effect Effects 0.000 title description 4
- 210000003491 skin Anatomy 0.000 claims abstract description 190
- 230000035876 healing Effects 0.000 claims abstract description 67
- 230000006378 damage Effects 0.000 claims abstract description 64
- 210000002615 epidermis Anatomy 0.000 claims abstract description 45
- 244000075850 Avena orientalis Species 0.000 claims description 64
- -1 vaseline Substances 0.000 claims description 47
- 239000003963 antioxidant agent Substances 0.000 claims description 44
- 102000004169 proteins and genes Human genes 0.000 claims description 44
- 108090000623 proteins and genes Proteins 0.000 claims description 44
- 235000006708 antioxidants Nutrition 0.000 claims description 43
- 235000018102 proteins Nutrition 0.000 claims description 43
- 239000003795 chemical substances by application Substances 0.000 claims description 36
- 230000003078 antioxidant effect Effects 0.000 claims description 35
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 29
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 28
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 26
- 150000001875 compounds Chemical class 0.000 claims description 23
- 210000004207 dermis Anatomy 0.000 claims description 20
- 238000002360 preparation method Methods 0.000 claims description 20
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 claims description 18
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 17
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 16
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 16
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 16
- 108010073771 Soybean Proteins Proteins 0.000 claims description 15
- 102000007544 Whey Proteins Human genes 0.000 claims description 15
- 108010046377 Whey Proteins Proteins 0.000 claims description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 14
- 235000019710 soybean protein Nutrition 0.000 claims description 14
- 229920001661 Chitosan Polymers 0.000 claims description 13
- 235000021119 whey protein Nutrition 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 12
- 239000004909 Moisturizer Substances 0.000 claims description 11
- 229960005070 ascorbic acid Drugs 0.000 claims description 11
- 239000003974 emollient agent Substances 0.000 claims description 11
- 239000006210 lotion Substances 0.000 claims description 11
- 230000001333 moisturizer Effects 0.000 claims description 11
- 235000019198 oils Nutrition 0.000 claims description 11
- 239000006071 cream Substances 0.000 claims description 10
- 239000002674 ointment Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 235000019172 retinyl palmitate Nutrition 0.000 claims description 9
- 229940108325 retinyl palmitate Drugs 0.000 claims description 9
- 239000011769 retinyl palmitate Substances 0.000 claims description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- 108010016626 Dipeptides Proteins 0.000 claims description 8
- 239000003921 oil Substances 0.000 claims description 8
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 7
- 229920002498 Beta-glucan Polymers 0.000 claims description 7
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 7
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 7
- 229940042585 tocopherol acetate Drugs 0.000 claims description 7
- 230000033616 DNA repair Effects 0.000 claims description 6
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 6
- 230000003750 conditioning effect Effects 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 6
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 5
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 claims description 5
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 5
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 5
- CAHKINHBCWCHCF-UHFFFAOYSA-N N-acetyltyrosine Chemical compound CC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 CAHKINHBCWCHCF-UHFFFAOYSA-N 0.000 claims description 5
- 108010038807 Oligopeptides Proteins 0.000 claims description 5
- 102000015636 Oligopeptides Human genes 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 5
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 230000001771 impaired effect Effects 0.000 claims description 5
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims description 5
- 239000004926 polymethyl methacrylate Substances 0.000 claims description 5
- 235000010241 potassium sorbate Nutrition 0.000 claims description 5
- 239000004302 potassium sorbate Substances 0.000 claims description 5
- 229940069338 potassium sorbate Drugs 0.000 claims description 5
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims description 5
- 229940035936 ubiquinone Drugs 0.000 claims description 5
- 102000009091 Amyloidogenic Proteins Human genes 0.000 claims description 4
- 108010048112 Amyloidogenic Proteins Proteins 0.000 claims description 4
- 240000007124 Brassica oleracea Species 0.000 claims description 4
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 4
- 108010068370 Glutens Proteins 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 239000005864 Sulphur Substances 0.000 claims description 4
- 229930003316 Vitamin D Natural products 0.000 claims description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 4
- 239000004411 aluminium Substances 0.000 claims description 4
- 229910052782 aluminium Inorganic materials 0.000 claims description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- 235000005911 diet Nutrition 0.000 claims description 4
- 230000037213 diet Effects 0.000 claims description 4
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 239000003205 fragrance Substances 0.000 claims description 4
- 229920005573 silicon-containing polymer Polymers 0.000 claims description 4
- 235000019166 vitamin D Nutrition 0.000 claims description 4
- 239000011710 vitamin D Substances 0.000 claims description 4
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 4
- 229940046008 vitamin d Drugs 0.000 claims description 4
- 230000029663 wound healing Effects 0.000 claims description 4
- YXIBXUGCDCJBPD-JYJNAYRXSA-N (2s)-2,6-diamino-n-[2-[[(2s)-1-[[(2s)-1,6-diamino-1-oxohexan-2-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]hexanamide Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(N)=O)CC1=CN=CN1 YXIBXUGCDCJBPD-JYJNAYRXSA-N 0.000 claims description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 claims description 3
- 108010082495 Dietary Plant Proteins Proteins 0.000 claims description 3
- 108010024636 Glutathione Proteins 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 3
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 claims description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 3
- 239000004327 boric acid Substances 0.000 claims description 3
- 235000010338 boric acid Nutrition 0.000 claims description 3
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 3
- 239000004088 foaming agent Substances 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 235000003969 glutathione Nutrition 0.000 claims description 3
- 229960003180 glutathione Drugs 0.000 claims description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 239000002002 slurry Substances 0.000 claims description 3
- 239000012049 topical pharmaceutical composition Substances 0.000 claims description 3
- 229940099259 vaseline Drugs 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- GFEYWOGCSROPRT-OBXVVNIGSA-N (2s)-1-[(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carboxylic acid Chemical compound C([C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=CC=C1 GFEYWOGCSROPRT-OBXVVNIGSA-N 0.000 claims description 2
- QTEWJFPLRGWOOU-IHRRRGAJSA-N (2s)-2-[[(2s)-2-[[(2s)-2-(3-aminopropanoylamino)-3-(1h-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1h-imidazol-5-yl)propanoic acid Chemical compound C([C@H](NC(=O)CCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 QTEWJFPLRGWOOU-IHRRRGAJSA-N 0.000 claims description 2
- NOUIAHOPEGZYFE-JPLJXNOCSA-N (3S)-4-[[(2S)-1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-[[(2S)-2,6-diaminohexanoyl]amino]-4-oxobutanoic acid Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O NOUIAHOPEGZYFE-JPLJXNOCSA-N 0.000 claims description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 2
- 239000005995 Aluminium silicate Substances 0.000 claims description 2
- HWSISDHAHRVNMT-UHFFFAOYSA-N Bismuth subnitrate Chemical compound O[NH+]([O-])O[Bi](O[N+]([O-])=O)O[N+]([O-])=O HWSISDHAHRVNMT-UHFFFAOYSA-N 0.000 claims description 2
- BYUQATUKPXLFLZ-UIOOFZCWSA-N CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 BYUQATUKPXLFLZ-UIOOFZCWSA-N 0.000 claims description 2
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 2
- 108010087806 Carnosine Proteins 0.000 claims description 2
- NFPWMUOQSJXGGZ-ZZTWKDBPSA-N N-[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]tetradecanamide Chemical compound CCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O NFPWMUOQSJXGGZ-ZZTWKDBPSA-N 0.000 claims description 2
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims description 2
- 101800001147 Octapeptide 1 Proteins 0.000 claims description 2
- 108010047657 Phe-Val-Ala-Pro-Phe-Pro Proteins 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 241000251778 Squalus acanthias Species 0.000 claims description 2
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 claims description 2
- 229960000458 allantoin Drugs 0.000 claims description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
- 235000012211 aluminium silicate Nutrition 0.000 claims description 2
- 229940024545 aluminum hydroxide Drugs 0.000 claims description 2
- 150000001277 beta hydroxy acids Chemical class 0.000 claims description 2
- 229960001482 bismuth subnitrate Drugs 0.000 claims description 2
- 229960002645 boric acid Drugs 0.000 claims description 2
- 229940105847 calamine Drugs 0.000 claims description 2
- 235000011092 calcium acetate Nutrition 0.000 claims description 2
- 239000001639 calcium acetate Substances 0.000 claims description 2
- 229960005147 calcium acetate Drugs 0.000 claims description 2
- 229940044199 carnosine Drugs 0.000 claims description 2
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims description 2
- 239000004744 fabric Substances 0.000 claims description 2
- 230000009969 flowable effect Effects 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 229910052864 hemimorphite Inorganic materials 0.000 claims description 2
- 229940093441 palmitoyl oligopeptide Drugs 0.000 claims description 2
- 108010090674 phenylalanyl-glycyl-histidyl-statyl-alanyl-phenylalanine methyl ester Proteins 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 235000013311 vegetables Nutrition 0.000 claims description 2
- 239000011667 zinc carbonate Substances 0.000 claims description 2
- 235000004416 zinc carbonate Nutrition 0.000 claims description 2
- 229910000010 zinc carbonate Inorganic materials 0.000 claims description 2
- 239000011787 zinc oxide Substances 0.000 claims description 2
- 235000014692 zinc oxide Nutrition 0.000 claims description 2
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 claims description 2
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 claims 2
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 claims 2
- 235000020238 sunflower seed Nutrition 0.000 claims 2
- RJZNPROJTJSYLC-LLINQDLYSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical group OC(=O)CC[C@H](NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O RJZNPROJTJSYLC-LLINQDLYSA-N 0.000 claims 1
- KNFLNGRLKALWRF-LDXSYGEZSA-N CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 KNFLNGRLKALWRF-LDXSYGEZSA-N 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 229940123550 Glycosaminoglycan stimulant Drugs 0.000 claims 1
- DUKURNFHYQXCJG-UHFFFAOYSA-N Lewis A pentasaccharide Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)OC1CO DUKURNFHYQXCJG-UHFFFAOYSA-N 0.000 claims 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims 1
- 235000009470 Theobroma cacao Nutrition 0.000 claims 1
- 244000299461 Theobroma cacao Species 0.000 claims 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 claims 1
- DBJUEJCZPKMDPA-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O DBJUEJCZPKMDPA-UHFFFAOYSA-N 0.000 claims 1
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical group [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims 1
- 238000005260 corrosion Methods 0.000 claims 1
- 230000036571 hydration Effects 0.000 claims 1
- 238000006703 hydration reaction Methods 0.000 claims 1
- 229950006780 n-acetylglucosamine Drugs 0.000 claims 1
- AOBMIXQSBXYCFW-UHFFFAOYSA-M sodium;bis(2-ethylhexyl) phosphate Chemical compound [Na+].CCCCC(CC)COP([O-])(=O)OCC(CC)CCCC AOBMIXQSBXYCFW-UHFFFAOYSA-M 0.000 claims 1
- 125000001655 ubiquinone group Chemical group 0.000 claims 1
- 238000005067 remediation Methods 0.000 abstract description 19
- 230000003902 lesion Effects 0.000 abstract description 12
- 230000002500 effect on skin Effects 0.000 abstract description 10
- 235000007319 Avena orientalis Nutrition 0.000 description 58
- 235000007558 Avena sp Nutrition 0.000 description 47
- 238000011282 treatment Methods 0.000 description 34
- 239000000306 component Substances 0.000 description 30
- 230000000699 topical effect Effects 0.000 description 28
- 239000004615 ingredient Substances 0.000 description 20
- 239000003755 preservative agent Substances 0.000 description 18
- 230000002335 preservative effect Effects 0.000 description 18
- 230000000638 stimulation Effects 0.000 description 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 14
- 239000003153 chemical reaction reagent Substances 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 230000000845 anti-microbial effect Effects 0.000 description 13
- 229940121375 antifungal agent Drugs 0.000 description 12
- 239000003429 antifungal agent Substances 0.000 description 12
- 238000011084 recovery Methods 0.000 description 12
- 230000004913 activation Effects 0.000 description 11
- 239000003242 anti bacterial agent Substances 0.000 description 11
- 206010039509 Scab Diseases 0.000 description 10
- 239000003995 emulsifying agent Substances 0.000 description 10
- 235000019256 formaldehyde Nutrition 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 235000004252 protein component Nutrition 0.000 description 10
- 239000000080 wetting agent Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 229960004279 formaldehyde Drugs 0.000 description 9
- 235000011187 glycerol Nutrition 0.000 description 9
- 229960005150 glycerol Drugs 0.000 description 9
- 230000007062 hydrolysis Effects 0.000 description 9
- 238000006460 hydrolysis reaction Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 210000000981 epithelium Anatomy 0.000 description 8
- HLUCICHZHWJHLL-UHFFFAOYSA-N hematein Chemical compound C12=CC=C(O)C(O)=C2OCC2(O)C1=C1C=C(O)C(=O)C=C1C2 HLUCICHZHWJHLL-UHFFFAOYSA-N 0.000 description 8
- 230000000670 limiting effect Effects 0.000 description 8
- 235000002639 sodium chloride Nutrition 0.000 description 8
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 7
- 102000002322 Egg Proteins Human genes 0.000 description 7
- 108010000912 Egg Proteins Proteins 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 description 7
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 7
- 208000003251 Pruritus Diseases 0.000 description 7
- 229920002385 Sodium hyaluronate Polymers 0.000 description 7
- 230000003213 activating effect Effects 0.000 description 7
- 235000014103 egg white Nutrition 0.000 description 7
- 210000000969 egg white Anatomy 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 239000000945 filler Substances 0.000 description 7
- 230000003020 moisturizing effect Effects 0.000 description 7
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 7
- 229940060184 oil ingredients Drugs 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 229940010747 sodium hyaluronate Drugs 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 6
- 244000020551 Helianthus annuus Species 0.000 description 6
- 235000003222 Helianthus annuus Nutrition 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 206010000496 acne Diseases 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 239000003002 pH adjusting agent Substances 0.000 description 6
- 239000003223 protective agent Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 5
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 5
- 208000002874 Acne Vulgaris Diseases 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 229940121668 Collagen stimulant Drugs 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 206010042496 Sunburn Diseases 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 238000004945 emulsification Methods 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 229920002674 hyaluronan Polymers 0.000 description 5
- 229960003160 hyaluronic acid Drugs 0.000 description 5
- 230000000116 mitigating effect Effects 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 229960004063 propylene glycol Drugs 0.000 description 5
- 238000009418 renovation Methods 0.000 description 5
- 229940083466 soybean lecithin Drugs 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 239000002562 thickening agent Substances 0.000 description 5
- MXOAEAUPQDYUQM-QMMMGPOBSA-N (S)-chlorphenesin Chemical compound OC[C@H](O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-QMMMGPOBSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 4
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 229910052691 Erbium Inorganic materials 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 239000004166 Lanolin Substances 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 4
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 229960003993 chlorphenesin Drugs 0.000 description 4
- 229940052366 colloidal oatmeal Drugs 0.000 description 4
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 229940039717 lanolin Drugs 0.000 description 4
- 235000019388 lanolin Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 235000013930 proline Nutrition 0.000 description 4
- 229960002429 proline Drugs 0.000 description 4
- 235000013772 propylene glycol Nutrition 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229940083542 sodium Drugs 0.000 description 4
- 235000015424 sodium Nutrition 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 4
- 230000037303 wrinkles Effects 0.000 description 4
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 3
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 3
- 208000028990 Skin injury Diseases 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 3
- 241000159241 Toxicodendron Species 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 239000003212 astringent agent Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 229920001971 elastomer Polymers 0.000 description 3
- 239000000806 elastomer Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000013265 extended release Methods 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 229960004884 fluconazole Drugs 0.000 description 3
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 3
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 229940045109 genistein Drugs 0.000 description 3
- 235000006539 genistein Nutrition 0.000 description 3
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 3
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 3
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical class COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 238000002647 laser therapy Methods 0.000 description 3
- 238000013532 laser treatment Methods 0.000 description 3
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- 231100000075 skin burn Toxicity 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 229940031439 squalene Drugs 0.000 description 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 229960000580 terconazole Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229930003799 tocopherol Natural products 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000002023 wood Substances 0.000 description 3
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 2
- CXQWRCVTCMQVQX-LSDHHAIUSA-N (+)-taxifolin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-LSDHHAIUSA-N 0.000 description 2
- MQHLMHIZUIDKOO-OKZBNKHCSA-N (2R,6S)-2,6-dimethyl-4-[(2S)-2-methyl-3-[4-(2-methylbutan-2-yl)phenyl]propyl]morpholine Chemical compound C1=CC(C(C)(C)CC)=CC=C1C[C@H](C)CN1C[C@@H](C)O[C@@H](C)C1 MQHLMHIZUIDKOO-OKZBNKHCSA-N 0.000 description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 2
- HFGZFHCWKKQGIS-NOZJJQNGSA-N (2r,3r)-2-(2,4-difluorophenyl)-3-methylsulfonyl-1-(1,2,4-triazol-1-yl)butan-2-ol Chemical compound C([C@@](O)([C@@H](C)S(C)(=O)=O)C=1C(=CC(F)=CC=1)F)N1C=NC=N1 HFGZFHCWKKQGIS-NOZJJQNGSA-N 0.000 description 2
- MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 description 2
- MPTJIDOGFUQSQH-UHFFFAOYSA-N 1-(2,4-dichloro-10,11-dihydrodibenzo[a,d][7]annulen-5-yl)imidazole Chemical compound C12=CC=CC=C2CCC2=CC(Cl)=CC(Cl)=C2C1N1C=CN=C1 MPTJIDOGFUQSQH-UHFFFAOYSA-N 0.000 description 2
- AFNXATANNDIXLG-SFHVURJKSA-N 1-[(2r)-2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1CS[C@H](C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 AFNXATANNDIXLG-SFHVURJKSA-N 0.000 description 2
- ZSTBJMFRJPALNV-UHFFFAOYSA-N 1-[(5-chloro-1-benzofuran-2-yl)-(2-chlorophenyl)methyl]imidazole Chemical compound C=1C2=CC(Cl)=CC=C2OC=1C(N1C=NC=C1)C1=CC=CC=C1Cl ZSTBJMFRJPALNV-UHFFFAOYSA-N 0.000 description 2
- ZCJYUTQZBAIHBS-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-{[4-(phenylsulfanyl)benzyl]oxy}ethyl]imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C=CC(SC=2C=CC=CC=2)=CC=1)CN1C=NC=C1 ZCJYUTQZBAIHBS-UHFFFAOYSA-N 0.000 description 2
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 2
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 description 2
- JLGKQTAYUIMGRK-UHFFFAOYSA-N 1-{2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C2=CC=CC(Cl)=C2SC=1)CN1C=NC=C1 JLGKQTAYUIMGRK-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- XQKYUBTUOHHNDV-UHFFFAOYSA-N 2-[2,6-dichloro-4-(3,5-dioxo-1,2,4-triazin-2-yl)phenyl]-2-(4-fluorophenyl)acetonitrile Chemical compound C1=CC(F)=CC=C1C(C#N)C1=C(Cl)C=C(N2C(NC(=O)C=N2)=O)C=C1Cl XQKYUBTUOHHNDV-UHFFFAOYSA-N 0.000 description 2
- MBRHNTMUYWQHMR-UHFFFAOYSA-N 2-aminoethanol;6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one Chemical compound NCCO.ON1C(=O)C=C(C)C=C1C1CCCCC1 MBRHNTMUYWQHMR-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- DXRKLUVKXMAMOV-UHFFFAOYSA-N 3-heptadecylcatechol Chemical compound CCCCCCCCCCCCCCCCCC1=CC=CC(O)=C1O DXRKLUVKXMAMOV-UHFFFAOYSA-N 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 2
- GZSOSUNBTXMUFQ-NJGQXECBSA-N 5,7,3'-Trihydroxy-4'-methoxyflavone 7-O-rutinoside Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](Oc2cc(O)c3C(=O)C=C(c4cc(O)c(OC)cc4)Oc3c2)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 GZSOSUNBTXMUFQ-NJGQXECBSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 2
- UDYUIWXQUBNDHC-UHFFFAOYSA-N 6-[[4-(4-chlorophenoxy)phenoxy]methyl]-1-hydroxy-4-methylpyridin-2-one Chemical compound ON1C(=O)C=C(C)C=C1COC(C=C1)=CC=C1OC1=CC=C(Cl)C=C1 UDYUIWXQUBNDHC-UHFFFAOYSA-N 0.000 description 2
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 108010064760 Anidulafungin Proteins 0.000 description 2
- 235000011303 Brassica alboglabra Nutrition 0.000 description 2
- 235000006008 Brassica napus var napus Nutrition 0.000 description 2
- 235000011302 Brassica oleracea Nutrition 0.000 description 2
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 2
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- 108010020326 Caspofungin Proteins 0.000 description 2
- 241001674939 Caulanthus Species 0.000 description 2
- WHPAGCJNPTUGGD-UHFFFAOYSA-N Croconazole Chemical compound ClC1=CC=CC(COC=2C(=CC=CC=2)C(=C)N2C=NC=C2)=C1 WHPAGCJNPTUGGD-UHFFFAOYSA-N 0.000 description 2
- 241000256113 Culicidae Species 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- CTETYYAZBPJBHE-UHFFFAOYSA-N Haloprogin Chemical compound ClC1=CC(Cl)=C(OCC#CI)C=C1Cl CTETYYAZBPJBHE-UHFFFAOYSA-N 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 102000004407 Lactalbumin Human genes 0.000 description 2
- 108090000942 Lactalbumin Proteins 0.000 description 2
- ZRTQSJFIDWNVJW-WYMLVPIESA-N Lanoconazole Chemical compound ClC1=CC=CC=C1C(CS\1)SC/1=C(\C#N)N1C=NC=C1 ZRTQSJFIDWNVJW-WYMLVPIESA-N 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- VPHPQNGOVQYUMG-UHFFFAOYSA-N Liranaftate Chemical compound COC1=CC=CC(N(C)C(=S)OC=2C=C3CCCCC3=CC=2)=N1 VPHPQNGOVQYUMG-UHFFFAOYSA-N 0.000 description 2
- YTAOBBFIOAEMLL-REQDGWNSSA-N Luliconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@H](CS\1)SC/1=C(\C#N)N1C=NC=C1 YTAOBBFIOAEMLL-REQDGWNSSA-N 0.000 description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 2
- 241001448624 Miliaria Species 0.000 description 2
- LBHLFPGPEGDCJG-UHFFFAOYSA-N N(4)-{2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl}pentane-1,4-diamine Chemical compound COC=1C=C(NC(C)CCCN)C2=NC(OC)=CC(C)=C2C=1OC1=CC=CC(C(F)(F)F)=C1 LBHLFPGPEGDCJG-UHFFFAOYSA-N 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- WWONQJFKRJJVLO-DUNLUGFTSA-L P(=O)([O-])([O-])O.C(C)(=O)C1(O)[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO.[Na+].[Na+] Chemical compound P(=O)([O-])([O-])O.C(C)(=O)C1(O)[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO.[Na+].[Na+] WWONQJFKRJJVLO-DUNLUGFTSA-L 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- TYBHXIFFPVFXQW-UHFFFAOYSA-N abafungin Chemical compound CC1=CC(C)=CC=C1OC1=CC=CC=C1C1=CSC(NC=2NCCCN=2)=N1 TYBHXIFFPVFXQW-UHFFFAOYSA-N 0.000 description 2
- 229950006373 abafungin Drugs 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- UHIXWHUVLCAJQL-MPBGBICISA-N albaconazole Chemical compound C([C@@](O)([C@H](N1C(C2=CC=C(Cl)C=C2N=C1)=O)C)C=1C(=CC(F)=CC=1)F)N1C=NC=N1 UHIXWHUVLCAJQL-MPBGBICISA-N 0.000 description 2
- 229950006816 albaconazole Drugs 0.000 description 2
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 description 2
- 229960002669 albendazole Drugs 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 229960003204 amorolfine Drugs 0.000 description 2
- 229960003348 anidulafungin Drugs 0.000 description 2
- JHVAMHSQVVQIOT-MFAJLEFUSA-N anidulafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@@H](C)O)[C@H](O)[C@@H](O)C=2C=CC(O)=CC=2)[C@@H](C)O)=O)C=C1 JHVAMHSQVVQIOT-MFAJLEFUSA-N 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 229960005261 aspartic acid Drugs 0.000 description 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 2
- 229960004099 azithromycin Drugs 0.000 description 2
- 150000003851 azoles Chemical class 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 229950005694 becliconazole Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 229960002962 butenafine Drugs 0.000 description 2
- ABJKWBDEJIDSJZ-UHFFFAOYSA-N butenafine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)CC1=CC=C(C(C)(C)C)C=C1 ABJKWBDEJIDSJZ-UHFFFAOYSA-N 0.000 description 2
- 229960005074 butoconazole Drugs 0.000 description 2
- SWLMUYACZKCSHZ-UHFFFAOYSA-N butoconazole Chemical compound C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 SWLMUYACZKCSHZ-UHFFFAOYSA-N 0.000 description 2
- XQKKWWCELHKGKB-UHFFFAOYSA-L calcium acetate monohydrate Chemical compound O.[Ca+2].CC([O-])=O.CC([O-])=O XQKKWWCELHKGKB-UHFFFAOYSA-L 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- SIXOAUAWLZKQKX-UHFFFAOYSA-N carbonic acid;prop-1-ene Chemical compound CC=C.OC(O)=O SIXOAUAWLZKQKX-UHFFFAOYSA-N 0.000 description 2
- JYIKNQVWKBUSNH-WVDDFWQHSA-N caspofungin Chemical compound C1([C@H](O)[C@@H](O)[C@H]2C(=O)N[C@H](C(=O)N3CC[C@H](O)[C@H]3C(=O)N[C@H](NCCN)[C@H](O)C[C@@H](C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N2)[C@@H](C)O)=O)NC(=O)CCCCCCCC[C@@H](C)C[C@@H](C)CC)[C@H](O)CCN)=CC=C(O)C=C1 JYIKNQVWKBUSNH-WVDDFWQHSA-N 0.000 description 2
- 229960003034 caspofungin Drugs 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- WDFKMLRRRCGAKS-UHFFFAOYSA-N chloroxine Chemical compound C1=CN=C2C(O)=C(Cl)C=C(Cl)C2=C1 WDFKMLRRRCGAKS-UHFFFAOYSA-N 0.000 description 2
- 229960004736 chloroxine Drugs 0.000 description 2
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 2
- RTIXKCRFFJGDFG-UHFFFAOYSA-N chrysin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 RTIXKCRFFJGDFG-UHFFFAOYSA-N 0.000 description 2
- 229950001002 cianidanol Drugs 0.000 description 2
- 229960004375 ciclopirox olamine Drugs 0.000 description 2
- KDULJHFMZBRAHO-UHFFFAOYSA-N cioteronel Chemical compound C1C(=O)CC2C(CCCCC(CC)OC)CCC21 KDULJHFMZBRAHO-UHFFFAOYSA-N 0.000 description 2
- 229950000970 cioteronel Drugs 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 229960004022 clotrimazole Drugs 0.000 description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 229960002042 croconazole Drugs 0.000 description 2
- ZXJXZNDDNMQXFV-UHFFFAOYSA-M crystal violet Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1[C+](C=1C=CC(=CC=1)N(C)C)C1=CC=C(N(C)C)C=C1 ZXJXZNDDNMQXFV-UHFFFAOYSA-M 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- GZSOSUNBTXMUFQ-YFAPSIMESA-N diosmin Chemical compound C1=C(O)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 GZSOSUNBTXMUFQ-YFAPSIMESA-N 0.000 description 2
- 229960004352 diosmin Drugs 0.000 description 2
- IGBKNLGEMMEWKD-UHFFFAOYSA-N diosmin Natural products COc1ccc(cc1)C2=C(O)C(=O)c3c(O)cc(OC4OC(COC5OC(C)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 IGBKNLGEMMEWKD-UHFFFAOYSA-N 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229960003062 eberconazole Drugs 0.000 description 2
- 229960003913 econazole Drugs 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 229960001274 fenticonazole Drugs 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 229960004413 flucytosine Drugs 0.000 description 2
- 229960000690 flutrimazole Drugs 0.000 description 2
- QHMWCHQXCUNUAK-UHFFFAOYSA-N flutrimazole Chemical compound C1=CC(F)=CC=C1C(N1C=NC=C1)(C=1C(=CC=CC=1)F)C1=CC=CC=C1 QHMWCHQXCUNUAK-UHFFFAOYSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960001235 gentian violet Drugs 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 229960001906 haloprogin Drugs 0.000 description 2
- 230000036074 healthy skin Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 2
- 235000010209 hesperetin Nutrition 0.000 description 2
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 description 2
- 229960001587 hesperetin Drugs 0.000 description 2
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 2
- DCAYPVUWAIABOU-UHFFFAOYSA-N hexadecane Chemical compound CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 208000000069 hyperpigmentation Diseases 0.000 description 2
- 230000003810 hyperpigmentation Effects 0.000 description 2
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 description 2
- 229960004135 idebenone Drugs 0.000 description 2
- 239000005414 inactive ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229920000831 ionic polymer Polymers 0.000 description 2
- 229960004849 isoconazole Drugs 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 150000002515 isoflavone derivatives Chemical class 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 229950010163 lanoconazole Drugs 0.000 description 2
- 229950005045 letrazuril Drugs 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229950010148 liranaftate Drugs 0.000 description 2
- 229960000570 luliconazole Drugs 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- CKFGINPQOCXMAZ-UHFFFAOYSA-N methanediol Chemical compound OCO CKFGINPQOCXMAZ-UHFFFAOYSA-N 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000006109 methionine Nutrition 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229960002509 miconazole Drugs 0.000 description 2
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 229940042472 mineral oil Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 229960000951 mycophenolic acid Drugs 0.000 description 2
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
- 229960004313 naftifine Drugs 0.000 description 2
- OZGNYLLQHRPOBR-DHZHZOJOSA-N naftifine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OZGNYLLQHRPOBR-DHZHZOJOSA-N 0.000 description 2
- 235000010298 natamycin Nutrition 0.000 description 2
- 239000004311 natamycin Substances 0.000 description 2
- 229960003255 natamycin Drugs 0.000 description 2
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 2
- 229960000988 nystatin Drugs 0.000 description 2
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 2
- 229960004031 omoconazole Drugs 0.000 description 2
- JMFOSJNGKJCTMJ-ZHZULCJRSA-N omoconazole Chemical compound C1=CN=CN1C(/C)=C(C=1C(=CC(Cl)=CC=1)Cl)\OCCOC1=CC=C(Cl)C=C1 JMFOSJNGKJCTMJ-ZHZULCJRSA-N 0.000 description 2
- 229960003483 oxiconazole Drugs 0.000 description 2
- QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 description 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229960001589 posaconazole Drugs 0.000 description 2
- RAGOYPUPXAKGKH-XAKZXMRKSA-N posaconazole Chemical compound O=C1N([C@H]([C@H](C)O)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3C[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 RAGOYPUPXAKGKH-XAKZXMRKSA-N 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- OPAHEYNNJWPQPX-RCDICMHDSA-N ravuconazole Chemical compound C=1SC([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=1C1=CC=C(C#N)C=C1 OPAHEYNNJWPQPX-RCDICMHDSA-N 0.000 description 2
- 229950004154 ravuconazole Drugs 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 229950006862 rilopirox Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229960005429 sertaconazole Drugs 0.000 description 2
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 2
- 229960004245 silymarin Drugs 0.000 description 2
- 235000017700 silymarin Nutrition 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 239000001540 sodium lactate Substances 0.000 description 2
- 235000011088 sodium lactate Nutrition 0.000 description 2
- 229940005581 sodium lactate Drugs 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 229960002607 sulconazole Drugs 0.000 description 2
- 229950000856 tafenoquine Drugs 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229960002722 terbinafine Drugs 0.000 description 2
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 229960004214 tioconazole Drugs 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 229960004880 tolnaftate Drugs 0.000 description 2
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 229960004740 voriconazole Drugs 0.000 description 2
- BCEHBSKCWLPMDN-MGPLVRAMSA-N voriconazole Chemical compound C1([C@H](C)[C@](O)(CN2N=CN=C2)C=2C(=CC(F)=CC=2)F)=NC=NC=C1F BCEHBSKCWLPMDN-MGPLVRAMSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- DFKDOZMCHOGOBR-NCSQYGPNSA-N zaragozic acid A Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CC[C@]12[C@H](O)[C@H]([C@](O2)(C(O)=O)[C@@](O)([C@H](O1)C(O)=O)C(O)=O)OC(=O)/C=C/[C@@H](C)C[C@@H](C)CC)C1=CC=CC=C1 DFKDOZMCHOGOBR-NCSQYGPNSA-N 0.000 description 2
- DFKDOZMCHOGOBR-UHFFFAOYSA-N zaragozic acid A Natural products O1C(C(O)(C(O2)C(O)=O)C(O)=O)(C(O)=O)C(OC(=O)C=CC(C)CC(C)CC)C(O)C21CCC(=C)C(OC(C)=O)C(C)CC1=CC=CC=C1 DFKDOZMCHOGOBR-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- JCZPMGDSEAFWDY-SQOUGZDYSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanamide Chemical compound NC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO JCZPMGDSEAFWDY-SQOUGZDYSA-N 0.000 description 1
- FTSXCFQXTFOYQH-BDQAORGHSA-N (2s)-2-(octadecanoylamino)pentanedioic acid;sodium Chemical compound [Na].CCCCCCCCCCCCCCCCCC(=O)N[C@H](C(O)=O)CCC(O)=O FTSXCFQXTFOYQH-BDQAORGHSA-N 0.000 description 1
- GYDYJUYZBRGMCC-INIZCTEOSA-N (2s)-2-amino-6-(dodecanoylamino)hexanoic acid Chemical compound CCCCCCCCCCCC(=O)NCCCC[C@H](N)C(O)=O GYDYJUYZBRGMCC-INIZCTEOSA-N 0.000 description 1
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- LCTORNIWLGOBPB-DVKNGEFBSA-N (2s,3r,4s,5s,6r)-2-amino-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound N[C@@]1(O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O LCTORNIWLGOBPB-DVKNGEFBSA-N 0.000 description 1
- CUVSTAMIHSSVKL-UWVGGRQHSA-N (4s)-4-[(2-aminoacetyl)amino]-5-[[(2s)-6-amino-1-(carboxymethylamino)-1-oxohexan-2-yl]amino]-5-oxopentanoic acid Chemical compound NCCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CN CUVSTAMIHSSVKL-UWVGGRQHSA-N 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 1
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
- RBNPOMFGQQGHHO-UHFFFAOYSA-N -2,3-Dihydroxypropanoic acid Natural products OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 description 1
- NAOLWIGVYRIGTP-UHFFFAOYSA-N 1,3,5-trihydroxyanthracene-9,10-dione Chemical compound C1=CC(O)=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1 NAOLWIGVYRIGTP-UHFFFAOYSA-N 0.000 description 1
- IECCBIAUDOFPQL-UHFFFAOYSA-N 1,3-oxazolidin-2-ylurea Chemical compound O1C(NCC1)NC(=O)N IECCBIAUDOFPQL-UHFFFAOYSA-N 0.000 description 1
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 1
- GZAGDUDNLKUBSZ-UHFFFAOYSA-N 1-bromo-2-nitropropane Chemical compound BrCC(C)[N+]([O-])=O GZAGDUDNLKUBSZ-UHFFFAOYSA-N 0.000 description 1
- WIPNUQPJVZZAOG-UHFFFAOYSA-N 1-methylpyridin-1-ium-2-carboxylate;hydrochloride Chemical compound [Cl-].C[N+]1=CC=CC=C1C(O)=O WIPNUQPJVZZAOG-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HANWHVWXFQSQGJ-UHFFFAOYSA-N 1-tetradecoxytetradecane Chemical compound CCCCCCCCCCCCCCOCCCCCCCCCCCCCC HANWHVWXFQSQGJ-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 1
- NMMHHSLZJLPMEG-UHFFFAOYSA-N 2-(chloroamino)ethanesulfonic acid Chemical compound OS(=O)(=O)CCNCl NMMHHSLZJLPMEG-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- 229940100555 2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- RWRXDIMAXLSQMK-UHFFFAOYSA-N 3h-1,2,3-benzodithiazole Chemical compound C1=CC=C2NSSC2=C1 RWRXDIMAXLSQMK-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- NYCXYKOXLNBYID-UHFFFAOYSA-N 5,7-Dihydroxychromone Natural products O1C=CC(=O)C=2C1=CC(O)=CC=2O NYCXYKOXLNBYID-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229920006310 Asahi-Kasei Polymers 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000932522 Avena hispanica Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 229910052582 BN Inorganic materials 0.000 description 1
- 241000003910 Baronia <angiosperm> Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 244000205479 Bertholletia excelsa Species 0.000 description 1
- 235000012284 Bertholletia excelsa Nutrition 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- PZNSFCLAULLKQX-UHFFFAOYSA-N Boron nitride Chemical compound N#B PZNSFCLAULLKQX-UHFFFAOYSA-N 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 1
- PGSQGVDBMYSHGO-UHFFFAOYSA-N C(C1=CC=CC=C1)C=1NC=CC1.C1=CC=CC=C1 Chemical class C(C1=CC=CC=C1)C=1NC=CC1.C1=CC=CC=C1 PGSQGVDBMYSHGO-UHFFFAOYSA-N 0.000 description 1
- GWBOEEVOSDBARW-SPXLVGSKSA-N C([C@@H](O)[C@H]1C(=O)N[C@@H](CO)C(=O)N2C[C@H](C)[C@H](O)[C@H]2C(=O)N[C@H](O)[C@H](O)C[C@@H](C(N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)N1)[C@@H](C)O)=O)NC(=O)CCCCCCCCCCC(C)CC)C1=CC=C(O)C=C1 Chemical compound C([C@@H](O)[C@H]1C(=O)N[C@@H](CO)C(=O)N2C[C@H](C)[C@H](O)[C@H]2C(=O)N[C@H](O)[C@H](O)C[C@@H](C(N[C@H](C(=O)N2C[C@H](O)C[C@H]2C(=O)N1)[C@@H](C)O)=O)NC(=O)CCCCCCCCCCC(C)CC)C1=CC=C(O)C=C1 GWBOEEVOSDBARW-SPXLVGSKSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 208000009043 Chemical Burns Diseases 0.000 description 1
- 208000018380 Chemical injury Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- 240000009226 Corylus americana Species 0.000 description 1
- 235000001543 Corylus americana Nutrition 0.000 description 1
- 235000007466 Corylus avellana Nutrition 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 description 1
- 101100094857 Danio rerio slc22a6 gene Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- 240000000902 Diospyros discolor Species 0.000 description 1
- 235000003115 Diospyros discolor Nutrition 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- GHJWNRRCRIGGIO-UHFFFAOYSA-N Fosfluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(OP(O)(=O)O)CN1C=NC=N1 GHJWNRRCRIGGIO-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010002537 Fruit Proteins Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- 241000208680 Hamamelis mollis Species 0.000 description 1
- 206010019973 Herpes virus infection Diseases 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 101710169043 Legumin A Proteins 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010021062 Micafungin Proteins 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- YXOLAZRVSSWPPT-UHFFFAOYSA-N Morin Chemical compound OC1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 YXOLAZRVSSWPPT-UHFFFAOYSA-N 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 1
- BNSTVBLCTRZUDD-CBQIKETKSA-N N-acetyl-D-glucoseamine Chemical compound CC(=O)N[C@@]1(O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O BNSTVBLCTRZUDD-CBQIKETKSA-N 0.000 description 1
- ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 description 1
- NPHFFBWJNRVQNH-UHFFFAOYSA-H NN.S(=O)(=O)([O-])[O-].[Al+3].S(=O)(=O)([O-])[O-].S(=O)(=O)([O-])[O-].[Al+3] Chemical compound NN.S(=O)(=O)([O-])[O-].[Al+3].S(=O)(=O)([O-])[O-].S(=O)(=O)([O-])[O-].[Al+3] NPHFFBWJNRVQNH-UHFFFAOYSA-H 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 101150010952 OAT gene Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 108010084695 Pea Proteins Proteins 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- AEKNYBWUEYNWMJ-QWOOXDRHSA-N Pramiconazole Chemical compound O=C1N(C(C)C)CCN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(CO3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 AEKNYBWUEYNWMJ-QWOOXDRHSA-N 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- IKGXIBQEEMLURG-UHFFFAOYSA-N Rutin Chemical compound OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-UHFFFAOYSA-N 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 244000044822 Simmondsia californica Species 0.000 description 1
- 235000004433 Simmondsia californica Nutrition 0.000 description 1
- 206010040954 Skin wrinkling Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000004280 Sodium formate Substances 0.000 description 1
- FBPFZTCFMRRESA-NQAPHZHOSA-N Sorbitol Chemical compound OCC(O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-NQAPHZHOSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- GGSVZPLREMJSBU-PPHQHOOGSA-N Sultriecin Natural products CCCCCC=CC=C/C=C/C(O)C(C)C(CC=CC1OC(=O)C=CC1O)OS(=O)(=O)O GGSVZPLREMJSBU-PPHQHOOGSA-N 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- YQNQNVDNTFHQSW-UHFFFAOYSA-N acetic acid [2-[[(5-nitro-2-thiazolyl)amino]-oxomethyl]phenyl] ester Chemical compound CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 YQNQNVDNTFHQSW-UHFFFAOYSA-N 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000000159 acid neutralizing agent Substances 0.000 description 1
- YZODJQFXMFEJRM-UHFFFAOYSA-N acrisorcin Chemical compound CCCCCCC1=CC=C(O)C=C1O.C1=CC=C2C(N)=C(C=CC=C3)C3=NC2=C1 YZODJQFXMFEJRM-UHFFFAOYSA-N 0.000 description 1
- 229960004124 acrisorcin Drugs 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 229950006790 adenosine phosphate Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 229960000250 adipic acid Drugs 0.000 description 1
- SOSLMHZOJATCCP-AEIZVZFYSA-N afzelin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=CC(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O SOSLMHZOJATCCP-AEIZVZFYSA-N 0.000 description 1
- SOSLMHZOJATCCP-PADPQNGGSA-N afzelin Natural products O([C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O1)C1=C(c2ccc(O)cc2)Oc2c(c(O)cc(O)c2)C1=O SOSLMHZOJATCCP-PADPQNGGSA-N 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- JLGKQTAYUIMGRK-IBGZPJMESA-N arasertaconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C2=CC=CC(Cl)=C2SC=1)CN1C=NC=C1 JLGKQTAYUIMGRK-IBGZPJMESA-N 0.000 description 1
- 229950003019 arasertaconazole Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 235000013532 brandy Nutrition 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 229960003168 bronopol Drugs 0.000 description 1
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 1
- 229930189902 calbistrin Natural products 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- FYHXNYLLNIKZMR-UHFFFAOYSA-N calcium;carbonic acid Chemical compound [Ca].OC(O)=O FYHXNYLLNIKZMR-UHFFFAOYSA-N 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229940073669 ceteareth 20 Drugs 0.000 description 1
- 229950009789 cetomacrogol 1000 Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- FLASNYPZGWUPSU-SICDJOISSA-N chitosan Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)N)O[C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)N)O[C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)N)O[C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)N)O[C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)N)O[C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H](O[C@@H](O[C@@H]2[C@H](O[C@@H](O)[C@H](N)[C@H]2O)CO)[C@H](N)[C@H]1O)CO)NC(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1N FLASNYPZGWUPSU-SICDJOISSA-N 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015838 chrysin Nutrition 0.000 description 1
- 229940043370 chrysin Drugs 0.000 description 1
- 229960003749 ciclopirox Drugs 0.000 description 1
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- NGPTYCZGBCGWBE-UHFFFAOYSA-N decanoic acid hexadecanoic acid octadecanoic acid octanoic acid propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCC(O)=O.CCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O NGPTYCZGBCGWBE-UHFFFAOYSA-N 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 108010063315 deoxymulundocandin Proteins 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- WCOATMADISNSBV-UHFFFAOYSA-K diacetyloxyalumanyl acetate Chemical compound [Al+3].CC([O-])=O.CC([O-])=O.CC([O-])=O WCOATMADISNSBV-UHFFFAOYSA-K 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- KQNGHARGJDXHKF-UHFFFAOYSA-N dihydrotamarixetin Natural products C1=C(O)C(OC)=CC=C1C1C(O)C(=O)C2=C(O)C=C(O)C=C2O1 KQNGHARGJDXHKF-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 108700003601 dimethylglycine Proteins 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229950002209 efungumab Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- DTTVNCZEOYSFFF-UHFFFAOYSA-N ethoxyurea Chemical compound CCONC(N)=O DTTVNCZEOYSFFF-UHFFFAOYSA-N 0.000 description 1
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000011318 facial edema Diseases 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002195 fatty ethers Chemical class 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 229950008518 fosfluconazole Drugs 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 229940100242 glycol stearate Drugs 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 229940087603 grape seed extract Drugs 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 1
- 229910000271 hectorite Inorganic materials 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- TZMQHOJDDMFGQX-UHFFFAOYSA-N hexane-1,1,1-triol Chemical compound CCCCCC(O)(O)O TZMQHOJDDMFGQX-UHFFFAOYSA-N 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 150000001469 hydantoins Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- ISJVOEOJQLKSJU-QURBUZHQSA-N hydroxyitraconazole Chemical compound O=C1N(C(C)C(O)C)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 ISJVOEOJQLKSJU-QURBUZHQSA-N 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 235000014705 isoleucine Nutrition 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229940093629 isopropyl isostearate Drugs 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229910052622 kaolinite Inorganic materials 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- HBOQXIRUPVQLKX-UHFFFAOYSA-N linoleic acid triglyceride Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC HBOQXIRUPVQLKX-UHFFFAOYSA-N 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- QWDJLDTYWNBUKE-UHFFFAOYSA-L magnesium bicarbonate Chemical compound [Mg+2].OC([O-])=O.OC([O-])=O QWDJLDTYWNBUKE-UHFFFAOYSA-L 0.000 description 1
- 239000002370 magnesium bicarbonate Substances 0.000 description 1
- 229910000022 magnesium bicarbonate Inorganic materials 0.000 description 1
- 235000014824 magnesium bicarbonate Nutrition 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 229960002159 micafungin Drugs 0.000 description 1
- PIEUQSKUWLMALL-YABMTYFHSA-N micafungin Chemical compound C1=CC(OCCCCC)=CC=C1C1=CC(C=2C=CC(=CC=2)C(=O)N[C@@H]2C(N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N3C[C@H](C)[C@H](O)[C@H]3C(=O)N[C@H](O)[C@H](O)C2)[C@H](O)CC(N)=O)[C@H](O)[C@@H](O)C=2C=C(OS(O)(=O)=O)C(O)=CC=2)[C@@H](C)O)=O)=NO1 PIEUQSKUWLMALL-YABMTYFHSA-N 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 239000002068 microbial inoculum Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 108700019599 monomethylolglycine Proteins 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 235000007708 morin Nutrition 0.000 description 1
- DCYOADKBABEMIQ-OWMUPTOHSA-N myricitrin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=C(O)C=2)OC2=CC(O)=CC(O)=C2C1=O DCYOADKBABEMIQ-OWMUPTOHSA-N 0.000 description 1
- DCYOADKBABEMIQ-FLCVNNLFSA-N myricitrin Natural products O([C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O1)C1=C(c2cc(O)c(O)c(O)c2)Oc2c(c(O)cc(O)c2)C1=O DCYOADKBABEMIQ-FLCVNNLFSA-N 0.000 description 1
- 229940078812 myristyl myristate Drugs 0.000 description 1
- RVAKDGYPIVSYEU-UHFFFAOYSA-N n',n'-diethyl-n-(6-methoxy-4-methylquinolin-8-yl)hexane-1,6-diamine Chemical compound C1=CN=C2C(NCCCCCCN(CC)CC)=CC(OC)=CC2=C1C RVAKDGYPIVSYEU-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960002480 nitazoxanide Drugs 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 1
- 210000002221 olecranon process Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000019702 pea protein Nutrition 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 235000018192 pine bark supplement Nutrition 0.000 description 1
- 229950008282 poliglusam Drugs 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 150000004291 polyenes Chemical class 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 1
- 229940043349 potassium metabisulfite Drugs 0.000 description 1
- 235000010263 potassium metabisulphite Nutrition 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 229950001086 pramiconazole Drugs 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 108060006613 prolamin Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- NEOZOXKVMDBOSG-UHFFFAOYSA-N propan-2-yl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC(C)C NEOZOXKVMDBOSG-UHFFFAOYSA-N 0.000 description 1
- XXRYFVCIMARHRS-UHFFFAOYSA-N propan-2-yl n-dimethoxyphosphorylcarbamate Chemical compound COP(=O)(OC)NC(=O)OC(C)C XXRYFVCIMARHRS-UHFFFAOYSA-N 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 229940106796 pycnogenol Drugs 0.000 description 1
- KOUKXHPPRFNWPP-UHFFFAOYSA-N pyrazine-2,5-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CN=C(C(O)=O)C=N1 KOUKXHPPRFNWPP-UHFFFAOYSA-N 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 150000004040 pyrrolidinones Chemical class 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 229920002050 silicone resin Polymers 0.000 description 1
- 229950008038 sitamaquine Drugs 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- GAYWDMXGCWYFCK-CRKRICINSA-M sodium [(1E,4S,5S,6S,7Z,9Z,11E)-6-hydroxy-1-[(2S,3S)-3-hydroxy-6-oxo-2,3-dihydropyran-2-yl]-5-methylheptadeca-1,7,9,11-tetraen-4-yl] sulfate Chemical compound [Na+].CCCCC\C=C\C=C/C=C\[C@H](O)[C@H](C)[C@@H](OS([O-])(=O)=O)C\C=C\[C@@H]1OC(=O)C=C[C@@H]1O GAYWDMXGCWYFCK-CRKRICINSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 1
- 235000019254 sodium formate Nutrition 0.000 description 1
- 229940101011 sodium hydroxymethylglycinate Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
- 235000010334 sodium propionate Nutrition 0.000 description 1
- 239000004324 sodium propionate Substances 0.000 description 1
- 229960003212 sodium propionate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- CITBNDNUEPMTFC-UHFFFAOYSA-M sodium;2-(hydroxymethylamino)acetate Chemical compound [Na+].OCNCC([O-])=O CITBNDNUEPMTFC-UHFFFAOYSA-M 0.000 description 1
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 229940075554 sorbate Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- QIMCUSGGYZHVEF-OKBBACTKSA-N sordaricin Chemical compound C([C@@H]1[C@H](C)CC[C@H]11)[C@]2(CO)[C@@H]3C=C(C(C)C)[C@]2(C(O)=O)[C@]1(C=O)C3 QIMCUSGGYZHVEF-OKBBACTKSA-N 0.000 description 1
- QIMCUSGGYZHVEF-UHFFFAOYSA-N sordaricin Natural products C12CCC(C)C2CC2(CO)C3C=C(C(C)C)C2(C(O)=O)C1(C=O)C3 QIMCUSGGYZHVEF-UHFFFAOYSA-N 0.000 description 1
- 235000013597 soy food Nutrition 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940070720 stearalkonium Drugs 0.000 description 1
- 125000005502 stearalkonium group Chemical group 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 229940094879 tetrapeptide-21 Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- 229940068778 tocotrienols Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 108010038909 turmerin Proteins 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 239000011727 vitamin B9 Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000001717 vitis vinifera seed extract Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229940118846 witch hazel Drugs 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/26—Aluminium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/645—Proteins of vegetable origin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/732—Starch; Amylose; Amylopectin; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/736—Chitin; Chitosan; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0076—Sprayable compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/88—Two- or multipart kits
- A61K2800/884—Sequential application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/21—Acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Birds (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Materials Engineering (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本文提供了包括局部损伤愈合组合物、局部舒缓组合物和表皮/真皮损伤愈合/修复组合物的局部生物相容性组合物。本文还提供了使用生物相容性组合物治疗和/或防止易受损的皮肤的方法,以及产生生物相容性组合物的方法。
Description
发明领域
本文的主题涉及操作后的皮肤护理系统和包括该操作后的皮肤护理系统的试剂盒、治疗易受损的皮肤的局部组合物以及它们的使用方法。
发明背景
皮肤表面重修被用于去除表皮和/或真皮中的各层以通过例如使胶原蛋白、弹性蛋白和表皮再生而促进更健康的皮肤。此外,皮肤表面重修可使面部皮肤恢复活力,并且改善细纹和皱纹的外观。皮肤表面重修还可去除表面斑点,例如老化的褐斑、毛细血管扩张和小角质。
目前广泛用于皮肤表面重修的一个操作涉及暴露于激光,包括例如烧蚀激光技术和/或非烧蚀激光技术。因为任何给定的激光器发射出仅一个波长(或者颜色)的光,它们通过被称为选择性光热解作用的过程用于美容应用。为了有效起见,光束的波长必须与将要处理的靶标的颜色同步,无论是褐斑、不雅的红色破裂的毛细血管或者是一些其它不良的皮肤病况。治疗色素病变(例如晒斑、老年斑黄褐斑和其它形式的色素沉着过度)的最常用的激光为脉冲染料激光、Nd:YAG激光和点阵(Fraxel)激光,以及非激光的、基于光的治疗,例如IPL。
用于美容操作的激光还包括CO2(二氧化碳)激光或者铒YAG,其用于治疗细纹和皱纹、去除疣和皮赘、痤疮疤痕以及在激光辅助手术中切割皮肤。脉冲染料激光连同较低攻击性的基于非激光(例如强脉冲光(IPL)光子嫩肤和LED光子嫩肤)的治疗也已显示获得一些成功。大多数美容激光操作提供一定程度的表面紧致,这是因为它们产生受控的皮肤损伤,这促进产生更多的胶原蛋白。为了更显著的紧致结果,可使用CO2激光或者基于非激光的治疗,例如Titan红外线装置和基于Thermage射频的系统。
表面重修方法还包括化学脱皮术和擦皮术。化学脱皮引起化学烧伤。机械擦皮术去除表皮和真皮的可变层。最近,已将快速扫描装置添加至切割激光,能够使可预测的皮肤深度受到破坏。表面重修方法治疗表面的皱纹并且修复受光照而老化的皮肤。
皮肤表面重修操作产生可预测的术后后遗症,包括面部水肿、损伤渗出物、红斑、疼痛、瘙痒、色素沉着过度、粟粒疹形成和痤疮。
发明概述
本文的主题涉及生物相容性局部组合物、包含该组合物的试剂盒以及促进操作后的皮肤或者其它易受损的皮肤的损伤愈合的方法。更具体地,本文提供了局部损伤愈合组合物、局部舒缓组合物和表皮/真皮修复组合物。本文所述的局部损伤愈合组合物例如使用食品级的高效能蛋白成分、止血剂和抗真菌剂的用于增强皮肤组织修复的独特的、新型的组合系统。
本文所述的局部损伤愈合组合物可包含一种或多种收敛剂,或者由一种或多种收敛剂组成。局部损伤愈合组合物还可包含一种或多种蛋白质、蛋白质复合物和/或壳聚糖。局部损伤愈合组合物还可包含填充剂或者载体。本文所述的局部损伤愈合组合物还可包含pH调节剂、着色剂和/或非释放甲醛的防腐剂。
本文所述的局部损伤愈合组合物可以不含有以下的一种或多种:谷蛋白;维生素D;生长激素;对羟基苯甲酸酯;EU26芳香过敏原和释放甲醛的防腐剂。
本文还提供了局部舒缓组合物。局部舒缓组合物可包含以下的一种或多种,或者由以下的一种或多种组成:糖胺聚糖(GAG)刺激剂、抗炎剂、抗氧化剂和DNA修复组分。
修复易受损的皮肤的GAG刺激剂可以是刺激糖胺聚糖的任何物质。例如,GAG刺激剂可以是乙酰氨基葡萄糖磷酸二钠(DAGP)。
用于局部舒缓组合物中的抗炎剂组分或者抗刺激剂组分可包括例如以下的一种或多种:甘蓝(Brassica Oleracea,西兰花)提取物;向日葵(Helianthus Annuus,葵花)籽油;燕麦(Avena Sativa,Oat)仁粉蛋白质和/或β-葡聚糖。
用于局部舒缓组合物中的一种或多种抗氧化剂可包括例如包括以下的一种或多种抗氧化剂:例如,泛醌(辅酶Q10);生育酚乙酸酯;抗坏血酸和棕榈酸视黄酯。抗氧化剂组分可包括配制为12小时延时释放胶囊的抗氧化剂复合物。抗氧化剂复合物可包含以下或者由以下组成:聚甲基丙烯酸甲酯和一种或多种生育酚乙酸酯、抗坏血酸和棕榈酸视黄酯或者其它适合的抗氧化剂。
局部舒缓制剂可包含DNA修复组分。DNA修复组分可包括以下的一种或多种,或者由以下的一种或多种组成:三磷酸腺苷、水解植物蛋白、脯氨酸、乙酰酪氨酸等。
局部舒缓组合物还可包含以下的一种或多种,或者由以下的一种或多种组成:吸收促进剂、抗菌剂、抗微生物剂、抗真菌剂、润肤剂、自乳化弹性体凝胶、乳化剂、溶剂、表面活性剂、防腐剂、护肤剂、保湿剂、抗炎剂、湿润剂和/或芳香剂。
此外,本文提供了表皮/真皮损伤愈合/修复组合物。表皮/真皮损伤愈合/修复组合物可包含一种或多种护肤剂,或者由一种或多种护肤剂组成,以保护和缓解由于刺激造成的干燥和瘙痒或者其它易受损的皮肤。如本文所用,表皮/真皮损伤愈合/修复组合物可被称为表皮/真皮损伤愈合组合物、表皮损伤愈合/修复组合物、表皮/真皮损伤修复组合物等。肽可包含在表皮/真皮损伤愈合/修复组合物中。修复组合物还可包含保湿剂。一种或多种抗炎剂还可包含在表皮修复组合物中,以缓和发红以及舒缓受刺激的皮肤或者其它易受损的皮肤。
表皮/真皮损伤愈合/修复组合物可包含一种或多种抗氧化剂或者抗氧化剂复合物。抗氧化剂复合物可被配制为12小时延时释放胶囊。
任选地,局部损伤愈合组合物或表皮修复组合物还可包含以下的一种或多种:载体、溶剂、增稠剂、湿润剂、乳化剂、抗菌剂、抗微生物剂、抗真菌剂、润肤剂、乳化试剂、皮肤保护活性剂、中和剂、防腐剂、胶原蛋白刺激剂、DNA保护剂、保湿试剂、大豆磷脂、DNA修复剂和皮肤调理剂。
本文还提供操作后的皮肤试剂盒。操作后的皮肤试剂盒可包含以下的一种或多种,或者由以下的一种或多种组成:局部损伤愈合组合物、局部舒缓组合物和表皮/真皮损伤愈合/修复组合物。试剂盒可进一步包含使用说明书、包装以及用于治疗操作后的皮肤或者其它易受损的皮肤的其它组合物。
本文所述的主题还涉及降低对象的皮肤刺激的方法,其包括或者由向对象局部施用治疗有效量的本文所述的一种或多种生物相容性局部组合物组成。
本文所述的主题还涉及治疗对象的易受损的皮肤的方法,其包括向需要其的对象局部施用治疗有效量的一种或多种本文所述的生物相容性局部组合物。
本文所述的主题还涉及治疗对象的操作后的皮肤的方法,其包括向需要其的对象局部施用治疗有效量的一种或多种本文所述的生物相容性局部组合物。
本文所述的主题还涉及本文所述的生物相容性局部组合物在制备用于降低对象的皮肤刺激的药物中的用途。
本文所述的主题还涉及本文所述的生物相容性局部组合物在制备用于治疗对象的易受损的皮肤的药物中的用途。
本文所述的主题还涉及本文所述的生物相容性局部组合物在制备用于治疗对象的操作后的皮肤的药物中的用途。
本文所述的主题还涉及包含本文所述的局部损伤愈合组合物的试剂盒在制备用于降低对象的皮肤刺激、治疗对象的易受损的皮肤或治疗对象的操作后的皮肤的药物中的用途。
本文所述的主题还涉及本文所述的局部损伤愈合组合物在制备用于治疗对象的易受损的皮肤的药物中的用途。
本文所述的主题还涉及本文所述的局部损伤愈合组合物在制备用于治疗对象的操作后的皮肤的药物中的用途。
附图简述
图1表示患者在操作前的正面照,即操作前的对象。
图2A表示在指导下使用本文的操作后生物相容性局部组合物后,经化学脱皮后两(2)天患者的右侧视图,即在操作后2天对象的恢复后侧面;
图2B表示在指导下使用对比性操作后局部方案后的同一天,同一患者的左侧视图,即在操作后2天对比的恢复后侧面。
图3A表示在指导下使用本文的操作后生物相容性局部组合物后,经化学脱皮后五(5)天患者的右侧视图,即在操作后5天对象的恢复后侧面;
图3B表示在指导下使用对比性操作后局部方案后的同一天,同一患者的左侧视图,即在操作后5天对比的恢复后侧面。
图4A表示在指导下使用本文的操作后生物相容性局部组合物后,经化学脱皮后九(9)天患者的右侧视图,即在操作后9天对象的恢复后侧面;
图4B表示在指导下使用对比性操作后局部方案后的同一天,同一患者的左侧视图,即在操作后9天对比的恢复后侧面。
发明详述
定义
如本文所用的术语“约”指基于其所使用的上下文数量、水平、数值、尺寸、大小或者用量的一定程度的变化。例如,该变化可多达5%。至少,各个数值参数可根据所报道的有效数字的位数以及采用常规的舍入技术进行解释。
如本文所使用,术语“施用(administer)”、“施用(administering)”和“施用(administration)”指在可靠的医疗实践中以提供治疗效果的方式向对象递送组合物的任何方法。
为了本文所述主题的目的,可局部施用本文的局部生物相容性组合物。例如,施用可包括但不限于直接局部施用。例如,包括诸如乳膏剂、凝胶、软膏剂的粘性制剂,或者油膏制剂或者诸如溶液的液体制剂,可以直接施用于所需的皮肤表面。还可经由敷布或者湿敷完成施用。例如,可将本文所述的局部组合物的制剂(液体,例如溶液、乳液、悬浮液等)经由敷布或者湿敷施用于皮肤表面。
如本文所用的术语“抗菌剂”,指杀死细菌或者抑制其生长的物质。适合的抗菌剂的非限制性实例包括氯苯甘醚和山梨酸钾。
如本文所用的术语“抗真菌剂”,指杀死真菌或者抑制其生长的物质。适合的抗真菌剂包括以下的一种或多种:氯苯甘醚、山梨酸钾5-氟胞嘧啶、阿巴芬净(Abafungin)、吖啶琐辛(Acrisorcin)、阿莫罗芬(Amorolfme)、阿巴康唑(Albaconazole)、阿苯达唑(Albendazole)、阿莫罗芬(Amorolfme)、两性霉素B、阿尼芬净(Anidulafungin)、阿拉康唑(Arasertaconazole)、阿奇霉素(Azithromycin)、贝康唑(Becliconazole)、苯并二噻唑、联苯苄唑、布替萘芬(Butenafine)、布康唑(Butoconazole)、Calbistrin、卡泊芬净(Caspofungin)、氯喔星(Chloroxine)、氯苯甘醚、环吡酮胺(Ciclopirox olamine)、环匹罗司(Ciclopirox)、塞奥罗奈(Cioteronel)、克霉唑(Clotrimazole)、氯康唑(Croconazole)、Cytoporins、氧牡仓康定(Deoxymulundocandin)、依柏康唑(Eberconazole)、益康唑(Econazole)、依芬古单抗(Efungumab)、芬替康唑(Fenticonazole)、黄酮苷类(Flavanoidglycosides)、氟康唑(Fluconazole)、氟曲马唑(Flutrimazole)、氟胞嘧啶(Flucytosine)、福司氟康唑(Fosfluconazole)、京纳康唑(Genaconazole)、龙胆紫(Gentian violet)、灰黄霉素(Griseofulvin)、灰黄霉素-PEG(Griseofulvin-PEG)、卤普罗近(Haloprogin)、羟基伊曲康唑(Hydroxy itraconazole)、异康唑(Isoconazole)、伊曲康唑、酮康唑、拉诺康唑(Lanoconazole)、来曲珠利(Letrazuril)、利拉萘酯(Liranaftate)、卢立康唑(Luliconazole)、米卡芬净(Micafungin)、咪康唑(Miconazole)、霉酚酸(Mycophenolicacid)、萘替芬(Naftifine)、N-氯牛磺酸(N-chlorotaurine)、纳他霉素(Natamycin)、硝唑尼特(Nitazoxanide)、硝基乙烯基抗真菌剂、制霉菌素(Nystatin)、奥莫康唑(Omoconazole)、奥昔康唑(Oxiconazole)、多烯大环内脂、泊沙康唑(Posaconazole)、普拉康唑(Pramiconazole)、喹诺酮(Quinolone)类似物、雷帕霉素(Rapamycin)、雷夫康唑(Ravuconazole)、利洛吡司(Rilopirox)、Samidazole、舍他康唑(Sertaconazole)、西他马喹(Sitamaquine)、Sordaricin、角鲨抑素(Squalestatin)、角鲨烯(Squalene)、角鲨烯环氧化酶(Squaline Expoxidase)抑制剂、硫康唑(Sulconazole)、Sultriecin、他非诺喹(Tafenoquine)、特比萘芬(Terbinafine)、特康唑(Terconazole)、噻康唑(Tioconazole)、托萘酯(Tolnaftate)以及伏立康唑(Voriconazole)、丙酸钠、甲酸钠、丙酸和甲酸。
如本文所用的术语“抗微生物剂”,指杀死微生物或者抑制其生长的物质。抗微生物剂可包括抵抗细菌的抗菌剂和抵抗真菌的抗真菌剂。抗微生物剂还可包括抗病毒剂。
如本文所使用,术语“抗炎剂”,指用于减少炎症的一种或多种适应症的任何物质(例如,化合物),此类适应症包括但不限于肿胀、发红、变软和疼痛。此类化合物可包括但不限于β-葡聚糖、燕麦(Avena Sativa,Oat)仁膳食、燕麦(Avena Sativa,Oat)仁蛋白质USP、燕麦(Avena Sativa,Oat)仁粉、乳清蛋白质浓缩物以及它们的组合。
术语“燕麦(Avena Sativa)”,指燕麦(Oat)。术语“燕麦仁”指燕麦的无外壳的仁。燕麦(Avena Sativa)可包括任何形式的燕麦(Oat),其包括胶状燕麦片、燕麦提取物、燕麦仁和燕麦蛋白质。天然燕麦不含谷蛋白。胶状燕麦片被FDA分类为护肤剂并且为磨成细粉的燕麦。燕麦包含β-葡聚糖;包括燕麦球蛋白和燕麦蛋白的蛋白质,其中无外壳的燕麦仁包含多至24%的此类蛋白质;生物碱;脂肪;矿物质;皂苷;甾醇类黄酮以及维生素B。燕麦可包含燕麦生物碱。胶状燕麦片可包含淀粉、β-葡聚糖以及可吸收紫外线的燕麦酚。适用于本文所述的局部组合物的燕麦可包括但不限于以下的一种或多种:燕麦仁、燕麦仁蛋白质和胶状燕麦片。
“吸收促进剂”指适用于本文的局部生物相容性组合物的脂肪酸的一种或多种组合。吸收促进剂的非限制性实例包括以下的一种或多种:辛酸/癸酸甘油三酯(Migyo l810和Migyo l812)、辛酸/癸酸/亚油酸甘油三酯(Miglyo l818)、辛酸/癸酸/肉豆蔻酸/硬脂酸脂肪酸甘油三酯(Softisan 378)、辛酸/癸酸/琥珀酸脂肪酸甘油三酯(Miglyo l829)、具有司拉氯铵(stearalkonium)铝和碳酸丙烯酯的辛酸/癸酸甘油三酯(Migyol Gel T)、具有司拉氯铵水辉石和碳酸丙烯酯的辛酸/癸酸甘油三酯(Migyol Gel B)。
术语“抗氧化剂”指具有比另一个原子或者分子更高的氧化电势的原子或者分子,以便所述抗氧化剂而不是另一个原子或者分子优先被氧化。例如,抗氧化剂可具有比苏木因更高的氧化电势,因此有助于防止苏木因氧化为氧基苏木因。此外,抗氧化剂还可发挥还原剂的作用,例如将氧基苏木因转化回为苏木因的还原剂。抗氧化剂可以以约1mM至约1M的浓度范围存在于所公开的组合物中,例如,约5mM至约500mM,例如约50mM至约150mM。
抗氧化剂的非限制性实例包括生育酚乙酸酯、抗坏血酸和/或棕榈酸视黄酯、可溶性大豆蛋白质、艾地苯醌(Idebenone)、辅酶Q10、番茄红素、表没食子儿茶素3-没食子酸酯(EGCG)、绿茶多酚(GTP)、水飞蓟素(Silymarin)、(VDF FutureCeuticals:从咖啡树咖啡铝的果实中提取的抗氧化剂)、葡萄籽提取物、石榴提取物、染料木黄酮、碧萝芷(pycnogenol)、烟酰胺、蛋氨酸、谷胱甘肽、生育三烯酚、二甲基甘氨酸、甜菜碱(betaine)、丁基化羟基苯甲醚、丁基化羟基甲苯、姜黄素(turmerin)、维生素E、棕榈酸抗坏血酸酯、甲磺酸迪特奥希姆(deteroxime mesylate)、对羟基苯甲酸甲酯、对羟基苯甲酸乙酯、丁基化羟基苯甲醚、丁基化羟基甲苯、没食子酸丙酯、焦亚硫酸钠或者焦亚硫酸钾、钠或者钾铝、α生育酚或其衍生物、抗坏血酸钠、依地酸二钠、BHA(丁基化羟基苯甲醚)、类黄酮、上述化合物的药物可接受的盐或者酯以及它们的混合物。类黄酮包括例如槲皮素、桑色素、柚皮素和橙皮素、黄杉素、阿福豆苷(afzelin)、槲皮苷、杨梅苷、染料木黄酮、芹菜素和鹰嘴豆素A、黄酮、黄酮吡啶酚、诸如大豆异黄酮的异黄酮、染料木黄酮、诸如儿茶素表没食子儿茶素没食子酸盐的儿茶素、黄酮醇、表儿茶素、橙皮素、白杨素、地奥司明(diosmin)、橘皮苷、木犀草素和芸香苷。
短语“抗氧化剂复合物”指包含聚甲基丙烯酸酯和一种或多种抗氧化剂的延迟释放制剂、延长释放制剂或者延时释放制剂。抗氧化剂复合物可以是12小时延长释放制剂。
如本文使用的术语“收敛剂”或者“收敛剂组分”,指在施用于皮肤或者黏膜时引起局部和有限的蛋白质凝结作用的任何物质。收敛性物质使机体组织收缩或者收紧,因此被用作护肤剂。适合的收敛剂可包括任何生物相容的非处方(OTC)收敛剂,其包括例如但不限于十四水合硫酸铝和一水合乙酸钙的组合,它们在一起可以反应以形成收敛剂乙酸铝。其它适合的收敛性物质可包括但不限于硫酸铝和金缕梅。
如本文所用的术语“生物相容的”或者“生理学上相容的”,指与活系统接触而不产生严重的副作用(例如,无毒、无害或者无生理学上的反应性)的能力。
如本文所用,术语“壳聚糖”,指由随机分布的β-(1-4)-连接的D-葡萄糖胺(去乙酰化单元)和N-乙酰基-D-葡萄糖胺(乙酰化单元)组成的直链多糖。本文的壳聚糖的含义还包括盐及其衍生物,包括例如壳聚糖季铵化衍生物。壳聚糖是水溶性的生物聚合物。术语“壳聚糖盐”指壳聚糖的盐,其包括例如但不限于琥珀酸、乳酸、抗坏血酸和盐酸的盐中的一种或多种。壳聚糖还通常被称为聚氨葡糖、脱乙酰基甲壳质和聚-(D)葡糖胺。脱乙酰化度可以为60%至100%、70%至90%、90%至95%、90%至100%、95%至100%或者98%至100%,包括例如90%、95%和98%或者100%(以ORISTARTM壳聚糖出售)脱乙酰化。
如本文所述,壳聚糖具有以下化学式:
如本文所用,组合物和/或活性剂或者成分(在本文中是同义的)的短语“有效量”或者“治疗有效量”,指在施用时足以具有治疗效果的活性剂的量。治疗有效量的活性剂可期望(将期望或者期望)引起症状的减轻。活性剂的有效量将随所治疗的特定一种或多种病况、病况的严重程度、治疗的持续时间、所用组合物的特定组分等因素而变化。例如,本文所述的组合物可以以足够覆盖受感染区域的量进行局部施用。本文所述的组合物可以以足够覆盖受感染区域加受感染区域周围的健康皮肤边缘或者组织边缘(例如,约0.5英寸的边缘)的量进行局部施用。
如本文所用,术语“润肤剂”指应用于皮肤舒缓皮肤刺激的任何产物,包括例如软膏剂、搽剂、洗剂、乳膏剂、保湿剂、油、皮肤软化剂、皂、洗发剂、防晒剂、化妆品等。适用于本文的生物相容性局部组合物的润肤剂的非限制性实例包括,例如氢化聚异丁烯、C-12-C-15醇类苯甲酸酯、肉豆蔻酸异丙酯、矿物油、羊毛脂和羊毛脂衍生物以及甘油三酯,例如椰子油、十六醇十八醇混合物、鲸蜡醇、棕榈酸异丙酯、辛酸/癸酸甘油三酯、PPG-2肉豆蔻基醚丙酸酯、聚二甲基硅氧烷、聚甲基硅氧烷、矿脂、羊毛脂和矿物油。
如本文所用,“乳化剂”指在用于乳液防止液体分离中作为稳定剂的化合物或者物质。适用于本文的生物相容性局部组合物的乳化剂的非限制性实例包括:PEG-15/十二烷基聚二甲基硅氧烷交联聚合物、聚甘油基-4异硬脂酸酯和/或十六烷基PEG/PPG 10/1聚二甲基硅氧烷和/或月桂酸己酯、来源于十八烷醇的聚氧乙烯脂肪醚、异硬脂酸异丙酯、十六烷醇、聚乙二醇硬脂酸酯、乙二醇硬脂酸酯、甘油硬脂酸酯、鲸蜡硬脂醇、鲸蜡硬脂醇聚醚20、甲基纤维素、聚西托醇1000和卵磷脂。术语“填充剂”和“载体”意指添加至本文所述的生物相容性局部组合物中的一种或多种中以增加体积、重量、粘度、透明度或者强度的任何惰性物质或者非惰性物质。填充剂可以为例如以下的一种或多种:复合的支化葡聚糖、水、三山嵛精、天然蜡组分或者人造蜡组分、滑石、云母、二氧化硅、高岭土、纤维素粉、糊精、粉末状预凝胶淀粉、非凝胶支链淀粉和葡萄糖聚合物合成锂皂石、诸如粉末的聚酰胺粉末、聚-β-丙氨酸粉末和聚乙烯粉末、四氟乙烯聚合物的粉末、月桂酰赖氨酸、淀粉、氮化硼、诸如丙烯酸共聚物颗粒的丙烯酸聚合物的颗粒以及硅酮树脂微球、沉淀的碳酸钙、磷酸二钙、碳酸镁、碳酸氢镁、羟磷灰石。至少一种填充剂可以是或者可以不是表面处理过的,例如,以使其是亲脂性的。
术语“湿润剂”指能够减少水分损失的物质。湿润剂的非限制性实例包括,例如,甘油、透明质酸钠、甘油、丙三醇、丙二醇、三乙酸甘油酯、诸如PPG-12-PEG50的羊毛脂产物、多元醇、水溶性烷氧基化非离子聚合物以及它们的混合物。本文所用的多元醇包括甘油、山梨糖醇、丙二醇、丁二醇、己二醇、乙氧基化葡萄糖、1,2-己二醇、己三醇、二丙二醇、赤藓糖醇、海藻糖、双甘油、木糖醇、麦芽糖醇、麦芽糖、葡萄糖、果糖、软骨素硫酸钠、透明质酸钠、腺苷磷酸钠、乳酸钠、吡咯烷酮碳酸酯、葡萄糖胺、环糊精以及它们的混合物。本文所用的水溶性烷基化非离子聚合物包括具有高至约1000的分子量的聚乙二醇和聚丙二醇,例如CTFA命名为PEG-200、PEG-400、PEG-600、PEG-1000的那些以及它们的混合物。本文可商购获得的湿润剂包括:可从宝洁公司获得的商品名为STAR和SUPEROL的甘油,可从Croda Universal有限公司获得的CRODEROL GA7000,可从Unichema获得且可从NOF获得以相同商品名作为化学名称的PRECERIN系列;可从Inolex获得的商品名为LEXOL PG-865/855的丙二醇,可从BASF获得的1,2-丙二醇USP;可从Lipo获得的商品名为LIPONIC系列的山梨糖醇,可从ICI获得的SORBO、ALEX、A-625和A-641以及可从UPI获得的UNISWEET 70、UNISWEET CONC;可从BASF获得的具有相同商品名的二丙二醇;可从Solvay GmbH获得的商品名为DIGLYCEROL的双甘油;可从Kyowa和Eizai获得的具有相同商品名的木糖醇;可从Hayashibara获得的商品名为MALBIT的麦芽糖醇,可从Freeman and Bioiberica获得的具有相同商品名的软骨素硫酸钠,以及可从Atomergic Chemetals获得的商品名为ATOMERGIC SODIUM CHONDROITINSULFATE的软骨素硫酸钠;可从Active Organics获得的商品名为ACTIMOIST的透明质酸钠,可从Intergen获得的AVIAN透明质酸钠系列,可从Ichimaru Pharcos获得的透明质酸钠;可从Asahikasei、Kyowa和Daiichi Seiyaku获得的具有相同商品名的腺苷磷酸钠;可从Merck、Wako和Showa Kako获得的具有相同商品名的乳酸钠,可从美国Maize获得的商品名为CAVITRON的环糊精,可从Rhone-Poulenc获得的RHODOCAP系列,以及可从Tomen获得的DEXPEARL;以及可从Union Carbide获得的商品名为CARBOWAX系列的聚乙二醇。
如本文所用,术语“保湿剂”指在施用于表面(例如,皮肤、黏膜组织损伤等)时引起水分保留在表面内、表面附近或者表面上的组合物。适用于本文的生物相容性局部组合物的保湿剂的非限制性实例包括赤藓糖醇和/或龙虾肌碱HCl、透明质酸钠、芦荟、磷脂、磷脂混合物、透明质酸钠、尿素的甘油、羟乙基尿素、甘油、乳木果油、肉豆蔻酸肉豆蔻酯、季戊四醇二硬脂酸酯、乙酰化乙二醇硬脂酸酯、硬脂酰谷氨酸钠、氢化聚异丁烯、氢化卵磷脂、戊二醇、葡萄糖、聚二甲基硅氧烷、透明质酸钠、VP/VA共聚物、神经酰胺III、氨基聚二甲基硅氧烷。
如本文所用,术语“pH调节剂”和“中和剂”指适用于调节本文所述的局部组合物而不对其任何性能产生负面影响的任何组合物、化合物或者试剂。适合的pH调节剂可包括任何酸或者碱。适合的pH调节剂可包括但不限于氨甲基丙醇、盐酸、硫酸、柠檬酸、乙酸、甲酸、磷酸、酒石酸和三乙醇胺。
在本文可交换使用的术语“蛋白质系统”、“蛋白质组分”和“多蛋白复合物”,指一种或多种美容上可接受的可溶性蛋白质组分。此类蛋白质组分可包括但不限于一种或多种药物可接受的可溶性蛋白质组分,其包括例如美容上可接受的可溶性蛋白质组分。此类蛋白质组分可包括但不限于一种或多种药物可接受的可溶性蛋白质组份。此类蛋白质组分可包括乳或者乳清来源的美容上可接受的可溶性蛋白质组分。适合的美容上可接受的可溶性蛋白质组分可包括但不限于燕麦仁蛋白质、大豆蛋白质和乳清蛋白质中的一种或多种。适合的美容上可接受的可溶性蛋白质组分还可包括以下的一种或多种:水解乳蛋白质、水解大豆蛋白质、水解玉米蛋白质、水解牛油果蛋白质、水解甜杏仁蛋白质、水解大麦蛋白质、水解大麻籽蛋白质、水解巴西胡桃蛋白质、水解芝麻蛋白质、水解豌豆蛋白质、水解棉籽蛋白质和水解榛仁蛋白质。
适合的蛋白质系统和/或可混合的蛋白质系统可包含以下或者由以下组成:大豆蛋白质、乳清蛋白质和燕麦仁蛋白质。适合的蛋白质系统还可包含大豆蛋白质和乳清蛋白质或者由大豆蛋白质和乳清蛋白质组成。
如本文所用,“护肤剂”指能够保护、治疗易受损的皮肤的任何材料。护肤剂的非限制性实例包括以下的一种或多种:乙酸钙、硫酸铝、辅酶Q10、矿脂、维生素E乙酸酯、丁二醇和/或乙酰酪氨酸和/或脯氨酸和/或氢化植物蛋白和/或三磷酸腺苷和/或水、燕麦(Avenasativa,Oat)仁膳食、燕麦(Avena sativa,Oat)仁蛋白质USP、燕麦(Avena sativa,Oat)仁粉、尿囊素、氢氧化铝凝胶、次硝酸铋、硼酸、炉甘石、可可油、聚二甲基硅氧烷、甘油、高岭土、活性酵母细胞衍生物、鲨鱼肝油、碳酸氢钠、硫磺、乙酸锌、碳酸锌、α-羟基酸、β-羟基酸、α-酮酸、它们的衍生物以及它们的混合物。
如本文所用,术语“盐”指某些成分的盐,所述成分具有与未修饰的化合物相同的活性并且既无生物学方面也无其它方面不需要的活性。可由例如有机酸或者无机酸形成盐。适合的酸的非限制性实例包括乙酸、乙酰水杨酸、己二酸、海藻酸、抗坏血酸、天冬氨酸、苯甲酸、苯磺酸、二磺酸、硼酸、丁酸、樟脑酸、樟脑磺酸、碳酸、柠檬酸、环戊烷丙酸、二葡萄糖酸、十二烷基磺酸、乙磺酸、甲酸、富马酸、甘油酸、甘油磷酸、甘氨酸、葡庚糖酸、葡萄糖酸、谷氨酸、戊二酸、乙醇酸、半硫酸、庚酸、己酸、马尿酸、氢溴酸、盐酸、氢碘酸、羟基乙磺酸、乳酸、马来酸、苹果酸、丙二酸、扁桃酸、甲磺酸、粘酸、萘磺酸、萘甲酸、烟酸、亚硝酸、草酸、壬酸、磷酸、丙酸、糖精、水杨酸、山梨酸、琥珀酸、硫酸、酒石酸、硫氰酸、巯基乙酸、硫代硫酸、对甲苯磺酸、十一烯酸以及天然和合成来源的氨基酸。
如本文所用,术语“防腐剂”指通过抑制细菌和/或真菌和/或通过抑制氧化起作用的任何已知的生物相容性防腐剂。适合的防腐剂可包括但不限于抗微生物剂和/或抗氧化剂。适合的抗微生物剂可包括但不限于苯甲酸酯、苄醇、苯甲酸钠、正烷基二甲基苄基氯化铵、氯苯甘醚、对羟基苯甲酸甲酯、对羟基苯甲酸丙酯、乙基己基甘油、苯氧基乙醇、氯甲酚、山梨酸钾、山梨酸、溴硝丙二醇、甲基氯异噻唑啉酮、甲基异噻唑啉酮、山梨酸酯、丙酸酯和亚硝酸盐。适合的抗氧化剂可包括但不限于维生素C、丁基化羟基甲苯(BHT)、亚硫酸盐和维生素E。
如本文所用,“肽”指天然存在的肽和合成的肽。肽能够促进上皮再形成、FGF/胶原蛋白刺激和细胞增殖(例如,基质重塑、组织修复、损伤愈合)。适合的肽包括但不限于,例如,肉豆蔻酰五肽-11、肉豆蔻酰五肽-8、肉豆蔻酰六肽-4、肉豆蔻酰八肽-1、三肽-1、乙酰基六肽-8、乙酰基二肽-1、己酰基四肽-3、肌肽、谷胱甘肽、海洋寡肽、海洋寡肽、棕榈酰寡肽、人寡肽-1(EGF)、乙酰基四肽-3、棕榈酰四肽-7、乙酰基四肽-5、棕榈酰六肽-14、五肽-3、九肽-1、乙酰基六肽、六肽-11、SH-多肽-15、己酰基二肽-3、乙酰基八肽-3、棕榈酰三肽-5、棕榈酰二肽-5、棕榈酰二肽-6、乙酰基四肽-2以及肉豆蔻酰五肽-17、乙酰基四肽-3。适合的防腐剂可包括任何非甲醛供体防腐剂,包括例如山梨酸钾。
如本文所用,短语“释放甲醛的防腐剂”,指在产物的保存期内释放甲二醇(甲醛的醇形式)的防腐剂。释放甲醛的防腐剂可包括但不限于二甲基-二甲基(DMDM)乙内酰脲、咪唑烷基脲、咪唑烷基脲、六亚甲基四胺、季铵-15、2-溴-2-硝基丙烷-1,3-二醇、三(羟甲基)硝基甲烷和羟甲基甘氨酸钠。
如本文所用,术语“易受损的皮肤”,指表示皮肤完整性受损的皮肤。此类受损皮肤可包括易受损的的面部皮肤以及手、颈部和/或胸部的皮肤。皮肤完整性受损可由皮肤损坏、皮肤操作、皮肤刺激、皮肤炎症、皮肤灼伤(例如,晒伤)、由疾病或者病症(例如,酒渣鼻、痤疮、湿疹、带状疱疹、水痘等)引起的慢性皮肤病况、过敏性接触性皮炎(例如,由于暴露于含有漆酚(例如,毒葛、毒栎和毒漆树)的漆树属的植物)、异位性皮炎引起,或者可以是治疗过程中的皮肤病副作用。
如本文所用,术语“皮肤操作”指用于治疗皮肤的任何操作,并且可包括但不限于例如一种或多种皮肤恢复操作。皮肤恢复操作可包括皮肤表面重修操作,包括例如化学脱皮、激光表面重修和擦皮术或者真皮刨平。激光表面重修可包括烧蚀激光治疗(CO2激光、点阵式CO2激光)、铒激光表面重修、非烧蚀激光治疗或者它们的组合。其它皮肤操作可包括基于非激光的治疗(IPL,红外线治疗)、等离子体表面重修治疗(PORTRAIT)以及基于热射频的治疗中的一种或多种。
化学脱皮可包括但不限于例如乙醇酸脱皮、三氯乙酸脱皮和苯酚脱皮。
烧蚀激光表面重修治疗可包括但不限于点阵式CO2表面重修、具有ER:YAG激光的铒激光治疗和烧蚀点阵式表面重修治疗。点阵式CO2表面重修和铒激光治疗被用于治疗深度皱纹、晒伤和老年斑。点阵激光光热作用(FP)提供与CO2激光类似的结果,但是结疤的风险更低并且停机时间更短。
非烧蚀激光治疗可包括但不限于非烧蚀激光点阵式表面重修和脉冲染料激光治疗。
基于非激光的治疗可包括但不限于强脉冲光(IPL)治疗、红外线治疗和光动力治疗。强脉冲光(IPL)采用宽的光谱,与由激光器发射的单波长相反。
如本文所用,术语“操作后反应”指由皮肤操作引起的任何反应。此类反应可包括以下的一种或多种:炎症、刺激、发红(红斑)、肿胀、水肿、损伤渗出物、变色、皮肤增白、色素沉着过度、伤疤、挫伤、发痒(瘙痒)、刺痛、疱疹感染活化、细菌感染、水疱、斑疤、粟粒疹形成和痤疮。
如本文所用,术语“操作后的皮肤”指已经经过如本文所述的皮肤操作的皮肤。
本文所述的局部组合物中的一种或多种可局部施用于患者的皮肤,以治疗以下的一种或多种:易受损的皮肤;操作后的皮肤;皮肤刺激;皮肤炎症;皮肤损伤;皮肤灼伤和皮肤晒伤。
易受损的皮肤、操作后的皮肤、烧伤的皮肤和/或损伤的皮肤可表现出以下的一种或多种:皮肤刺激、皮肤炎症、肿胀、发红、斑疤、发痒和疼痛。
皮肤刺激和/或皮肤炎症还可由以下的一种或多种引起:操作;过敏反应;与皮肤刺激剂接触,例如毒葛、毒栎、毒漆树、蚊虫叮咬、皂、洗剂、化妆品和/或金属(金属首饰);感染;诸如痤疮治疗(例如,局部类维生素A或者口服类维生素A、乙酰水杨酸、过氧化苯甲酰等)的皮肤治疗;以及创伤。
如本文所用的短语“基本上纯的”指单独的化合物形式,其基本上没有其它所有的形式和降解产物的形式以及任何残余溶剂,并且以重量%计至少为85%纯,除非另外说明。化合物形式可具有以重量%计至少为93%的纯度、以重量%计至少为95%的纯度或者以重量%计至少为97%的纯度。如本文所用,基本上纯的指用于局部组合物中的食品级成分。
如本文所用,“对象”或者“个体”或者“动物”或者“患者”或者“哺乳动物”,指需要诊断、预后或者治疗的任何对象(特别是哺乳动物对象),例如人。
如本文所用,疾病、病症或者病况的“治疗(treatment)”或者“治疗(treating)”涵盖减轻其中的至少一种症状、降低其严重程度或者延迟或者抑制其进展。治疗并不需要意指完全治愈疾病、病症或者病况。本文所用的组合物仅需要降低疾病、病症或者病况的严重程度,降低与其相关的症状的严重程度,对患者或者对象的生活质量提供改善,或者延迟或者抑制疾病、病症或者病况的发作。
如本文所用,短语“上皮再形成”,指在局部使用本文所述的局部生物相容性组合物中的一种或多种时,以比在未使用本文所述的局部生物相容性组合物中的一种或多种时更大的速率促进天然的上皮再形成过程和皮肤(此类皮肤包括例如操作后的皮肤、损伤的皮肤、烧伤的皮肤、受刺激的皮肤和/或发炎的皮肤)的细胞再生。
术语“乳清蛋白质”指在由凝乳酶凝结的牛乳乳清中所发现的可溶性蛋白质,其实例包括α-乳白蛋白、乳球蛋白和乳铁蛋白。本文所述的局部组合物可包含乳清蛋白质或者可不含乳清蛋白质。
本文所述的任何浓度范围、百分比范围或者比率范围,将被理解为包括范围内的任何整数的浓度、百分比或者比率以及它们的分数,例如整数的十分之一和一百分之一,除非另外指明。
本文所述的与任何物理特性(例如聚合物亚单元、大小或者厚度)有关的任何数字范围,将被理解为包括所述范围内的任何整数,除非另外指明。
应当理解,如以上以及本文别处所用的术语“一个/一种(a)”和“一个/一种(an)”指所枚举组分的“一个/一种或者多个/多种”。本领域的技术人员应当清楚,单数的用途包括复数,除非另外具体说明。因此,术语“一个/一种(a)”、“一个/一种(an)”和“至少一个/至少一种”在本申请中可互换使用。例如,“一种”收敛性组分指一种收敛性组分或者包含两种或者更多种收敛性组分的混合物。
除非另外指明,用于说明书和权利要求中的表达数量、百分比或者比例的所有数字以及其它数值,将被理解为在所有情况下以术语“约”加以修饰。因此,除非相反地指明,在以下说明书和所附权利要求中所述的数字参数是可根据试图获得的所需性能进行变化的近似值。
在本申请、各种实施方案的描述中使用术语“包含”,例如针对本文所述的组合物的实施方案,例如,生物相容性局部组合物、局部生物相容性组合物、局部损伤愈合组合物、局部舒缓组合物、表皮/真皮修复组合物、表皮/真皮损伤愈合组合物、表皮/真皮损伤愈合/修复组合物、操作后生物相容性局部组合物和表皮修复组合物;然而,本领域的技术人员能够理解,在一些具体实例中,可选择性地使用用语“基本上由…组成”或者“由…组成”来描述实施方案。可交替使用本文所述的术语“包含”或“基本上由…组成”,该用语表明本文所述的局部损伤愈合组合物还可包含一种或多种赋形剂、辅料、载体、媒介物和/或杂质等,诸如溶剂、增稠剂、湿润剂、乳化剂、抗菌剂、抗微生物剂、抗真菌剂、润肤剂、乳化试剂、皮肤保护活性剂、中和剂、防腐剂、胶原蛋白刺激剂、DNA保护剂、保湿试剂、大豆磷脂、DNA修复剂和皮肤调理剂等。
如本文所用的其它术语、短语或用语意在由本领域所熟知的含义来定义。
局部生物相容性组合物
本文所述的局部生物相容性组合物包括,例如,局部治愈组合物(包括例如收敛性溶液粉末)、局部舒缓组合物和表皮修复组合物。
可以以任何形式提供本文所述的局部生物相容性组合物,所述任意形式包括但不限于凝胶、乳膏剂、洗剂、软膏剂、泡沫剂、气雾剂、粉末、溶液、乳液和浆液。
局部损伤愈合组合物
可以以任何形式提供本文所述的局部损伤愈合组合物。例如,当与水混合形成溶液时,可以以水溶性的、可流动粉末的形式提供局部损伤愈合组合物,当施用于易受损的皮肤时,溶液可缓和刺激、减轻炎症、防止斑疤和/或可防止或者改善操作后反应。
本文所述的局部损伤愈合组合物可通过形成皮肤屏障提供舒缓刺激、有效的减轻刺激,以帮助保护易受损的皮肤和帮助使从易受损的皮肤经皮流失的水分的增加最小化,并且可使该皮肤与水化合以防止斑疤和结皮。当施用于皮肤时,局部损伤愈合组合物可以是不可见的,或者基本上不可见的。添加的抗微生物作用可保护易受损的皮肤免受感染。乳清蛋白质促进皮肤恢复,而燕麦蛋白质和大豆蛋白质可防止发红和刺激。壳聚糖可在恢复过程中防止斑疤和结皮。结合的这些多模式生物效应帮助加速损伤愈合过程并且使操作后的恢复时间最小。
本文所述的局部损伤愈合组合物可包含一种或多种收敛剂,或者由一种或多种收敛剂组成。一种或多种收敛剂可在所述局部生物相容性组合物中以以下的量存在:例如,约20wt%至约95wt%;约40wt%至约90wt%;约60wt%至约90wt%;约70wt%至约85wt%;约75wt%至约83wt%;约78%至约81wt%;约75wt%、约76wt%、约77wt%、约78wt%、约79wt%、约80wt%、约81wt%、约82wt%、约83wt%、约84wt%或者约85wt%。
局部损伤愈合组合物还可包含一种或多种蛋白质、蛋白质复合物和/或壳聚糖。蛋白质复合物可包含蛋白质或者由蛋白质组成,所述蛋白质例如燕麦(Avena Sativa,Oat)仁蛋白质USP、可溶性大豆蛋白质和/或乳清蛋白质。
根据本文的主题,一种或多种蛋白质可以是具有特定蛋白质含量的食品级蛋白质。一种或多种蛋白质可基本上是纯的,如以上本文所述。例如,燕麦仁可具有存在的蛋白质重量的约>10%的特定蛋白质含量。大豆蛋白质可以是具有约>5%(TBC)的特定蛋白质含量的单独的大豆食品/饮料级蛋白质。乳清蛋白质可以是具有>80%的特定蛋白质含量的食品/饮料级乳清蛋白质。
可用于局部愈合组合物中的燕麦蛋白质的一个实例为#11-080。燕麦蛋白质可具有约为大于约10重量%、12.50重量%或者19.00重量%燕麦蛋白质的特定蛋白质含量。燕麦蛋白质的脂肪含量可以大于5.00%、6.00%或者9.00%。燕麦可任选地包括例如约0.01%或者更多的量的灰分脂肪或者碳水化合物。
可用于本发明的组合物中的大豆蛋白质的一个实例为CLARISOYTM100。大豆蛋白质可以是微粒化的大豆蛋白质。大豆蛋白质可以是在溶解时形成基本上透明的溶液的水溶性大豆蛋白质。大豆蛋白质可以是100%水溶的。
根据本文主题的乳清蛋白质的实例为AVONLACTM 182GLC。乳清蛋白质可包括80重量%或者更多的特定蛋白质。
用于局部损伤愈合组合物中的任何蛋白质或者蛋白质复合物还可包括维生素、氨基酸、水分、脂肪、矿物质、糖类等。例如,蛋白质可包括维生素,其包括但不限于例如维生素A、维生素B1、维生素B3、维生素B6、维生素B7、维生素B9、维生素B12、维生素C、维生素D、维生素E、维生素K。此外,用于本文的蛋白质中的氨基酸可包括,例如,甘氨酸、丙氨酸、缬氨酸、亮氨酸、异亮氨酸、丝氨酸、半胱氨酸、硒代半胱氨酸、苏氨酸、蛋氨酸、脯氨酸、苯丙氨酸、酪氨酸、色氨酸、组氨酸、赖氨酸、精氨酸、天冬氨酸、谷氨酸、天冬酰胺和谷氨酰胺。
一种或多种蛋白质和/或蛋白质复合物中的每一种都可在局部损伤愈合组合物中以以下的量存在:例如,0.01wt%至约10wt%;0.01wt%至约9wt%;0.01wt%至约8wt%;0.01wt%至约7wt%;0.01wt%至约6wt%;0.01wt%至约5wt%;0.01wt%至约4.5wt%;0.01wt%至约4wt%;0.01wt%至约3.5wt%;0.01wt%至约3wt%;0.01wt%至约2.5wt%;0.01wt%至约2wt%;0.01wt%至约2.25wt%;0.01wt%至约2wt%;约0.01%至约4wt%;约0.01wt%至约3wt%;约0.01wt%至约2.5wt%;约0.01wt%至约2.25wt%;约0.01wt%至约2wt%;约0.01wt%至约1.5wt%;约0.01wt%至约1wt%;约0.01wt%至约0.5wt%;0.25wt%至约30wt%;0.25wt%至约25wt%;0.25wt%至约20wt%;0.25wt%至约15wt%;0.25wt%至约10wt%;0.25wt%至约9wt%;0.25wt%至约8wt%;0.25wt%至约7wt%;0.25wt%至约6wt%;0.25wt%至约5wt%;0.25wt%至约4.5wt%;0.25wt%至约4wt%;0.25wt%至约3.5wt%;0.25wt%至约3wt%;0.25wt%至约2.5wt%;0.25wt%至约2wt%;0.25wt%至约2.25wt%;0.25wt%至约1.75wt%;0.1wt%至约10wt%;0.1wt%至约9wt%;0.1wt%至约8wt%;0.1wt%至约7wt%;0.1wt%至约6wt%;0.1wt%至约5wt%;0.1wt%至约4.5wt%;0.1wt%至约4wt%;0.1wt%至约3.5wt%;0.1wt%至约3wt%;0.1wt%至约2.5wt%;0.1wt%至约2wt%;0.1wt%至约2.25wt%;0.1wt%至约2wt%;约0.1%至约4wt%;约0.1wt%至约3wt%;约0.1wt%至约2.5wt%;约0.1wt%至约2.25wt%;约0.1wt%至约2wt%;约0.1wt%至约1.5wt%;约0.1wt%至约1wt%;约0.1wt%至约0.5wt%;0.25wt%至约30wt%;0.25wt%至约25wt%;0.25wt%至约20wt%;0.25wt%至约15wt%;0.25wt%至约10wt%;0.25wt%至约9wt%;0.25wt%至约8wt%;0.25wt%至约7wt%;0.25wt%至约6wt%;0.25wt%至约5wt%;0.25wt%至约4.5wt%;0.25wt%至约4wt%;0.25wt%至约3.5wt%;0.25wt%至约3wt%;0.25wt%至约2.5wt%;0.25wt%至约2wt%;0.25wt%至约2.25wt%;0.25wt%至约1.75wt%;0.5wt%至约10wt%;0.5wt%至约9wt%;0.5wt%至约8wt%;0.5wt%至约7wt%;0.5wt%至约6wt%;0.5wt%至约5wt%;0.5wt%至约4.5wt%;0.5wt%至约4wt%;0.5wt%至约3.5wt%;0.5wt%至约3wt%;0.5wt%至约2.5wt%;0.5wt%至约2wt%;0.5wt%至约2.25wt%;0.5wt%至约2wt%;约0.5%至约4wt%;约0.5wt%至约3wt%;约0.5wt%至约2.5wt%;约0.5wt%至约2.25wt%;约0.5wt%至约2wt%;约0.5wt%至约1.5wt%;约0.5wt%至约1wt%;0.7wt%至约10wt%;0.7wt%至约9wt%;0.7wt%至约8wt%;0.7wt%至约7wt%;0.7wt%至约6wt%;0.7wt%至约5wt%;0.7wt%至约4.5wt%;0.7wt%至约4wt%;0.7wt%至约3.5wt%;0.7wt%至约3wt%;0.7wt%至约2.5wt%;0.7wt%至约2wt%;0.7wt%至约2.25wt%;0.7wt%至约2wt%;约0.7%至约4wt%;约0.7wt%至约3wt%;约0.7wt%至约2.5wt%;约0.7wt%至约2.25wt%;约0.7wt%至约2wt%;约0.7wt%至约1.5wt%;约0.7wt%至约1wt%;0.9wt%至约10wt%;0.9wt%至约9wt%;0.9wt%至约8wt%;0.9wt%至约7wt%;0.9wt%至约6wt%;0.9wt%至约5wt%;0.9wt%至约4.5wt%;0.9wt%至约4wt%;0.9wt%至约3.5wt%;0.9wt%至约3wt%;0.9wt%至约2.5wt%;0.9wt%至约2wt%;0.9wt%至约2.25wt%;0.9wt%至约2wt%;约0.9%至约4wt%;约0.9wt%至约3wt%;约0.9wt%至约2.5wt%;约0.9wt%至约2.25wt%;约0.9wt%至约2wt%;约0.9wt%至约1.5wt%;约0.9wt%至约1wt%;1wt%至约10wt%;1wt%至约9wt%;1wt%至约8wt%;1wt%至约7wt%;1wt%至约6wt%;1wt%至约5wt%;1wt%至约4.5wt%;1wt%至约4wt%;1wt%至约3.5wt%;1wt%至约3wt%;1wt%至约2.5wt%;1wt%至约2wt%;1wt%至约2.25wt%;1wt%至约2wt%;约1%至约4wt%;约1wt%至约3wt%;约1wt%至约2.5wt%;约1wt%至约2.25wt%;约1wt%至约2wt%;约1wt%至约1.5wt%;约1.5wt%至约10wt%;约1.5wt%至约9wt%;约1.5wt%至约8wt%;约1.5wt%至约7wt%;约1.5wt%至约6wt%;约1.5wt%至约5wt%;约1.5wt%至约4.5wt%;约1.5wt%至约4wt%;约1.5wt%至约3.5wt%;约1.5wt%至约3wt%;约1.5wt%至约2.5wt%;约1.5wt%至约2.25wt%;约1.5wt%至约2wt%;或者以任何以上范围内的任何其它量。
壳聚糖可在局部损伤愈合组合物中以以下的量存在:>0.01wt%至约50wt%;>0.01wt%至约20wt%;>0.01wt%至约10wt%;0.01wt%至约9wt%;0.01wt%至约8wt%;0.01wt%至约7wt%;0.01wt%至约6wt%;0.01wt%至约5wt%;0.01wt%至约4.5wt%;0.01wt%至约4wt%;0.01wt%至约3.5wt%;0.01wt%至约3wt%;0.01wt%至约2.5wt%;0.01wt%至约2wt%;0.01wt%至约2.25wt%;0.01wt%至约2wt%;约0.01%至约4wt%;约0.01wt%至约3wt%;约0.01wt%至约2.5wt%;约0.01wt%至约2.25wt%;约0.01wt%至约2wt%;约0.01wt%至约1.5wt%;约0.01wt%至约1wt%;约0.01wt%至约0.5wt%;0.25wt%至约30wt%;0.25wt%至约25wt%;0.25wt%至约20wt%;0.25wt%至约15wt%;0.25wt%至约10wt%;0.25wt%至约9wt%;0.25wt%至约8wt%;0.25wt%至约7wt%;0.25wt%至约6wt%;0.25wt%至约5wt%;0.25wt%至约4.5wt%;0.25wt%至约4wt%;0.25wt%至约3.5wt%;0.25wt%至约3wt%;0.25wt%至约2.5wt%;0.25wt%至约2wt%;0.25wt%至约2.25wt%;0.25wt%至约1.75wt%;0.1wt%至约10wt%;0.1wt%至约9wt%;0.1wt%至约8wt%;0.1wt%至约7wt%;0.1wt%至约6wt%;0.1wt%至约5wt%;0.1wt%至约4.5wt%;0.1wt%至约4wt%;0.1wt%至约3.5wt%;0.1wt%至约3wt%;0.1wt%至约2.5wt%;0.1wt%至约2wt%;0.1wt%至约2.25wt%;0.1wt%至约2wt%;约0.1%至约4wt%;约0.1wt%至约3wt%;约0.1wt%至约2.5wt%;约0.1wt%至约2.25wt%;约0.1wt%至约2wt%;约0.1wt%至约1.5wt%;约0.1wt%至约1wt%;约0.1wt%至约0.5wt%;0.25wt%至约50wt%;0.7wt%至约10wt%;0.7wt%至约9wt%;0.7wt%至约8wt%;0.7wt%至约7wt%;0.7wt%至约6wt%;0.7wt%至约5wt%;0.7wt%至约4.5wt%;0.7wt%至约4wt%;0.7wt%至约3.5wt%;0.7wt%至约3wt%;0.7wt%至约2.5wt%;0.7wt%至约2wt%;0.7wt%至约2.25wt%;0.7wt%至约2wt%;约0.7%至约4wt%;约0.7wt%至约3wt%;约0.7wt%至约2.5wt%;约0.7wt%至约2.25wt%;约0.7wt%至约2wt%;约0.7wt%至约1.5wt%;约0.7wt%至约1wt%;0.9wt%至约10wt%;0.9wt%至约9wt%;0.9wt%至约8wt%;0.9wt%至约7wt%;0.9wt%至约6wt%;0.9wt%至约5wt%;0.9wt%至约4.5wt%;0.9wt%至约4wt%;0.9wt%至约3.5wt%;0.9wt%至约3wt%;0.9wt%至约2.5wt%;0.9wt%至约2wt%;0.9wt%至约2.25wt%;0.9wt%至约2wt%;约0.9%至约4wt%;约0.9wt%至约3wt%;约0.9wt%至约2.5wt%;约0.9wt%至约2.25wt%;约0.9wt%至约2wt%;约0.9wt%至约1.5wt%;约0.9wt%至约1wt%;1wt%至约10wt%;1wt%至约9wt%;1wt%至约8wt%;1wt%至约7wt%;1wt%至约6wt%;1wt%至约5wt%;1wt%至约4.5wt%;1wt%至约4wt%;1wt%至约3.5wt%;1wt%至约3wt%;1wt%至约2.5wt%;1wt%至约2wt%;1wt%至约2.25wt%;1wt%至约2wt%;约1%至约4wt%;约1wt%至约3wt%;约1wt%至约2.5wt%;约1wt%至约2.25wt%;约1wt%至约2wt%;约1wt%至约1.5wt%;约1.5wt%至约10wt%;约1.5wt%至约9wt%;约1.5wt%至约8wt%;约1.5wt%至约7wt%;约1.5wt%至约6wt%;约1.5wt%至约5wt%;约1.5wt%至约4.5wt%;约1.5wt%至约4wt%;约1.5wt%至约3.5wt%;约1.5wt%至约3wt%;约1.5wt%至约2.5wt%;约1.5wt%至约2.25wt%;约1.5wt%至约2wt%;约3wt%至约10wt%;或者以任何以上范围内的任何其它量。
局部损伤愈合组合物还可包括填充剂或者载体,例如糊精。填充剂或者载体,例如糊精,可在损伤愈合组合物中以以下的量存在:0.01wt%至约50wt%;0.01wt%至约30wt%;0.01wt%至约25wt%;0.01wt%至约20wt%;0.01wt%至约15wt%;0.01wt%至约10wt%;0.01wt%至约9wt%;0.01wt%至约8wt%;0.01wt%至约7wt%;0.01wt%至约6wt%;0.01wt%至约5wt%;0.01wt%至约4.5wt%;0.01wt%至约4wt%;0.01wt%至约3.5wt%;0.01wt%至约3wt%;0.01wt%至约2.5wt%;0.01wt%至约2wt%;0.01wt%至约2.25wt%;0.01wt%至约2wt%;约0.01%至约4wt%;约0.01wt%至约3wt%;约0.01wt%至约2.5wt%;约0.01wt%至约2.25wt%;约0.01wt%至约2wt%;约0.01wt%至约1.5wt%;约0.01wt%至约1wt%;约0.01wt%至约0.5wt%;0.1wt%至约30wt%;0.1wt%至约25wt%;0.1wt%至约20wt%;0.1wt%至约15wt%;0.1wt%至约10wt%;0.1wt%至约9wt%;0.1wt%至约8wt%;0.1wt%至约7wt%;0.1wt%至约6wt%;0.1wt%至约5wt%;0.1wt%至约4.5wt%;0.1wt%至约4wt%;0.1wt%至约3.5wt%;0.1wt%至约3wt%;0.1wt%至约2.5wt%;0.1wt%至约2wt%;0.1wt%至约2.25wt%;0.1wt%至约2wt%;约0.1%至约4wt%;约0.1wt%至约3wt%;约0.1wt%至约2.5wt%;约0.1wt%至约2.25wt%;约0.1wt%至约2wt%;约0.1wt%至约1.5wt%;约0.1wt%至约1wt%;约0.1wt%至约0.5wt%;0.25wt%至约30wt%;0.25wt%至约25wt%;0.25wt%至约20wt%;0.25wt%至约15wt%;0.25wt%至约10wt%;0.25wt%至约9wt%;0.25wt%至约8wt%;0.25wt%至约7wt%;0.25wt%至约6wt%;0.25wt%至约5wt%;0.25wt%至约4.5wt%;0.25wt%至约4wt%;0.25wt%至约3.5wt%;0.25wt%至约3wt%;0.25wt%至约2.5wt%;0.25wt%至约2wt%;0.25wt%至约2.25wt%;0.25wt%至约1.75wt%;0.5wt%至约30wt%;0.5wt%至约25wt%;0.5wt%至约20wt%;0.5wt%至约15wt%;0.5wt%至约10wt%;0.5wt%至约9wt%;0.5wt%至约8wt%;0.5wt%至约7wt%;0.5wt%至约6wt%;0.5wt%至约5wt%;0.5wt%至约4.5wt%;0.5wt%至约4wt%;0.5wt%至约3.5wt%;0.5wt%至约3wt%;0.5wt%至约2.5wt%;0.5wt%至约2wt%;0.5wt%至约2.25wt%;0.5wt%至约2wt%;约0.5%至约4wt%;约0.5wt%至约3wt%;约0.5wt%至约2.5wt%;约0.5wt%至约2.25wt%;约0.5wt%至约2wt%;约0.5wt%至约1.5wt%;约0.5wt%至约1wt%;0.7wt%至约20wt%;0.7wt%至约10wt%;0.7wt%至约9wt%;0.7wt%至约8wt%;0.7wt%至约7wt%;0.7wt%至约6wt%;0.7wt%至约5wt%;0.7wt%至约4.5wt%;0.7wt%至约4wt%;0.7wt%至约3.5wt%;0.7wt%至约3wt%;0.7wt%至约2.5wt%;0.7wt%至约2wt%;0.7wt%至约2.25wt%;0.7wt%至约2wt%;约0.7%至约4wt%;约0.7wt%至约3wt%;约0.7wt%至约2.5wt%;约0.7wt%至约2.25wt%;约0.7wt%至约2wt%;约0.7wt%至约1.5wt%;约0.7wt%至约1wt%;0.9wt%至约20;0.9wt%至约10wt%;0.9wt%至约9wt%;0.9wt%至约8wt%;0.9wt%至约7wt%;0.9wt%至约6wt%;0.9wt%至约5wt%;0.9wt%至约4.5wt%;0.9wt%至约4wt%;0.9wt%至约3.5wt%;0.9wt%至约3wt%;0.9wt%至约2.5wt%;0.9wt%至约2wt%;0.9wt%至约2.25wt%;0.9wt%至约2wt%;约0.9%至约4wt%;约0.9wt%至约3wt%;约0.9wt%至约2.5wt%;约0.9wt%至约2.25wt%;约0.9wt%至约2wt%;约0.9wt%至约1.5wt%;约0.9wt%至约1wt%;1wt%至约30wt%;1wt%至约20wt%;1wt%至约10wt%;1wt%至约9wt%;1wt%至约8wt%;1wt%至约7wt%;1wt%至约6wt%;1wt%至约5wt%;1wt%至约4.5wt%;1wt%至约4wt%;1wt%至约3.5wt%;1wt%至约3wt%;1wt%至约2.5wt%;1wt%至约2wt%;1wt%至约2.25wt%;1wt%至约2wt%;约1%至约4wt%;约1wt%至约3wt%;约1wt%至约2.5wt%;约1wt%至约2.25wt%;约1wt%至约2wt%;约1wt%至约1.5wt%;约1.5wt%至约30wt%;约1.5wt%至约20wt%;约1.5wt%至约10wt%;约1.5wt%至约9wt%;约1.5wt%至约8wt%;约1.5wt%至约7wt%;约1.5wt%至约6wt%;约1.5wt%至约5wt%;约1.5wt%至约4.5wt%;约1.5wt%至约4wt%;约1.5wt%至约3.5wt%;约1.5wt%至约3wt%;约1.5wt%至约2.5wt%;约1.5wt%至约2.25wt%;约1.5wt%至约2wt%;约3wt%至约30wt%;约3wt%至约20wt%;约3wt%至约10wt%;约3wt%至约9wt%;约3wt%至约8wt%;约3wt%至约7wt%;约3wt%至约6wt%;约3wt%至约5wt%;约3wt%至约4.5wt%;约3wt%至约4wt%;约3wt%至约3.5wt%;约9wt%、约10wt%;约11wt%、约12wt%、约13wt%;约14wt%或者约15wt%,或者以任何以上范围内的任何其它量。
本文所述的局部损伤愈合组合物还可包括pH调节剂、着色剂和/或非释放甲醛防腐剂。所述pH调节剂、着色剂和/或非释放甲醛防腐剂中的每一种都可在所述局部生物相容性组合物中以以下的量存在:例如,约0.01wt%至约10wt%;0.01wt%至约9wt%;0.01wt%至约8wt%;0.01wt%至约7wt%;0.01wt%至约6wt%;0.01wt%至约5wt%;0.01wt%至约4.5wt%;0.01wt%至约4wt%;0.01wt%至约3.5wt%;0.01wt%至约3wt%;0.01wt%至约2.5wt%;0.01wt%至约2wt%;0.01wt%至约2.25wt%;0.01wt%至约2wt%;约0.01%至约4wt%;约0.01wt%至约3wt%;约0.01wt%至约2.5wt%;约0.01wt%至约2.25wt%;约0.01wt%至约2wt%;约0.01wt%至约1.5wt%;约0.01wt%至约1wt%;约0.01wt%至约0.5wt%;0.1wt%至约10wt%;0.1wt%至约9wt%;0.1wt%至约8wt%;0.1wt%至约7wt%;0.1wt%至约6wt%;0.1wt%至约5wt%;0.1wt%至约4.5wt%;0.1wt%至约4wt%;0.1wt%至约3.5wt%;0.1wt%至约3wt%;0.1wt%至约2.5wt%;0.1wt%至约2wt%;0.1wt%至约2.25wt%;0.1wt%至约2wt%;约0.1%至约4wt%;约0.1wt%至约3wt%;约0.1wt%至约2.5wt%;约0.1wt%至约2.25wt%;约0.1wt%至约2wt%;约0.1wt%至约1.5wt%;约0.1wt%至约1wt%;约0.1wt%至约0.5wt%;0.25wt%至约30wt%;0.25wt%至约25wt%;0.25wt%至约20wt%;0.25wt%至约15wt%;0.25wt%至约10wt%;0.25wt%至约9wt%;0.25wt%至约8wt%;0.25wt%至约7wt%;0.25wt%至约6wt%;0.25wt%至约5wt%;0.25wt%至约4.5wt%;0.25wt%至约4wt%;0.25wt%至约3.5wt%;0.25wt%至约3wt%;0.25wt%至约2.5wt%;0.25wt%至约2wt%;0.25wt%至约2.25wt%;0.25wt%至约1.75wt%;0.5wt%至约10wt%;0.5wt%至约9wt%;0.5wt%至约8wt%;0.5wt%至约7wt%;0.5wt%至约6wt%;0.5wt%至约5wt%;0.5wt%至约4.5wt%;0.5wt%至约4wt%;0.5wt%至约3.5wt%;0.5wt%至约3wt%;0.5wt%至约2.5wt%;0.5wt%至约2wt%;0.5wt%至约2.25wt%;0.5wt%至约2wt%;约0.5%至约4wt%;约0.5wt%至约3wt%;约0.5wt%至约2.5wt%;约0.5wt%至约2.25wt%;约0.5wt%至约2wt%;约0.5wt%至约1.5wt%;约0.5wt%至约1wt%;0.7wt%至约10wt%;0.7wt%至约9wt%;0.7wt%至约8wt%;0.7wt%至约7wt%;0.7wt%至约6wt%;0.7wt%至约5wt%;0.7wt%至约4.5wt%;0.7wt%至约4wt%;0.7wt%至约3.5wt%;0.7wt%至约3wt%;0.7wt%至约2.5wt%;0.7wt%至约2wt%;0.7wt%至约2.25wt%;0.7wt%至约2wt%;约0.7%至约4wt%;约0.7wt%至约3wt%;约0.7wt%至约2.5wt%;约0.7wt%至约2.25wt%;约0.7wt%至约2wt%;约0.7wt%至约1.5wt%;约0.7wt%至约1wt%;0.9wt%至约10wt%;0.9wt%至约9wt%;0.9wt%至约8wt%;0.9wt%至约7wt%;0.9wt%至约6wt%;0.9wt%至约5wt%;0.9wt%至约4.5wt%;0.9wt%至约4wt%;0.9wt%至约3.5wt%;0.9wt%至约3wt%;0.9wt%至约2.5wt%;0.9wt%至约2wt%;0.9wt%至约2.25wt%;0.9wt%至约2wt%;约0.9%至约4wt%;约0.9wt%至约3wt%;约0.9wt%至约2.5wt%;约0.9wt%至约2.25wt%;约0.9wt%至约2wt%;约0.9wt%至约1.5wt%;约0.9wt%至约1wt%;1wt%至约10wt%;1wt%至约9wt%;1wt%至约8wt%;1wt%至约7wt%;1wt%至约6wt%;1wt%至约5wt%;1wt%至约4.5wt%;1wt%至约4wt%;1wt%至约3.5wt%;1wt%至约3wt%;1wt%至约2.5wt%;1wt%至约2wt%;1wt%至约2.25wt%;1wt%至约2wt%;约1%至约4wt%;约1wt%至约3wt%;约1wt%至约2.5wt%;约1wt%至约2.25wt%;约1wt%至约2wt%;约1wt%至约1.5wt%;约1.5wt%至约10wt%;约1.5wt%至约9wt%;约1.5wt%至约8wt%;约1.5wt%至约7wt%;约1.5wt%至约6wt%;约1.5wt%至约5wt%;约1.5wt%至约4.5wt%;约1.5wt%至约4wt%;约1.5wt%至约3.5wt%;约1.5wt%至约3wt%;约1.5wt%至约2.5wt%;约1.5wt%至约2.25wt%;约1.5wt%至约2wt%;约3wt%至约10wt%;约3wt%至约9wt%;约3wt%至约8wt%;约3wt%至约7wt%;约3wt%至约6wt%;约3wt%至约5wt%;约3wt%至约4.5wt%;约3wt%至约4wt%;约3wt%至约3.5wt%;约0.9wt%;约1wt%或者约1.1wt%,或者以任何以上范围内的任何其它量。
本文所述的局部损伤愈合组合物可以不含有以下的一种或多种:谷蛋白;维生素D;生长激素;对羟基苯甲酸酯;EU26芳香过敏原和释放甲醛的防腐剂。
任选地,局部损伤愈合组合物也可包含载体、溶剂、增稠剂、湿润剂、乳化剂、抗菌剂、抗微生物剂、抗真菌剂、润肤剂、乳化试剂、皮肤保护活性剂、中和剂、防腐剂、胶原蛋白刺激剂、DNA保护剂、保湿试剂、大豆磷脂、DNA修复剂和皮肤调理剂的一种或多种。
局部舒缓组合物
局部舒缓组合物可以是提供多功能水合作用和脂质补充以恢复受破坏的屏障功能或者其它易受损的皮肤的软膏剂。局部舒缓组合物可以是抗刺激剂,所述抗刺激剂可以例如在愈合/恢复过程中抑制炎症反应以提高舒适度。此外,局部舒缓组合物可保护易受损的皮肤或者暴露的皮肤免受环境攻击者的伤害。
此外,局部舒缓组合物可促进细胞再生以及葡糖氨基葡聚糖的合成、维持皮肤水合作用、恢复屏障功能、缓和受刺激的皮肤或者其它易受损的皮肤、减轻结皮/斑疤和/或增强DNA修复和保护。
局部舒缓组合物可包括延长释放组分或者延时释放组分,包括例如用于氧化应激保护的一种或多种延时释放抗氧化剂组分或者延长释放抗氧化剂组分。
局部舒缓组合物可包含一种或多种组分,所述组分包括但不限于糖胺聚糖(GAG)刺激剂、抗炎剂、抗氧化剂和DNA修复组分。
修复易受损的皮肤的GAG刺激剂可以是刺激糖胺聚糖的任何物质。例如,GAG刺激剂可以是乙酰氨基葡萄糖磷酸二钠(DAGP)。
一种或多种GAG刺激剂可在局部舒缓组合物中以以下的量存在:例如,>0.01wt%至约3wt%;>0.01wt%至约1wt%;>0.05wt%至约3wt%;>0.05wt%至约1wt%;约0.05wt%至约0.5wt%;约0.07wt%至约0.4wt%;约0.08wt%至约0.4wt%;约0.08wt%至约0.35wt%;约0.08wt%至约0.3wt%;约0.08wt%至约0.25wt%;约0.09wt%至约0.4wt%;约0.09wt%至约0.3wt%;约0.09wt%至约0.25wt%;约0.1wt%至约0.25wt%;约0.11wt%至约0.24wt%;约0.12wt%至约0.23wt%;约0.13wt%至约0.22wt%;约0.14wt%至约0.21wt%;或者约0.15wt%至约0.2wt%。
细胞由糖合成聚合物,特别是在N-乙酰基-葡萄糖胺-6-磷酸盐(NAG6P)的基础上合成GAG和透明质酸。DAGP是通过酶促过程获得的分子,并且不是人生长因子。DAGP的二钠部分在皮肤中分离释放N-乙酰基-葡萄糖胺-6-磷酸盐(NAG6P)。GAG负责协助胶原蛋白纤维和弹性蛋白纤维维持水分的能力,而透明质酸(玻璃酸)调节皮肤水分平衡。
如在本文的局部舒缓组合物中所用,当在多至10天或者更久的时间段里以一天一次至五次施用于皮肤时,包含GAG刺激组分的局部组合物的施用可将GAG产量增加多至60%、70%、80%、81%、82%、83%、84%或者85%。此外,在0至48小时的时间段里以一天一次至5次施用包含GAG刺激组分的局部组合物,可将透明质酸的合成增加多至50%、75%、100%、150%、200%、250%、280%、281%、282%、283%、284%或者285%。
用于局部舒缓组合物中的抗炎剂组分或者抗刺激剂组分可包括例如以下的一种或多种:甘蓝(Brassica Oleracea,花椰菜)提取物;向日葵(Helianthus Annuus,葵花)籽油;燕麦(Avena Sativa,Oat)粒粉蛋白质和/或β-葡聚糖。
一种或多种抗炎剂或者抗刺激剂可单独或者组合地在局部舒缓组合物中以以下的量存在:例如,0.01wt%至约30wt%;0.01wt%至约25wt%;0.01wt%至约20wt%;0.01wt%至约15wt%;0.01wt%至约10wt%;0.01wt%至约9wt%;0.01wt%至约8wt%;0.01wt%至约7wt%;0.01wt%至约6wt%;0.01wt%至约5wt%;0.01wt%至约4.5wt%;0.01wt%至约4wt%;0.01wt%至约3.5wt%;0.01wt%至约3wt%;0.01wt%至约2.5wt%;0.01wt%至约2wt%;0.01wt%至约2.25wt%;0.01wt%至约2wt%;约0.01%至约4wt%;约0.01wt%至约3wt%;约0.01wt%至约2.5wt%;约0.01wt%至约2.25wt%;约0.01wt%至约2wt%;约0.01wt%至约1.5wt%;约0.01wt%至约1wt%;约0.01wt%至约0.5wt%;0.1wt%至约30wt%;0.1wt%至约25wt%;0.1wt%至约20wt%;0.1wt%至约15wt%;0.1wt%至约10wt%;0.1wt%至约9wt%;0.1wt%至约8wt%;0.1wt%至约7wt%;0.1wt%至约6wt%;0.1wt%至约5wt%;0.1wt%至约4.5wt%;0.1wt%至约4wt%;0.1wt%至约3.5wt%;0.1wt%至约3wt%;0.1wt%至约2.5wt%;0.1wt%至约2wt%;0.1wt%至约2.25wt%;0.1wt%至约2wt%;约0.1%至约4wt%;约0.1wt%至约3wt%;约0.1wt%至约2.5wt%;约0.1wt%至约2.25wt%;约0.1wt%至约2wt%;约0.1wt%至约1.5wt%;约0.1wt%至约1wt%;约0.1wt%至约0.5wt%;0.25wt%至约30wt%;0.25wt%至约25wt%;0.25wt%至约20wt%;0.25wt%至约15wt%;0.25wt%至约10wt%;0.25wt%至约9wt%;0.25wt%至约8wt%;0.25wt%至约7wt%;0.25wt%至约6wt%;0.25wt%至约5wt%;0.25wt%至约4.5wt%;0.25wt%至约4wt%;0.25wt%至约3.5wt%;0.25wt%至约3wt%;0.25wt%至约2.5wt%;0.25wt%至约2wt%;0.25wt%至约2.25wt%;0.25wt%至约1.75wt%;0.5wt%至约30wt%;0.5wt%至约25wt%;0.5wt%至约20wt%;0.5wt%至约15wt%;0.5wt%至约10wt%;0.5wt%至约9wt%;0.5wt%至约8wt%;0.5wt%至约7wt%;0.5wt%至约6wt%;0.5wt%至约5wt%;0.5wt%至约4.5wt%;0.5wt%至约4wt%;0.5wt%至约3.5wt%;0.5wt%至约3wt%;0.5wt%至约2.5wt%;0.5wt%至约2wt%;0.5wt%至约2.25wt%;0.5wt%至约2wt%;约0.5%至约4wt%;约0.5wt%至约3wt%;约0.5wt%至约2.5wt%;约0.5wt%至约2.25wt%;约0.5wt%至约2wt%;约0.5wt%至约1.5wt%;约0.5wt%至约1wt%;0.7wt%至约20wt%;0.7wt%至约10wt%;0.7wt%至约9wt%;0.7wt%至约8wt%;0.7wt%至约7wt%;0.7wt%至约6wt%;0.7wt%至约5wt%;0.7wt%至约4.5wt%;0.7wt%至约4wt%;0.7wt%至约3.5wt%;0.7wt%至约3wt%;0.7wt%至约2.5wt%;0.7wt%至约2wt%;0.7wt%至约2.25wt%;0.7wt%至约2wt%;约0.7%至约4wt%;约0.7wt%至约3wt%;约0.7wt%至约2.5wt%;约0.7wt%至约2.25wt%;约0.7wt%至约2wt%;约0.7wt%至约1.5wt%;约0.7wt%至约1wt%;0.9wt%至约20;0.9wt%至约10wt%;0.9wt%至约9wt%;0.9wt%至约8wt%;0.9wt%至约7wt%;0.9wt%至约6wt%;0.9wt%至约5wt%;0.9wt%至约4.5wt%;0.9wt%至约4wt%;0.9wt%至约3.5wt%;0.9wt%至约3wt%;0.9wt%至约2.5wt%;0.9wt%至约2wt%;0.9wt%至约2.25wt%;0.9wt%至约2wt%;约0.9%至约4wt%;约0.9wt%至约3wt%;约0.9wt%至约2.5wt%;约0.9wt%至约2.25wt%;约0.9wt%至约2wt%;约0.9wt%至约1.5wt%;约0.9wt%至约1wt%;1wt%至约30wt%;1wt%至约20wt%;1wt%至约10wt%;1wt%至约9wt%;1wt%至约8wt%;1wt%至约7wt%;1wt%至约6wt%;1wt%至约5wt%;1wt%至约4.5wt%;1wt%至约4wt%;1wt%至约3.5wt%;1wt%至约3wt%;1wt%至约2.5wt%;1wt%至约2wt%;1wt%至约2.25wt%;1wt%至约2wt%;约1%至约4wt%;约1wt%至约3wt%;约1wt%至约2.5wt%;约1wt%至约2.25wt%;约1wt%至约2wt%;约1wt%至约1.5wt%;约1.5wt%至约30wt%;约1.5wt%至约20wt%;约1.5wt%至约10wt%;约1.5wt%至约9wt%;约1.5wt%至约8wt%;约1.5wt%至约7wt%;约1.5wt%至约6wt%;约1.5wt%至约5wt%;约1.5wt%至约4.5wt%;约1.5wt%至约4wt%;约1.5wt%至约3.5wt%;约1.5wt%至约3wt%;约1.5wt%至约2.5wt%;约1.5wt%至约2.25wt%;约1.5wt%至约2wt%;约3wt%至约30wt%;约3wt%至约20wt%;约3wt%至约10wt%;约3wt%至约9wt%;约3wt%至约8wt%;约3wt%至约7wt%;约3wt%至约6wt%;约3wt%至约5wt%;约3wt%至约4.5wt%;约3wt%至约4wt%;约3wt%至约3.5wt%;约1wt%、约5wt%;约2wt%、约3wt%、约4wt%;约5wt%或者约6wt%,或者以任何以上范围内的任何其它量。
用于局部舒缓组合物中的一种或多种抗氧化剂可包括,例如包括以下的一种或多种抗氧化剂:例如,泛醌(辅酶Q10);生育酚乙酸酯;抗坏血酸和棕榈酸视黄酯。抗氧化剂组分可包括配制为12小时延时释放胶囊的抗氧化剂复合物。抗氧化剂复合物可包含以下或者由以下组成:聚甲基丙烯酸甲酯和一种或多种生育酚乙酸酯、抗坏血酸和棕榈酸视黄酯或者其它适合的抗氧化剂。
一种或多种抗氧化剂可单独或者组合地在局部舒缓组合物中以以下的量存在:例如,约0.01wt%至约10wt%;0.01wt%至约9wt%;0.01wt%至约8wt%;0.01wt%至约7wt%;0.01wt%至约6wt%;0.01wt%至约5wt%;0.01wt%至约4.5wt%;0.01wt%至约4wt%;0.01wt%至约3.5wt%;0.01wt%至约3wt%;0.01wt%至约2.5wt%;0.01wt%至约2wt%;0.01wt%至约2.25wt%;0.01wt%至约2wt%;约0.01%至约4wt%;约0.01wt%至约3wt%;约0.01wt%至约2.5wt%;约0.01wt%至约2.25wt%;约0.01wt%至约2wt%;约0.01wt%至约1.5wt%;约0.01wt%至约1wt%;约0.01wt%至约0.5wt%;0.1wt%至约10wt%;0.1wt%至约9wt%;0.1wt%至约8wt%;0.1wt%至约7wt%;0.1wt%至约6wt%;0.1wt%至约5wt%;0.1wt%至约4.5wt%;0.1wt%至约4wt%;0.1wt%至约3.5wt%;0.1wt%至约3wt%;0.1wt%至约2.5wt%;0.1wt%至约2wt%;0.1wt%至约2.25wt%;0.1wt%至约2wt%;约0.1%至约4wt%;约0.1wt%至约3wt%;约0.1wt%至约2.5wt%;约0.1wt%至约2.25wt%;约0.1wt%至约2wt%;约0.1wt%至约1.5wt%;约0.1wt%至约1wt%;约0.1wt%至约0.5wt%;0.25wt%至约30wt%;0.25wt%至约25wt%;0.25wt%至约20wt%;0.25wt%至约15wt%;0.25wt%至约10wt%;0.25wt%至约9wt%;0.25wt%至约8wt%;0.25wt%至约7wt%;0.25wt%至约6wt%;0.25wt%至约5wt%;0.25wt%至约4.5wt%;0.25wt%至约4wt%;0.25wt%至约3.5wt%;0.25wt%至约3wt%;0.25wt%至约2.5wt%;0.25wt%至约2wt%;0.25wt%至约2.25wt%;0.25wt%至约1.75wt%;0.5wt%至约10wt%;0.5wt%至约9wt%;0.5wt%至约8wt%;0.5wt%至约7wt%;0.5wt%至约6wt%;0.5wt%至约5wt%;0.5wt%至约4.5wt%;0.5wt%至约4wt%;0.5wt%至约3.5wt%;0.5wt%至约3wt%;0.5wt%至约2.5wt%;0.5wt%至约2wt%;0.5wt%至约2.25wt%;0.5wt%至约2wt%;约0.5%至约4wt%;约0.5wt%至约3wt%;约0.5wt%至约2.5wt%;约0.5wt%至约2.25wt%;约0.5wt%至约2wt%;约0.5wt%至约1.5wt%;约0.5wt%至约1wt%;0.7wt%至约10wt%;0.7wt%至约9wt%;0.7wt%至约8wt%;0.7wt%至约7wt%;0.7wt%至约6wt%;0.7wt%至约5wt%;0.7wt%至约4.5wt%;0.7wt%至约4wt%;0.7wt%至约3.5wt%;0.7wt%至约3wt%;0.7wt%至约2.5wt%;0.7wt%至约2wt%;0.7wt%至约2.25wt%;0.7wt%至约2wt%;约0.7%至约4wt%;约0.7wt%至约3wt%;约0.7wt%至约2.5wt%;约0.7wt%至约2.25wt%;约0.7wt%至约2wt%;约0.7wt%至约1.5wt%;约0.7wt%至约1wt%;0.9wt%至约10wt%;0.9wt%至约9wt%;0.9wt%至约8wt%;0.9wt%至约7wt%;0.9wt%至约6wt%;0.9wt%至约5wt%;0.9wt%至约4.5wt%;0.9wt%至约4wt%;0.9wt%至约3.5wt%;0.9wt%至约3wt%;0.9wt%至约2.5wt%;0.9wt%至约2wt%;0.9wt%至约2.25wt%;0.9wt%至约2wt%;约0.9%至约4wt%;约0.9wt%至约3wt%;约0.9wt%至约2.5wt%;约0.9wt%至约2.25wt%;约0.9wt%至约2wt%;约0.9wt%至约1.5wt%;约0.9wt%至约1wt%;1wt%至约10wt%;1wt%至约9wt%;1wt%至约8wt%;1wt%至约7wt%;1wt%至约6wt%;1wt%至约5wt%;1wt%至约4.5wt%;1wt%至约4wt%;1wt%至约3.5wt%;1wt%至约3wt%;1wt%至约2.5wt%;1wt%至约2wt%;1wt%至约2.25wt%;1wt%至约2wt%;约1%至约4wt%;约1wt%至约3wt%;约1wt%至约2.5wt%;约1wt%至约2.25wt%;约1wt%至约2wt%;约1wt%至约1.5wt%;约1.5wt%至约10wt%;约1.5wt%至约9wt%;约1.5wt%至约8wt%;约1.5wt%至约7wt%;约1.5wt%至约6wt%;约1.5wt%至约5wt%;约1.5wt%至约4.5wt%;约1.5wt%至约4wt%;约1.5wt%至约3.5wt%;约1.5wt%至约3wt%;约1.5wt%至约2.5wt%;约1.5wt%至约2.25wt%;约1.5wt%至约2wt%;约3wt%至约10wt%;约3wt%至约9wt%;约3wt%至约8wt%;约3wt%至约7wt%;约3wt%至约6wt%;约3wt%至约5wt%;约3wt%至约4.5wt%;约3wt%至约4wt%;约3wt%至约3.5wt%;或者以任何以上范围内的任何其它量。
局部舒缓制剂可包括DNA修复组分。DNA修复组分可包含以下的一种或多种,或者由以下的一种或多种组成:三磷酸腺苷、水解植物蛋白、脯氨酸、乙酰酪氨酸等。
DNA修复组分可单独或者组合地在局部舒缓组合物中以以下的量存在:>0.01wt%至约1wt%;>0.05wt%至约1wt%;约0.05wt%至约0.5wt%;约0.08wt%至约0.4wt%;约0.08wt%至约0.35wt%;约0.08wt%至约0.3wt%;约0.08wt%至约0.25wt%;约0.09wt%至约0.4wt%;约0.09wt%至约0.3wt%;约0.09wt%至约0.25wt%;或者约0.1wt%至约0.25wt%。
局部舒缓组合物还可包含以下的一种或多种,或者由以下的一种或多种组成:吸收促进剂、抗菌剂、抗微生物剂、抗真菌剂、润肤剂、自乳化弹性体凝胶、乳化剂、溶剂、表面活性剂、防腐剂、护肤剂、保湿剂、抗炎剂、湿润剂和/或芳香剂。
吸收促进剂、抗菌剂、抗微生物剂、抗真菌剂、润肤剂、自乳化弹性体凝胶、乳化剂、溶剂、表面活性剂、防腐剂、护肤剂、保湿剂、抗炎剂、湿润剂和/或芳香剂中的每一种都可在局部舒缓组合物中以以下的量存在:例如,约>0.01wt%至约1wt%;>0.05wt%至约1wt%;约0.05wt%至约0.5wt%;约0.08wt%至约0.4wt%;约0.08wt%至约0.35wt%;约0.08wt%至约0.3wt%;约0.08wt%至约0.25wt%;约0.09wt%至约0.4wt%;约0.09wt%至约0.3wt%;约0.09wt%至约0.25wt%;约0.1wt%至约0.25wt%;约0.11wt%至约0.24wt%;约0.12wt%至约0.23wt%;约0.13wt%至约0.22wt%;约0.14wt%至约0.21wt%;约0.15wt%至约0.2wt%、约0.1wt%至约5wt%;约0.5wt%至约4wt%;约0.5wt%至约3wt%;约0.1wt%至约3%wt%;约0.5wt%至约2wt%;约0.5%至约1.5wt%、约0.1wt%至约15wt%;约0.5wt%至约10wt%;约1wt%至约8wt%;约2wt%至约7%wt%;约3wt%至约6wt%;约2%至约7wt%、约10wt%至约50wt%;约15wt%至约45wt%;约20wt%至约25wt%;约30wt%至约40%wt%;或者约33wt%至约38wt%;0.01wt%至约10wt%;0.01wt%至约9wt%;0.01wt%至约8wt%;0.01wt%至约7wt%;0.01wt%至约6wt%;0.01wt%至约5wt%;0.01wt%至约4.5wt%;0.01wt%至约4wt%;0.01wt%至约3.5wt%;0.01wt%至约3wt%;0.01wt%至约2.5wt%;0.01wt%至约2wt%;0.01wt%至约2.25wt%;0.01wt%至约2wt%;约0.01%至约4wt%;约0.01wt%至约3wt%;约0.01wt%至约2.5wt%;约0.01wt%至约2.25wt%;约0.01wt%至约2wt%;约0.01wt%至约1.5wt%;约0.01wt%至约1wt%;约0.01wt%至约0.5wt%;0.1wt%至约10wt%;0.1wt%至约9wt%;0.1wt%至约8wt%;0.1wt%至约7wt%;0.1wt%至约6wt%;0.1wt%至约5wt%;0.1wt%至约4.5wt%;0.1wt%至约4wt%;0.1wt%至约3.5wt%;0.1wt%至约3wt%;0.1wt%至约2.5wt%;0.1wt%至约2wt%;0.1wt%至约2.25wt%;0.1wt%至约2wt%;约0.1%至约4wt%;约0.1wt%至约3wt%;约0.1wt%至约2.5wt%;约0.1wt%至约2.25wt%;约0.1wt%至约2wt%;约0.1wt%至约1.5wt%;约0.1wt%至约1wt%;约0.1wt%至约0.5wt%;0.5wt%至约10wt%;0.5wt%至约9wt%;0.5wt%至约8wt%;0.5wt%至约7wt%;0.5wt%至约6wt%;0.5wt%至约5wt%;0.5wt%至约4.5wt%;0.5wt%至约4wt%;0.5wt%至约3.5wt%;0.5wt%至约3wt%;0.5wt%至约2.5wt%;0.5wt%至约2wt%;0.5wt%至约2.25wt%;0.5wt%至约2wt%;约0.5%至约4wt%;约0.5wt%至约3wt%;约0.5wt%至约2.5wt%;约0.5wt%至约2.25wt%;约0.5wt%至约2wt%;约0.5wt%至约1.5wt%;约0.5wt%至约1wt%;0.7wt%至约10wt%;0.7wt%至约9wt%;0.7wt%至约8wt%;0.7wt%至约7wt%;0.7wt%至约6wt%;0.7wt%至约5wt%;0.7wt%至约4.5wt%;0.7wt%至约4wt%;0.7wt%至约3.5wt%;0.7wt%至约3wt%;0.7wt%至约2.5wt%;0.7wt%至约2wt%;0.7wt%至约2.25wt%;0.7wt%至约2wt%;约0.7%至约4wt%;约0.7wt%至约3wt%;约0.7wt%至约2.5wt%;约0.7wt%至约2.25wt%;约0.7wt%至约2wt%;约0.7wt%至约1.5wt%;约0.7wt%至约1wt%;0.9wt%至约10wt%;0.9wt%至约9wt%;0.9wt%至约8wt%;0.9wt%至约7wt%;0.9wt%至约6wt%;0.9wt%至约5wt%;0.9wt%至约4.5wt%;0.9wt%至约4wt%;0.9wt%至约3.5wt%;0.9wt%至约3wt%;0.9wt%至约2.5wt%;0.9wt%至约2wt%;0.9wt%至约2.25wt%;0.9wt%至约2wt%;约0.9%至约4wt%;约0.9wt%至约3wt%;约0.9wt%至约2.5wt%;约0.9wt%至约2.25wt%;约0.9wt%至约2wt%;约0.9wt%至约1.5wt%;约0.9wt%至约1wt%;1wt%至约10wt%;1wt%至约9wt%;1wt%至约8wt%;1wt%至约7wt%;1wt%至约6wt%;1wt%至约5wt%;1wt%至约4.5wt%;1wt%至约4wt%;1wt%至约3.5wt%;1wt%至约3wt%;1wt%至约2.5wt%;1wt%至约2wt%;1wt%至约2.25wt%;1wt%至约2wt%;约1%至约4wt%;约1wt%至约3wt%;约1wt%至约2.5wt%;约1wt%至约2.25wt%;约1wt%至约2wt%;约1wt%至约1.5wt%;约1.5wt%至约10wt%;约1.5wt%至约9wt%;约1.5wt%至约8wt%;约1.5wt%至约7wt%;约1.5wt%至约6wt%;约1.5wt%至约5wt%;约1.5wt%至约4.5wt%;约1.5wt%至约4wt%;约1.5wt%至约3.5wt%;约1.5wt%至约3wt%;约1.5wt%至约2.5wt%;约1.5wt%至约2.25wt%;约1.5wt%至约2wt%;约3wt%至约10wt%;约3wt%至约9wt%;约3wt%至约8wt%;约3wt%至约7wt%;约3wt%至约6wt%;约3wt%至约5wt%;约3wt%至约4.5wt%;约3wt%至约4wt%;约3wt%至约3.5wt%;或者以任何以上范围内的任何其它量。
表皮修复组合物
表皮/真皮修复组合物可修复、治疗或者改善易受损的皮肤的症状。
表皮/真皮修复组合物可包含一种或多种护肤剂,或者由一种或多种护肤剂组成,以保护和缓解由于刺激造成的干燥和瘙痒或者其它易受损的皮肤。护肤剂可包含胶状燕麦片或者由胶状燕麦片组成。
护肤剂可在表皮/真皮修复组合物中以以下的量存在:例如,0.01wt%至约10wt%;0.01wt%至约9wt%;0.01wt%至约8wt%;0.01wt%至约7wt%;0.01wt%至约6wt%;0.01wt%至约5wt%;0.01wt%至约4.5wt%;0.01wt%至约4wt%;0.01wt%至约3.5wt%;0.01wt%至约3wt%;0.01wt%至约2.5wt%;0.01wt%至约2wt%;0.01wt%至约2.25wt%;0.01wt%至约2wt%;约0.01%至约4wt%;约0.01wt%至约3wt%;约0.01wt%至约2.5wt%;约0.01wt%至约2.25wt%;约0.01wt%至约2wt%;约0.01wt%至约1.5wt%;约0.01wt%至约1wt%;约0.01wt%至约0.5wt%;0.1wt%至约10wt%;0.1wt%至约9wt%;0.1wt%至约8wt%;0.1wt%至约7wt%;0.1wt%至约6wt%;0.1wt%至约5wt%;0.1wt%至约4.5wt%;0.1wt%至约4wt%;0.1wt%至约3.5wt%;0.1wt%至约3wt%;0.1wt%至约2.5wt%;0.1wt%至约2wt%;0.1wt%至约2.25wt%;0.1wt%至约2wt%;约0.1%至约4wt%;约0.1wt%至约3wt%;约0.1wt%至约2.5wt%;约0.1wt%至约2.25wt%;约0.1wt%至约2wt%;约0.1wt%至约1.5wt%;约0.1wt%至约1wt%;约0.1wt%至约0.5wt%;0.25wt%至约30wt%;0.25wt%至约25wt%;0.25wt%至约20wt%;0.25wt%至约15wt%;0.25wt%至约10wt%;0.25wt%至约9wt%;0.25wt%至约8wt%;0.25wt%至约7wt%;0.25wt%至约6wt%;0.25wt%至约5wt%;0.25wt%至约4.5wt%;0.25wt%至约4wt%;0.25wt%至约3.5wt%;0.25wt%至约3wt%;0.25wt%至约2.5wt%;0.25wt%至约2wt%;0.25wt%至约2.25wt%;0.25wt%至约1.75wt%;0.5wt%至约10wt%;0.5wt%至约9wt%;0.5wt%至约8wt%;0.5wt%至约7wt%;0.5wt%至约6wt%;0.5wt%至约5wt%;0.5wt%至约4.5wt%;0.5wt%至约4wt%;0.5wt%至约3.5wt%;0.5wt%至约3wt%;0.5wt%至约2.5wt%;0.5wt%至约2wt%;0.5wt%至约2.25wt%;0.5wt%至约2wt%;约0.5%至约4wt%;约0.5wt%至约3wt%;约0.5wt%至约2.5wt%;约0.5wt%至约2.25wt%;约0.5wt%至约2wt%;约0.5wt%至约1.5wt%;约0.5wt%至约1wt%;0.7wt%至约10wt%;0.7wt%至约9wt%;0.7wt%至约8wt%;0.7wt%至约7wt%;0.7wt%至约6wt%;0.7wt%至约5wt%;0.7wt%至约4.5wt%;0.7wt%至约4wt%;0.7wt%至约3.5wt%;0.7wt%至约3wt%;0.7wt%至约2.5wt%;0.7wt%至约2wt%;0.7wt%至约2.25wt%;0.7wt%至约2wt%;约0.7%至约4wt%;约0.7wt%至约3wt%;约0.7wt%至约2.5wt%;约0.7wt%至约2.25wt%;约0.7wt%至约2wt%;约0.7wt%至约1.5wt%;约0.7wt%至约1wt%;0.9wt%至约10wt%;0.9wt%至约9wt%;0.9wt%至约8wt%;0.9wt%至约7wt%;0.9wt%至约6wt%;0.9wt%至约5wt%;0.9wt%至约4.5wt%;0.9wt%至约4wt%;0.9wt%至约3.5wt%;0.9wt%至约3wt%;0.9wt%至约2.5wt%;0.9wt%至约2wt%;0.9wt%至约2.25wt%;0.9wt%至约2wt%;约0.9%至约4wt%;约0.9wt%至约3wt%;约0.9wt%至约2.5wt%;约0.9wt%至约2.25wt%;约0.9wt%至约2wt%;约0.9wt%至约1.5wt%;约0.9wt%至约1wt%;1wt%至约10wt%;1wt%至约9wt%;1wt%至约8wt%;1wt%至约7wt%;1wt%至约6wt%;1wt%至约5wt%;1wt%至约4.5wt%;1wt%至约4wt%;1wt%至约3.5wt%;1wt%至约3wt%;1wt%至约2.5wt%;1wt%至约2wt%;1wt%至约2.25wt%;1wt%至约2wt%;约1%至约4wt%;约1wt%至约3wt%;约1wt%至约2.5wt%;约1wt%至约2.25wt%;约1wt%至约2wt%;约1wt%至约1.5wt%;约1.5wt%至约10wt%;约1.5wt%至约9wt%;约1.5wt%至约8wt%;约1.5wt%至约7wt%;约1.5wt%至约6wt%;约1.5wt%至约5wt%;约1.5wt%至约4.5wt%;约1.5wt%至约4wt%;约1.5wt%至约3.5wt%;约1.5wt%至约3wt%;约1.5wt%至约2.5wt%;约1.5wt%至约2.25wt%;约1.5wt%至约2wt%;约3wt%至约10wt%;约3wt%至约9wt%;约3wt%至约8wt%;约3wt%至约7wt%;约3wt%至约6wt%;约3wt%至约5wt%;约3wt%至约4.5wt%;约3wt%至约4wt%;约3wt%至约3.5wt%;或者以任何以上范围内的任何其它量。
肽可包括在表皮/真皮修复组合物中。例如,在用于表皮/真皮修复组合物中时,四肽-21增强细胞外基质(ECM)蛋白质表达。四肽-21在皮肤中还刺激胶原蛋白1、纤连蛋白和透明质酸,导致上皮再形成并且加速愈合。肉豆蔻酰五肽-11促进细胞增殖以加速皮肤恢复。
一种或多种肽或者包含肽的组合物可在表皮修复组合物中以以下的量存在:例如,0.01wt%至约10wt%;0.01wt%至约9wt%;0.01wt%至约8wt%;0.01wt%至约7wt%;0.01wt%至约6wt%;0.01wt%至约5wt%;0.01wt%至约4.5wt%;0.01wt%至约4wt%;0.01wt%至约3.5wt%;0.01wt%至约3wt%;0.01wt%至约2.5wt%;0.01wt%至约2wt%;0.01wt%至约2.25wt%;0.01wt%至约2wt%;约0.01%至约4wt%;约0.01wt%至约3wt%;约0.01wt%至约2.5wt%;约0.01wt%至约2.25wt%;约0.01wt%至约2wt%;约0.01wt%至约1.5wt%;约0.01wt%至约1wt%;约0.01wt%至约0.5wt%;0.1wt%至约10wt%;0.1wt%至约9wt%;0.1wt%至约8wt%;0.1wt%至约7wt%;0.1wt%至约6wt%;0.1wt%至约5wt%;0.1wt%至约4.5wt%;0.1wt%至约4wt%;0.1wt%至约3.5wt%;0.1wt%至约3wt%;0.1wt%至约2.5wt%;0.1wt%至约2wt%;0.1wt%至约2.25wt%;0.1wt%至约2wt%;约0.1%至约4wt%;约0.1wt%至约3wt%;约0.1wt%至约2.5wt%;约0.1wt%至约2.25wt%;约0.1wt%至约2wt%;约0.1wt%至约1.5wt%;约0.1wt%至约1wt%;约0.1wt%至约0.5wt%;0.25wt%至约30wt%;0.25wt%至约25wt%;0.25wt%至约20wt%;0.25wt%至约15wt%;0.25wt%至约10wt%;0.25wt%至约9wt%;0.25wt%至约8wt%;0.25wt%至约7wt%;0.25wt%至约6wt%;0.25wt%至约5wt%;0.25wt%至约4.5wt%;0.25wt%至约4wt%;0.25wt%至约3.5wt%;0.25wt%至约3wt%;0.25wt%至约2.5wt%;0.25wt%至约2wt%;0.25wt%至约2.25wt%;0.25wt%至约1.75wt%;0.5wt%至约10wt%;0.5wt%至约9wt%;0.5wt%至约8wt%;0.5wt%至约7wt%;0.5wt%至约6wt%;0.5wt%至约5wt%;0.5wt%至约4.5wt%;0.5wt%至约4wt%;0.5wt%至约3.5wt%;0.5wt%至约3wt%;0.5wt%至约2.5wt%;0.5wt%至约2wt%;0.5wt%至约2.25wt%;0.5wt%至约2wt%;约0.5%至约4wt%;约0.5wt%至约3wt%;约0.5wt%至约2.5wt%;约0.5wt%至约2.25wt%;约0.5wt%至约2wt%;约0.5wt%至约1.5wt%;约0.5wt%至约1wt%;0.7wt%至约10wt%;0.7wt%至约9wt%;0.7wt%至约8wt%;0.7wt%至约7wt%;0.7wt%至约6wt%;0.7wt%至约5wt%;0.7wt%至约4.5wt%;0.7wt%至约4wt%;0.7wt%至约3.5wt%;0.7wt%至约3wt%;0.7wt%至约2.5wt%;0.7wt%至约2wt%;0.7wt%至约2.25wt%;0.7wt%至约2wt%;约0.7%至约4wt%;约0.7wt%至约3wt%;约0.7wt%至约2.5wt%;约0.7wt%至约2.25wt%;约0.7wt%至约2wt%;约0.7wt%至约1.5wt%;约0.7wt%至约1wt%;0.9wt%至约10wt%;0.9wt%至约9wt%;0.9wt%至约8wt%;0.9wt%至约7wt%;0.9wt%至约6wt%;0.9wt%至约5wt%;0.9wt%至约4.5wt%;0.9wt%至约4wt%;0.9wt%至约3.5wt%;0.9wt%至约3wt%;0.9wt%至约2.5wt%;0.9wt%至约2wt%;0.9wt%至约2.25wt%;0.9wt%至约2wt%;约0.9%至约4wt%;约0.9wt%至约3wt%;约0.9wt%至约2.5wt%;约0.9wt%至约2.25wt%;约0.9wt%至约2wt%;约0.9wt%至约1.5wt%;约0.9wt%至约1wt%;1wt%至约10wt%;1wt%至约9wt%;1wt%至约8wt%;1wt%至约7wt%;1wt%至约6wt%;1wt%至约5wt%;1wt%至约4.5wt%;1wt%至约4wt%;1wt%至约3.5wt%;1wt%至约3wt%;1wt%至约2.5wt%;1wt%至约2wt%;1wt%至约2.25wt%;1wt%至约2wt%;约1%至约4wt%;约1wt%至约3wt%;约1wt%至约2.5wt%;约1wt%至约2.25wt%;约1wt%至约2wt%;约1wt%至约1.5wt%;约1.5wt%至约10wt%;约1.5wt%至约9wt%;约1.5wt%至约8wt%;约1.5wt%至约7wt%;约1.5wt%至约6wt%;约1.5wt%至约5wt%;约1.5wt%至约4.5wt%;约1.5wt%至约4wt%;约1.5wt%至约3.5wt%;约1.5wt%至约3wt%;约1.5wt%至约2.5wt%;约1.5wt%至约2.25wt%;约1.5wt%至约2wt%;约3wt%至约10wt%;约3wt%至约9wt%;约3wt%至约8wt%;约3wt%至约7wt%;约3wt%至约6wt%;或者以任何以上范围内的任何其它量。
表皮/真皮修复组合物还可包括保湿剂。保湿剂可包含甘油或者由甘油组成,以补充经表皮的失水(TEWL)、使经表皮的失水与水化合以及使经表皮的失水最小。或者具有甘油的保湿组分或者单独的保湿组分还可包括以下的一种或多种:丙二醇、神经酰胺、乳木果油、荷荷巴油、可可油或者鳄梨油。
一种或多种保湿剂可单独或者组合地在表皮/真皮修复组合物中以以下的量存在:例如,0.01wt%至约10wt%;0.01wt%至约9wt%;0.01wt%至约8wt%;0.01wt%至约7wt%;0.01wt%至约6wt%;0.01wt%至约5wt%;0.01wt%至约4.5wt%;0.01wt%至约4wt%;0.01wt%至约3.5wt%;0.01wt%至约3wt%;0.01wt%至约2.5wt%;0.01wt%至约2wt%;0.01wt%至约2.25wt%;0.01wt%至约2wt%;约0.01%至约4wt%;约0.01wt%至约3wt%;约0.01wt%至约2.5wt%;约0.01wt%至约2.25wt%;约0.01wt%至约2wt%;约0.01wt%至约1.5wt%;约0.01wt%至约1wt%;约0.01wt%至约0.5wt%;0.1wt%至约10wt%;0.1wt%至约9wt%;0.1wt%至约8wt%;0.1wt%至约7wt%;0.1wt%至约6wt%;0.1wt%至约5wt%;0.1wt%至约4.5wt%;0.1wt%至约4wt%;0.1wt%至约3.5wt%;0.1wt%至约3wt%;0.1wt%至约2.5wt%;0.1wt%至约2wt%;0.1wt%至约2.25wt%;0.1wt%至约2wt%;约0.1%至约4wt%;约0.1wt%至约3wt%;约0.1wt%至约2.5wt%;约0.1wt%至约2.25wt%;约0.1wt%至约2wt%;约0.1wt%至约1.5wt%;约0.1wt%至约1wt%;约0.1wt%至约0.5wt%;0.25wt%至约30wt%;0.25wt%至约25wt%;0.25wt%至约20wt%;0.25wt%至约15wt%;0.25wt%至约10wt%;0.25wt%至约9wt%;0.25wt%至约8wt%;0.25wt%至约7wt%;0.25wt%至约6wt%;0.25wt%至约5wt%;0.25wt%至约4.5wt%;0.25wt%至约4wt%;0.25wt%至约3.5wt%;0.25wt%至约3wt%;0.25wt%至约2.5wt%;0.25wt%至约2wt%;0.25wt%至约2.25wt%;0.25wt%至约1.75wt%;0.5wt%至约10wt%;0.5wt%至约9wt%;0.5wt%至约8wt%;0.5wt%至约7wt%;0.5wt%至约6wt%;0.5wt%至约5wt%;0.5wt%至约4.5wt%;0.5wt%至约4wt%;0.5wt%至约3.5wt%;0.5wt%至约3wt%;0.5wt%至约2.5wt%;0.5wt%至约2wt%;0.5wt%至约2.25wt%;0.5wt%至约2wt%;约0.5%至约4wt%;约0.5wt%至约3wt%;约0.5wt%至约2.5wt%;约0.5wt%至约2.25wt%;约0.5wt%至约2wt%;约0.5wt%至约1.5wt%;约0.5wt%至约1wt%;0.7wt%至约10wt%;0.7wt%至约9wt%;0.7wt%至约8wt%;0.7wt%至约7wt%;0.7wt%至约6wt%;0.7wt%至约5wt%;0.7wt%至约4.5wt%;0.7wt%至约4wt%;0.7wt%至约3.5wt%;0.7wt%至约3wt%;0.7wt%至约2.5wt%;0.7wt%至约2wt%;0.7wt%至约2.25wt%;0.7wt%至约2wt%;约0.7%至约4wt%;约0.7wt%至约3wt%;约0.7wt%至约2.5wt%;约0.7wt%至约2.25wt%;约0.7wt%至约2wt%;约0.7wt%至约1.5wt%;约0.7wt%至约1wt%;0.9wt%至约10wt%;0.9wt%至约9wt%;0.9wt%至约8wt%;0.9wt%至约7wt%;0.9wt%至约6wt%;0.9wt%至约5wt%;0.9wt%至约4.5wt%;0.9wt%至约4wt%;0.9wt%至约3.5wt%;0.9wt%至约3wt%;0.9wt%至约2.5wt%;0.9wt%至约2wt%;0.9wt%至约2.25wt%;0.9wt%至约2wt%;约0.9%至约4wt%;约0.9wt%至约3wt%;约0.9wt%至约2.5wt%;约0.9wt%至约2.25wt%;约0.9wt%至约2wt%;约0.9wt%至约1.5wt%;约0.9wt%至约1wt%;1wt%至约10wt%;1wt%至约9wt%;1wt%至约8wt%;1wt%至约7wt%;1wt%至约6wt%;1wt%至约5wt%;1wt%至约4.5wt%;1wt%至约4wt%;1wt%至约3.5wt%;1wt%至约3wt%;1wt%至约2.5wt%;1wt%至约2wt%;1wt%至约2.25wt%;1wt%至约2wt%;约1%至约4wt%;约1wt%至约3wt%;约1wt%至约2.5wt%;约1wt%至约2.25wt%;约1wt%至约2wt%;约1wt%至约1.5wt%;约1.5wt%至约10wt%;约1.5wt%至约9wt%;约1.5wt%至约8wt%;约1.5wt%至约7wt%;约1.5wt%至约6wt%;约1.5wt%至约5wt%;约1.5wt%至约4.5wt%;约1.5wt%至约4wt%;约1.5wt%至约3.5wt%;约1.5wt%至约3wt%;约1.5wt%至约2.5wt%;约1.5wt%至约2.25wt%;约1.5wt%至约2wt%;约3wt%至约10wt%;约3wt%至约9wt%;约3wt%至约8wt%;约3wt%至约7wt%;约3wt%至约6wt%;或者以任何以上范围内的任何其它量。
一种或多种抗炎剂还可包括在表皮/真皮修复组合物中,以缓和发红以及舒缓受刺激的皮肤或者其它易受损的皮肤。一种或多种抗炎剂可单独或者组合地在表皮/真皮修复组合物中以以下的量存在:例如,约0.01wt%至约10wt%;0.01wt%至约9wt%;0.01wt%至约8wt%;0.01wt%至约7wt%;0.01wt%至约6wt%;0.01wt%至约5wt%;0.01wt%至约4.5wt%;0.01wt%至约4wt%;0.01wt%至约3.5wt%;0.01wt%至约3wt%;0.01wt%至约2.5wt%;0.01wt%至约2wt%;0.01wt%至约2.25wt%;0.01wt%至约2wt%;约0.01%至约4wt%;约0.01wt%至约3wt%;约0.01wt%至约2.5wt%;约0.01wt%至约2.25wt%;约0.01wt%至约2wt%;约0.01wt%至约1.5wt%;约0.01wt%至约1wt%;约0.01wt%至约0.5wt%;0.1wt%至约10wt%;0.1wt%至约9wt%;0.1wt%至约8wt%;0.1wt%至约7wt%;0.1wt%至约6wt%;0.1wt%至约5wt%;0.1wt%至约4.5wt%;0.1wt%至约4wt%;0.1wt%至约3.5wt%;0.1wt%至约3wt%;0.1wt%至约2.5wt%;0.1wt%至约2wt%;0.1wt%至约2.25wt%;0.1wt%至约2wt%;约0.1%至约4wt%;约0.1wt%至约3wt%;约0.1wt%至约2.5wt%;约0.1wt%至约2.25wt%;约0.1wt%至约2wt%;约0.1wt%至约1.5wt%;约0.1wt%至约1wt%;约0.1wt%至约0.5wt%;0.25wt%至约30wt%;0.25wt%至约25wt%;0.25wt%至约20wt%;0.25wt%至约15wt%;0.25wt%至约10wt%;0.25wt%至约9wt%;0.25wt%至约8wt%;0.25wt%至约7wt%;0.25wt%至约6wt%;0.25wt%至约5wt%;0.25wt%至约4.5wt%;0.25wt%至约4wt%;0.25wt%至约3.5wt%;0.25wt%至约3wt%;0.25wt%至约2.5wt%;0.25wt%至约2wt%;0.25wt%至约2.25wt%;0.25wt%至约1.75wt%;0.5wt%至约10wt%;0.5wt%至约9wt%;0.5wt%至约8wt%;0.5wt%至约7wt%;0.5wt%至约6wt%;0.5wt%至约5wt%;0.5wt%至约4.5wt%;0.5wt%至约4wt%;0.5wt%至约3.5wt%;0.5wt%至约3wt%;0.5wt%至约2.5wt%;0.5wt%至约2wt%;0.5wt%至约2.25wt%;0.5wt%至约2wt%;约0.5%至约4wt%;约0.5wt%至约3wt%;约0.5wt%至约2.5wt%;约0.5wt%至约2.25wt%;约0.5wt%至约2wt%;约0.5wt%至约1.5wt%;约0.5wt%至约1wt%;0.7wt%至约10wt%;0.7wt%至约9wt%;0.7wt%至约8wt%;0.7wt%至约7wt%;0.7wt%至约6wt%;0.7wt%至约5wt%;0.7wt%至约4.5wt%;0.7wt%至约4wt%;0.7wt%至约3.5wt%;0.7wt%至约3wt%;0.7wt%至约2.5wt%;0.7wt%至约2wt%;0.7wt%至约2.25wt%;0.7wt%至约2wt%;约0.7%至约4wt%;约0.7wt%至约3wt%;约0.7wt%至约2.5wt%;约0.7wt%至约2.25wt%;约0.7wt%至约2wt%;约0.7wt%至约1.5wt%;约0.7wt%至约1wt%;0.9wt%至约10wt%;0.9wt%至约9wt%;0.9wt%至约8wt%;0.9wt%至约7wt%;0.9wt%至约6wt%;0.9wt%至约5wt%;0.9wt%至约4.5wt%;0.9wt%至约4wt%;0.9wt%至约3.5wt%;0.9wt%至约3wt%;0.9wt%至约2.5wt%;0.9wt%至约2wt%;0.9wt%至约2.25wt%;0.9wt%至约2wt%;约0.9%至约4wt%;约0.9wt%至约3wt%;约0.9wt%至约2.5wt%;约0.9wt%至约2.25wt%;约0.9wt%至约2wt%;约0.9wt%至约1.5wt%;约0.9wt%至约1wt%;1wt%至约10wt%;1wt%至约9wt%;1wt%至约8wt%;1wt%至约7wt%;1wt%至约6wt%;1wt%至约5wt%;1wt%至约4.5wt%;1wt%至约4wt%;1wt%至约3.5wt%;1wt%至约3wt%;1wt%至约2.5wt%;1wt%至约2wt%;1wt%至约2.25wt%;1wt%至约2wt%;约1%至约4wt%;约1wt%至约3wt%;约1wt%至约2.5wt%;约1wt%至约2.25wt%;约1wt%至约2wt%;约1wt%至约1.5wt%;约1.5wt%至约10wt%;约1.5wt%至约9wt%;约1.5wt%至约8wt%;约1.5wt%至约7wt%;约1.5wt%至约6wt%;约1.5wt%至约5wt%;约1.5wt%至约4.5wt%;约1.5wt%至约4wt%;约1.5wt%至约3.5wt%;约1.5wt%至约3wt%;约1.5wt%至约2.5wt%;约1.5wt%至约2.25wt%;约1.5wt%至约2wt%;约3wt%至约10wt%;约3wt%至约9wt%;约3wt%至约8wt%;约3wt%至约7wt%;约3wt%至约6wt%;约3wt%至约5wt%;约3wt%至约4.5wt%;约3wt%至约4wt%;约3wt%至约3.5wt%;或者以任何以上范围内的任何其它量。
表皮/真皮修复组合物可包括一种或多种抗氧化剂或者抗氧化剂复合物。用于局部舒缓组合物中的一种或多种抗氧化剂可包括,例如以下的一种或多种:泛醌(辅酶Q10);生育酚乙酸酯;抗坏血酸和棕榈酸视黄酯。抗氧化剂复合物可被配制为12小时延时释放胶囊。抗氧化剂复合物可包含以下或者由以下组成:聚甲基丙烯酸甲酯和一种或多种生育酚乙酸酯、抗坏血酸和棕榈酸视黄酯或者其它适合的抗氧化剂。
一种或多种抗氧化剂可单独或者组合地在表皮/真皮修复组合物中以以下的量存在:例如,0.01wt%至约10wt%;0.01wt%至约9wt%;0.01wt%至约8wt%;0.01wt%至约7wt%;0.01wt%至约6wt%;0.01wt%至约5wt%;0.01wt%至约4.5wt%;0.01wt%至约4wt%;0.01wt%至约3.5wt%;0.01wt%至约3wt%;0.01wt%至约2.5wt%;0.01wt%至约2wt%;0.01wt%至约2.25wt%;0.01wt%至约2wt%;约0.01%至约4wt%;约0.01wt%至约3wt%;约0.01wt%至约2.5wt%;约0.01wt%至约2.25wt%;约0.01wt%至约2wt%;约0.01wt%至约1.5wt%;约0.01wt%至约1wt%;约0.01wt%至约0.5wt%;0.1wt%至约10wt%;0.1wt%至约9wt%;0.1wt%至约8wt%;0.1wt%至约7wt%;0.1wt%至约6wt%;0.1wt%至约5wt%;0.1wt%至约4.5wt%;0.1wt%至约4wt%;0.1wt%至约3.5wt%;0.1wt%至约3wt%;0.1wt%至约2.5wt%;0.1wt%至约2wt%;0.1wt%至约2.25wt%;0.1wt%至约2wt%;约0.1%至约4wt%;约0.1wt%至约3wt%;约0.1wt%至约2.5wt%;约0.1wt%至约2.25wt%;约0.1wt%至约2wt%;约0.1wt%至约1.5wt%;约0.1wt%至约1wt%;约0.1wt%至约0.5wt%;0.25wt%至约30wt%;0.25wt%至约25wt%;0.25wt%至约20wt%;0.25wt%至约15wt%;0.25wt%至约10wt%;0.25wt%至约9wt%;0.25wt%至约8wt%;0.25wt%至约7wt%;0.25wt%至约6wt%;0.25wt%至约5wt%;0.25wt%至约4.5wt%;0.25wt%至约4wt%;0.25wt%至约3.5wt%;0.25wt%至约3wt%;0.25wt%至约2.5wt%;0.25wt%至约2wt%;0.25wt%至约2.25wt%;0.25wt%至约1.75wt%;0.5wt%至约10wt%;0.5wt%至约9wt%;0.5wt%至约8wt%;0.5wt%至约7wt%;0.5wt%至约6wt%;0.5wt%至约5wt%;0.5wt%至约4.5wt%;0.5wt%至约4wt%;0.5wt%至约3.5wt%;0.5wt%至约3wt%;0.5wt%至约2.5wt%;0.5wt%至约2wt%;0.5wt%至约2.25wt%;0.5wt%至约2wt%;约0.5%至约4wt%;约0.5wt%至约3wt%;约0.5wt%至约2.5wt%;约0.5wt%至约2.25wt%;约0.5wt%至约2wt%;约0.5wt%至约1.5wt%;约0.5wt%至约1wt%;0.7wt%至约10wt%;0.7wt%至约9wt%;0.7wt%至约8wt%;0.7wt%至约7wt%;0.7wt%至约6wt%;0.7wt%至约5wt%;0.7wt%至约4.5wt%;0.7wt%至约4wt%;0.7wt%至约3.5wt%;0.7wt%至约3wt%;0.7wt%至约2.5wt%;0.7wt%至约2wt%;0.7wt%至约2.25wt%;0.7wt%至约2wt%;约0.7%至约4wt%;约0.7wt%至约3wt%;约0.7wt%至约2.5wt%;约0.7wt%至约2.25wt%;约0.7wt%至约2wt%;约0.7wt%至约1.5wt%;约0.7wt%至约1wt%;0.9wt%至约10wt%;0.9wt%至约9wt%;0.9wt%至约8wt%;0.9wt%至约7wt%;0.9wt%至约6wt%;0.9wt%至约5wt%;0.9wt%至约4.5wt%;0.9wt%至约4wt%;0.9wt%至约3.5wt%;0.9wt%至约3wt%;0.9wt%至约2.5wt%;0.9wt%至约2wt%;0.9wt%至约2.25wt%;0.9wt%至约2wt%;约0.9%至约4wt%;约0.9wt%至约3wt%;约0.9wt%至约2.5wt%;约0.9wt%至约2.25wt%;约0.9wt%至约2wt%;约0.9wt%至约1.5wt%;约0.9wt%至约1wt%;1wt%至约10wt%;1wt%至约9wt%;1wt%至约8wt%;1wt%至约7wt%;1wt%至约6wt%;1wt%至约5wt%;1wt%至约4.5wt%;1wt%至约4wt%;1wt%至约3.5wt%;1wt%至约3wt%;1wt%至约2.5wt%;1wt%至约2wt%;1wt%至约2.25wt%;1wt%至约2wt%;约1%至约4wt%;约1wt%至约3wt%;约1wt%至约2.5wt%;约1wt%至约2.25wt%;约1wt%至约2wt%;约1wt%至约1.5wt%;约1.5wt%至约10wt%;约1.5wt%至约9wt%;约1.5wt%至约8wt%;约1.5wt%至约7wt%;约1.5wt%至约6wt%;约1.5wt%至约5wt%;约1.5wt%至约4.5wt%;约1.5wt%至约4wt%;约1.5wt%至约3.5wt%;约1.5wt%至约3wt%;约1.5wt%至约2.5wt%;约1.5wt%至约2.25wt%;约1.5wt%至约2wt%;约3wt%至约10wt%;约3wt%至约9wt%;约3wt%至约8wt%;约3wt%至约7wt%;约3wt%至约6wt%;约3wt%至约5wt%;约3wt%至约4.5wt%;约3wt%至约4wt%;约3wt%至约3.5wt%;或者以任何以上范围内的任何其它量。
任选地,表皮/真皮修复组合物还可包括以下的一种或多种:载体、溶剂、增稠剂、湿润剂、乳化剂、抗菌剂、抗微生物剂、抗真菌剂、润肤剂、乳化试剂、皮肤保护活性剂、中和剂、防腐剂、胶原蛋白刺激剂、DNA保护剂、保湿试剂、大豆磷脂、DNA修复剂和皮肤调理剂。
载体、溶剂、增稠剂、湿润剂、乳化剂、抗菌剂、抗微生物剂、抗真菌剂、润肤剂、乳化试剂、皮肤保护活性剂、中和剂、防腐剂、胶原蛋白刺激剂、DNA保护剂、保湿试剂、大豆磷脂、DNA修复剂和皮肤调理剂中的一种或多种中的每一种以任意量存在于表皮/真皮修复组合物中,所述量包括:例如,约>0.01wt%至约1wt%;>0.05wt%至约1wt%;约0.05wt%至约0.5wt%;约0.08wt%至约0.4wt%;约0.08wt%至约0.35wt%;约0.08wt%至约0.3wt%;约0.08wt%至约0.25wt%;约0.09wt%至约0.4wt%;约0.09wt%至约0.3wt%;约0.09wt%至约0.25wt%;约0.1wt%至约0.25wt%;约0.11wt%至约0.24wt%;约0.12wt%至约0.23wt%;约0.13wt%至约0.22wt%;约0.14wt%至约0.21wt%;约0.15wt%至约0.2wt%、约0.1wt%至约5wt%;约0.5wt%至约4wt%;约0.5wt%至约3wt%;约0.1wt%至约3%wt%;约0.5wt%至约2wt%;约0.5%至约1.5wt%、约0.1wt%至约15wt%;约0.5wt%至约10wt%;约1wt%至约8wt%;约2wt%至约7%wt%;约3wt%至约6wt%;约2%至约7wt%、约10wt%至约50wt%;约15wt%至约45wt%;约20wt%至约25wt%;约30wt%至约40%wt%或者约33wt%至约38wt%。
先前所述的局部生物相容性组合物中的每一个还可包括已知的生物相容性载体、赋形剂、填充剂,并且稀释剂是本领域的技术人员所熟知的,例如在以下所述的那些:MerckIndex,第十三版,Budavari等人(编者),Merck&Co.,Inc.,Rahway,N.J.(2001);CTFA(Cosmetic,Toiletry,and Fragrance Association)International CosmeticIngredient Dictionary and Handbook,第十版(2004);以及“Inactive IngredientGuide”,美国食品药品监督管理局(FDA)药物评价与研究中心(CDER)管理办公室,所有以上内容通过引用整体并入本文。
这些额外的非活性组分以及有效的制剂和施用操作在本领域中是熟知的,并且在标准教科书中描述,例如Goodman和Gillman的:Pharmacological Bases ofTherapeutics,第8版,Gilman等人(编者),Pergamon Press(1990)和Remington’sPharmaceutical Sciences,第18版,Mack Publishing Co.,Easton,Pa.(1990),以上两者通过引用整体并入本文。
所有本文所述的局部生物相容性组合物可配制为以下的一种或多种:粉末、溶液、乳液、凝胶、乳膏剂、洗剂、软膏剂、泡沫剂、气雾剂和浆液。
治疗方法
本文所述的局部生物相容性组合物包括局部损伤愈合组合物、局部舒缓组合物以及表皮/真皮修复组合物。本文还提供了使用生物相容性组合物治疗皮肤病况的方法。可通过局部施用本文的组合物进行治疗的非限制性病况包括但不限于以下的一种或多种:易受损的皮肤;操作后的皮肤;皮肤刺激;皮肤炎症;皮肤损伤;皮肤灼伤和皮肤晒伤。
操作后的皮肤是已经经过可包括但不限于以下的操作的皮肤:表面重修操作、化学脱皮、烧蚀激光治疗(CO2激光)、非烧蚀激光治疗、基于非激光的治疗(IPL,红外线治疗)、基于射频的治疗、擦皮术、真皮刨平或者它们的任意组合。
易受损的皮肤、操作后的皮肤、烧伤的皮肤和/或损伤的皮肤可表现出以下的一种或多种:皮肤刺激、皮肤炎症、肿胀、发红、斑疤和疼痛。
皮肤刺激和/或皮肤炎症可由以下的一种或多种引起:操作;过敏反应;与皮肤刺激剂接触,例如毒葛、毒栎、毒漆树、蚊虫叮咬、皂、洗剂、化妆品和/或金属(金属首饰);真菌感染;诸如痤疮治疗(例如,视黄醇)的皮肤治疗以及创伤。
治疗本文所述的皮肤病况的方法可包含或者由以下组成:向需要其的患者施用所述生物相容性组合物中的一种或多种。
局部生物相容性组合物可在试剂盒中提供以治疗操作后的皮肤或者其它易受损的皮肤。试剂盒可包括局部损伤愈合组合物和/或局部舒缓组合物和/或表皮/真皮修复组合物。因此,本文提供了通过施用如本文所提供的局部损伤愈合组合物治疗具有操作后的皮肤或者其它易受损的皮肤的对象的方法。所述方法还可包含施用本文所提供的局部舒缓组合物和/或如本文所提供的表皮修复组合物。
剂量
本文所述的生物相容性局部组合物可以以任何形式局部施用。可将足量的局部组合物施用于受感染区域和周围皮肤,例如以足够覆盖受感染区域加受感染区域周围的健康皮肤边缘或者组织边缘(如果可能,例如约0.5英寸的边缘)的量。可将组合物施用于任何皮肤表面,包括例如面部皮肤以及手、颈部和/或胸部的皮肤。
可将组合物以单独一次施用、一周一次、两周一次、一月一次或者每天一次至四次施用足以减轻症状的时间段,例如,以下时间段:一周、1周至12周或者更多、1周至6周、2周至12周、2周至12周、2周至8周、2周至6周、2周至4周、4周至12周、4周至8周或者4周至6周。本文的组合物可以以例如每天一次或者每天两次的频率进行施用。本文的组合物可以以每天一次进行局部施用以下时间段:1周至4周、1周至2周、1周、2周、3周、4周或者4周或更长。
本文所述的组合物可以以治疗有效量进行施用,例如以足够覆盖受感染区域加受感染区域周围的健康皮肤边缘或者组织边缘(例如,约0.5英寸的边缘)的量。适合的量(例如,每感染面积每次施用的量或者每感染面积每天积累的剂量(例如,24小时内两次施用))可包括,例如,约0.1克至约6克;约0.2克至约4.5克;约0.3克至约4克;约0.4克至约3.5克;约0.4克至约3克;约0.4克至约2.5克;约0.4克至约2克;约0.4克至约1.5克;约0.5克至约1.5克;约0.5克至约4.5克;5克至约4克;0.5克至约3.5克;0.5克至约3克;0.5克至约2.5克;0.5克至约2克;0.5克至约1克;约0.5克;约1克;约1.5克;约2克;约2.5克或者约3克。
若需要,可将其它治疗剂连同以上所述的组合物中的所提供的那些一起使用。可与载体材料结合以产生单一剂型的活性成分的量将根据所治疗的宿主,疾病、病症或者病况的性质以及活性成分的性质进行变化。
可以以每时间段(例如,每天、每周、每两周或者每月)单剂量或者多剂量提供生物相容性组合物。在实施方案中,可以以每时间段一次至四次提供生物相容性组合物。在另一实施方案中,可以以每周一次提供本文的组合物持续一周至六周,例如一周、两周、三周、四周、五周、六周。
然而,应当理解,对于任何特定患者的具体剂量水平将根据各种因素进行变化,所述因素包括具体活性剂的活性;患者的年龄、体重、总体健康状况、性别和饮食;施用时间;排泄速率;可能的药物组合;治疗的特定病况的严重程度;将要治疗的区域和施用形式。本领域的普通技术人员将理解此类因素的可变性,并且将能够仅使用常规实验建立具体剂量水平。
药物代谢动力学参数(例如,生物利用率、吸收速率常数、表观分布容积、未结合的部分、总清除率、未变化的排泄的部分、首过代谢、消除速率常数、半衰期和平均滞留时间)在本领域是熟知的。
最佳的生物相容性制剂将由本领域的技术人员根据注意事项(例如特定活性剂组合和所需的剂量)进行确定。参见,例如,“Remington’s Pharmaceutical Sciences”,第18版(1990,Mack Publishing Co.,Easton,PA18042),第1435-1712页,其公开内容通过引用并入本文。此类制剂可影响必需脂质的物理状态、稳定性、体内释放速率和体内清除速率。
根据本文所述的主题的本文的生物相容性组合物可以是包装在多次使用的包装或者单次使用的包装(例如,管、瓶、泵、容器或者瓶、小瓶、罐、小包或者泡罩包装)中的局部剂型。
可制备包含每天一次生物相容性组合物的量的单剂量试剂盒和包装。本文的生物相容性组合物的单剂量、单位剂量和每天一次的一次性容器应理解为在本文主题的范围内。
本文的生物相容性组合物在存储期间保持稳定,所述存储期间包括多至5年、约3个月至约5年、约3个月至约4年、约3个月至约3年以及在约6个月至约3年之间的可选任意时间段。
根据本文所述的主题的本文所述的生物相容性组合物在低于或者等于40℃的温度下保持稳定多至至少3年。在实施方案中,本文所述的局部制剂在低于或者等于40℃的温度下保持稳定至少2年。在实施方案中,本文所述的生物相容性组合物在低于或者等于40℃的温度和多至75%RH的湿度下保持稳定至少3年,在低于或者等于40℃的温度和多至75%RH的湿度下保持稳定至少2年,或者在低于或者等于30℃的温度和多至75%RH的湿度下保持稳定至少3年。在另一实施方案中,根据本文所述的主题的本文所述的生物相容性组合物在被包装在多次使用的容器(例如瓶子)中时,在延长的时间段保持稳定,并且在被包装在单次使用的包装(例如泡罩包装)中时,表现出相同的稳定性或者甚至更好的稳定性。
实施例
以下实施例是对本文的生物相容性组合物的阐述,而不是意图对其进行限制。
实施例1:收敛性粉末
A.制剂
根据本文的主题,局部愈合组合物按照以下表1所述进行配制:
表1
B.制造方法
为了制备以上所述的收敛剂,通过按照以下表2中所述的量结合所述成分(以干粉形式)并且混合所述成分直到实现均匀的混合物来制备1000lb的大量混合物。一旦实现均匀的混合物,大量均匀混合物可通过筛网筛分以分散任何团块。
表2
实施例1的收敛性粉末具有以下性能:
表3
实施例2:局部舒缓组合物
A.制剂
根据本文的主题,局部舒缓组合物按照以下表4所述进行配制:
表4
B.制造方法
为了制备以上所述的局部舒缓组合物,通过结合表5(如下所示)的部分A中所述的成分进入主要的混合容器并且将内容物加热至约70℃来制备1000lb的大量混合物。将加热产物进行搅拌直到所得的混合产物是均匀的。在分离池中,将列于表5的部分B中的成分进行结合并且加热至约70℃。一旦加热,将包括部分B中的成分的分离池的内容物添加至主要的混合容器中并且均化处理15分钟直到平滑以及均匀。将混合物冷却至45℃。以任何顺序或者以所列的特定顺序将列于部分C中的成分添加至主要的混合容器,所述混合容器包括来自部分A和部分B的成分。在混合/搅拌下添加来自部分C的各个成分,并且充分混合直到其是平滑和均匀的。将混合物冷却至35℃。
表5
实施例2的舒缓组合物具有以下性能:
表6
实施例3:表皮修复组合物
A.制剂
根据本文的主题,配制表皮/真皮修复乳膏剂以具有以下表7所述:
表7
B.制造方法
为了制备以上所述的表皮/真皮修复软膏剂,将卡波普(Carbopol)在第一容器中进行水合。将列于部分A中的剩余成分添加至主要容器并且加热至约75℃,并且进行混合直到均匀。在第二容器中,将列于部分B中的组分结合并且加热至约75℃,以及进行混合直到完全熔化并且均匀。将来自第二容器的混合物添加至第一容器并且将所得的混合物进行混合直到均匀。将列于部分C中的成分添加至第一容器的混合物中并且混合约20分钟直到均匀。将所得的混合物冷却至45℃。一旦达到45℃,将列于部分D中的成分添加至第一容器的混合物中。将成分以所列顺序进行添加并且在添加每一种成分之后,将混合物充分混合直到基本上均匀。一旦均匀,将所得的混合物冷却至35℃。
实施例3的表皮修复组合物保护剂具有以下性能:
表8
实施例4
为了评估本文的组合物和试剂盒的有效性,进行了本文的组合物和方法与先前已知的组合物的操作后愈合的对比并行分析。特别地,在25%三氯乙酸(“TCA”)脱皮之后,指示50岁的女性患者将本文保护主题的组合物施用于其脸部右侧并且将对比组合物施用于其脸部左侧。
患者被先前诊断为具有III型Fitzpatrick皮肤并带有光化损伤、日光皮肤变色、细纹和一般的老化迹象的明显日光暴露。由其皮肤科医生监控患者的炎症、表面皮肤脱皮、结皮、上皮再形成、患者不适和患者整体体验。
紧跟着25%TCA面部脱皮之后,用与医用级铜肽混合的粘性利多卡因(lidocaine)处理患者以提供麻醉作用并且降低不舒适度。指示患者将温和的医用清洁剂用于其整个脸部。患者还被提供两个操作后系统并且被告知在TCA脱皮后的清晨将实施例1-3中所述的后操作组合物用于其脸部的右侧上,并且将不同的可商购获得的操作后系统用于脸部左侧上。
具体关于本文所述的组合物,将实施例1的组合物如以上本文所述在操作后的第一个五(5)天进行施用。此外,还将实施例2的组合物在操作后的第一个5天如以上本文所述进行施用。将实施例3的组合物在操作后的5天至15天进行施用。
将对比组合物、恢复性软膏剂和TNS神经酰胺治疗乳膏剂施用于患者面部的相对侧。根据制造商的指示在皮肤科医生的监管下施用各个对比性产物。
图1表示在操作前患者的整个面部的正面照。正如所示,在TCA脱皮之前,对于经诊断的对象,患者表现出基本上正常的皮肤。
在手术后的第二天,医师对患者进行检查以评估两种治疗以及相关的方案。如图2A所示,在患者脸部的右侧上观察到早期的脱皮和上皮再形成,其分别使用了实施例1和实施例2的组合物。相反地,如图2B所示,在脸部的左侧上未观察到脱皮,其使用了恢复性软膏剂。此外,脸部的右侧比对比的左侧较少肿胀并且消散了更多。
在第五天,进行检查并且如图3A所示,在脸部的右侧上观察到比第2天更显著的上皮形成、更少的结皮和减少的肿胀。如图3B所示,用对比组合物治疗的脸部左侧表现出更少的上皮形成、更多留存的结皮以及更缓慢的愈合。此外,患者报告相比于左侧,在其脸部的右侧上感觉到的刺激、不舒适、干燥和瘙痒更少。
在操作后的第九天,由患者的皮肤科医生再次对其进行评估。如图4A所示,当与图4B所示的左侧对比时,右侧的侧面嘴角红色更浅。此外,右侧没有表现出斑疤并且接近完全的上皮再形成,以及整体上比左侧的红色更浅。左侧(对比侧)具有更多的结皮并且在下巴上显示斑疤。
当两个操作后恢复系统包括舒缓成分、水合成分和表皮刺激成分时,它们的制剂和方案是不同的。基于第2天、第5天和第9天的检查,表现出更加快速愈合、更早的上皮再形成、更少的肿胀和刺激的患者脸部的侧面为施用实施例1-3的组合物的侧面。因此,当与相似的组合物和治疗方案进行对比时,实施例1-3的组合物的操作后施用导致更快的愈合和更积极的患者体验。
在说明书中所引用的所有出版物表明了本文所述的主题所属领域的技术人员的水平。所有这些出版物通过引用并入本文,其引用程度如同特定并且单独地指示各独立出版物通过引用并入本文。
因此描述了本文的主题,显而易见,同样的主题可以以许多方式进行修改或者变化。此类修改和变化并不被认为背离本文主题的主旨和范围,并且所有此类修改和变化旨在包括在以下权利要求的范围内。
Claims (20)
1.局部损伤愈合组合物,其包含:
基于所述局部损伤愈合组合物的重量以40.0wt%至55.0wt%的量存在的十四水合硫酸铝,
基于所述局部损伤愈合组合物的重量以28.0wt%至39.0wt%的量存在的一水合乙酸钙,
基于所述局部损伤愈合组合物的重量以1.5wt%至4.5wt%的量存在的燕麦仁蛋白质,
基于所述局部损伤愈合组合物的重量以0.5wt%至2.5wt%的量存在的大豆蛋白质,以及
基于所述局部损伤愈合组合物的重量以0.25wt%至1.75wt%的量存在的乳清蛋白质;
基于所述局部损伤愈合组合物的重量以0.25wt%至1.75wt%的量存在的壳聚糖;
基于所述局部损伤愈合组合物的重量以0.25wt%至10wt%的量存在的山梨酸钾;以及
基于所述局部损伤愈合组合物的重量以5wt%至30wt%的量存在的糊精。
2.如权利要求1所述的局部损伤愈合组合物,其中所述局部损伤愈合组合物不包含以下的一种或多种:谷蛋白、二氧化硅、EU26芳香过敏原、对羟基苯甲酸酯、释放甲醛的防腐剂、生长因子或者维生素D。
3.水溶性、可流动的粉末,其包含权利要求1-2中任一项所述的局部损伤愈合组合物。
4.溶液,其包含权利要求1-2中任一项所述的局部损伤愈合组合物。
5.局部剂型,选自洗剂、软膏剂、泡沫剂、气雾剂、粉末、溶液、乳液和浆液,其包含权利要求1-2中任一项所述的损伤愈合组合物。
6.如权利要求5所述的局部剂型,其中所述软膏剂为乳膏剂。
7.试剂盒,其包含权利要求1-2中任一项所述的局部损伤愈合组合物。
8.权利要求1-2中任一项所述的局部损伤愈合组合物在制备用于治疗易受损的皮肤的药物中的用途,其中所述易受损的皮肤是指表示皮肤完整性受损的皮肤。
9.如权利要求8所述的用途,其中所述局部损伤愈合组合物为水溶液。
10.如权利要求9所述的用途,其中将包含所述溶液的敷布应用于所述易受损的皮肤。
11.权利要求1-2中任一项所述的局部损伤愈合组合物和局部舒缓组合物的组合在制备用于治疗易受损的皮肤的药物中的用途,其中所述局部舒缓组合物包含糖胺聚糖刺激剂、抗炎剂、抗氧化剂和DNA修复组分,其中所述糖胺聚糖刺激剂由乙酰氨基葡萄糖磷酸二钠组成;所述抗炎剂选自甘蓝提取物、向日葵籽油、燕麦仁粉蛋白质和/或β-葡聚糖;所述抗氧化剂选自泛醌、生育酚乙酸酯、抗坏血酸、棕榈酸视黄酯和聚甲基丙烯酸甲酯;所述DNA修复组分选自三磷酸腺苷、水解植物蛋白、脯氨酸和乙酰酪氨酸;以及其中所述易受损的皮肤是指表示皮肤完整性受损的皮肤。
12.权利要求1-2中任一项所述的局部损伤愈合组合物和表皮/真皮修复组合物的组合在制备用于治疗易受损的皮肤的药物中的用途,其中所述表皮/真皮修复组合物包含护肤剂、肽、抗炎剂和抗氧化剂,其中所述护肤剂选自乙酸钙、硫酸铝、辅酶Q10、矿脂、维生素E乙酸酯、丁二醇和/或乙酰酪氨酸和/或脯氨酸和/或氢化植物蛋白和/或三磷酸腺苷、燕麦仁膳食、燕麦仁蛋白质USP、燕麦仁粉、尿囊素、氢氧化铝凝胶、次硝酸铋、硼酸、炉甘石、可可油、聚二甲基硅氧烷、甘油、高岭土、活性酵母细胞衍生物、鲨鱼肝油、碳酸氢钠、硫磺、乙酸锌、碳酸锌、α-羟基酸、β-羟基酸和α-酮酸;所述肽选自肉豆蔻酰五肽-11、肉豆蔻酰五肽-8、肉豆蔻酰六肽-4、肉豆蔻酰八肽-1、三肽-1、乙酰基二肽-1、己酰基四肽-3、肌肽、谷胱甘肽、海洋寡肽、棕榈酰寡肽、人寡肽-1(EGF)、乙酰基四肽-3、棕榈酰四肽-7、乙酰基四肽-5、棕榈酰六肽-14、五肽-3、九肽-1、乙酰基六肽、六肽-11、SH-多肽-15、己酰基二肽-3、乙酰基八肽-3、棕榈酰三肽-5、棕榈酰二肽-5、棕榈酰二肽-6、乙酰基四肽-2和肉豆蔻酰五肽-17;所述抗炎剂选自甘蓝提取物、向日葵籽油、燕麦仁粉蛋白质和/或β-葡聚糖;所述抗氧化剂选自泛醌、生育酚乙酸酯、抗坏血酸、棕榈酸视黄酯和聚甲基丙烯酸甲酯,以及其中所述易受损的皮肤是指表示皮肤完整性受损的皮肤。
13.如权利要求12所述的用途,其中所述乙酰基六肽是乙酰基六肽-8。
14.如权利要求12所述的用途,其中所述护肤剂为保湿剂、润肤剂或皮肤调理剂。
15.如权利要求12所述的用途,其中所述抗氧化剂为12小时延时释放胶囊形式的抗氧化剂复合物。
16.权利要求1-2中任一项所述的局部损伤愈合组合物在制备用于在皮肤操作后治疗对象的操作后的皮肤的药物中的用途,所述局部损伤愈合组合物溶解于水以形成溶液,其中所述皮肤操作是指用于治疗皮肤的任何操作。
17.如权利要求16所述的用途,其中将包含所述溶液的敷布应用于所述对象的操作后的皮肤。
18.如权利要求16所述的用途,其中所述溶液的pH为3.5至5.3。
19.如权利要求17所述的用途,其中所述敷布为布料或者纱布垫。
20.如权利要求19所述的用途,其中从操作后的第1天开始在白天期间每两小时至三小时在压力下将包含所述溶液的所述敷布应用于所述操作后的皮肤的部分。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/811,264 | 2015-07-28 | ||
US14/811,264 US9248160B1 (en) | 2015-07-28 | 2015-07-28 | Post-procedure skin care systems, compositions, and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106390093A CN106390093A (zh) | 2017-02-15 |
CN106390093B true CN106390093B (zh) | 2019-04-05 |
Family
ID=55174798
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610585492.4A Active CN106390093B (zh) | 2015-07-28 | 2016-07-22 | 操作后的皮肤护理系统、组合物及其使用方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US9248160B1 (zh) |
EP (1) | EP3124033A1 (zh) |
JP (1) | JP6008457B1 (zh) |
CN (1) | CN106390093B (zh) |
BR (1) | BR102016015576A2 (zh) |
CA (1) | CA2935916A1 (zh) |
IL (1) | IL246763A (zh) |
MX (1) | MX353942B (zh) |
RU (1) | RU2640504C2 (zh) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3013459C (en) | 2016-02-04 | 2020-12-29 | ALASTIN Skincare, Inc. | Topical compositions comprising tripeptide-1 and hexapeptide-12 |
FR3060307B1 (fr) | 2016-12-16 | 2019-01-25 | L'oreal | Composition cosmetique comprenant des corps gras solides et un polymere gelifiant |
WO2019028275A1 (en) | 2017-08-03 | 2019-02-07 | ALASTIN Skincare, Inc. | COMPOSITIONS AND METHODS FOR IMPROVING LAXITY OF THE SKIN AND BODY CONTOUR |
CN107789207A (zh) * | 2017-11-03 | 2018-03-13 | 烟台康达尔药业有限公司 | 一种egf/维生素e乙酸酯‑环糊精脂质体及其制备方法、使用方法、应用 |
CN108187026A (zh) * | 2018-03-16 | 2018-06-22 | 南京财经大学 | 一种能够促进伤口愈合的产品 |
US20200000699A1 (en) * | 2018-06-28 | 2020-01-02 | Zo Skin Health, Inc. | Bioactive compositions and methods for treating skin |
CN108785163B (zh) * | 2018-07-03 | 2021-09-14 | 博凯药业有限公司 | 丰胸乳膏及其制备方法和使用方法 |
WO2020028694A1 (en) | 2018-08-02 | 2020-02-06 | ALASTIN Skincare, Inc. | Liposomal compositions and methods of use |
US20200164037A1 (en) * | 2018-11-27 | 2020-05-28 | Labo Cosprophar Ag | Dermocosmetic composition containing synthetic platelet-like molecules to treat skin aging and stimulate hair growth |
US10980855B2 (en) * | 2019-07-31 | 2021-04-20 | Hygia Bioscience | Treatment of dermatological conditions |
RU2710249C1 (ru) * | 2019-08-23 | 2019-12-25 | Ирина Сергеевна Егоровская | Порошок для пилинга |
CN112315863B (zh) * | 2020-11-10 | 2021-12-03 | 山东百奥生物医药有限公司 | 一种舒缓光电术中疼痛热感的组合物及制备方法和应用 |
CN117642415A (zh) * | 2021-05-20 | 2024-03-01 | 罗可欧普科有限公司 | 含有维生素c化合物的化妆品组合物及其用途 |
CN114225007B (zh) * | 2021-11-09 | 2023-08-25 | 西安润玉医疗科技有限公司 | 一种用于修复浅表性创面的乳清蛋白喷雾剂及制备方法 |
CN114209609B (zh) * | 2021-11-22 | 2023-08-18 | 新疆大德恒生物股份有限公司 | 护肤组合物及其制备方法、以及面膜粉 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4572906A (en) * | 1983-11-21 | 1986-02-25 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government | Chitosan based wound dressing materials |
US5510102A (en) * | 1995-01-23 | 1996-04-23 | The Regents Of The University Of California | Plasma and polymer containing surgical hemostatic adhesives |
CN1419453A (zh) * | 2000-03-27 | 2003-05-21 | 奇尔特恩药物有限公司 | 药物凝胶组合物 |
CN1919209A (zh) * | 2006-07-10 | 2007-02-28 | 江西3L医用制品集团有限公司 | 一种用于愈合皮肤伤口的药物组合物 |
CN103110935A (zh) * | 2013-01-25 | 2013-05-22 | 江苏圣宝罗药业有限公司 | 皮肤局部用水解胶原蛋白脂质体及其制备方法 |
CN103405353A (zh) * | 2013-07-18 | 2013-11-27 | 石磊 | 一种皮肤外用贴膜及其密集渗透生产技术 |
CN103784372A (zh) * | 2014-02-19 | 2014-05-14 | 北京德喜天地科贸有限公司 | 一种含有壳聚糖的化妆品 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5670169A (en) * | 1993-12-20 | 1997-09-23 | E.R. Squibb & Sons, Inc. | Wound hydrating gel with novel preservative system and low cytotoxicity |
SE9402531L (sv) | 1994-07-19 | 1996-01-20 | Medicarb Ab | Sårläkningsmedel |
FR2738487B1 (fr) * | 1995-09-11 | 1997-11-28 | Medix Lab | Composition dermatologique antiseptique et son procede de fabrication |
AU724800B2 (en) * | 1997-09-17 | 2000-09-28 | International Laboratory Technology Corp. | Burn treatment composition |
JP2001181189A (ja) * | 1999-12-28 | 2001-07-03 | Kyoto Dobutsu Kensa Center:Kk | 癒傷促進性基剤 |
JP2005075815A (ja) * | 2003-09-03 | 2005-03-24 | Masao Tanihara | 止血性組織修復材 |
US20050112078A1 (en) * | 2003-11-13 | 2005-05-26 | Sekhar Boddupalli | Plant-derived protein extract compositions and methods |
EP2337544A2 (en) * | 2007-04-30 | 2011-06-29 | Living Proof, Inc. | Use of matrix metalloproteinase inhibitors in skin care |
FR2925329B1 (fr) * | 2007-12-21 | 2010-02-26 | Vincience | Utilisation d'un hydrolysat d'avoine en tant que principe actif activateur de la synthese des aquaporines |
RU2370270C1 (ru) * | 2008-04-21 | 2009-10-20 | Игорь Николаевич Большаков | Композиция для лечения ран |
DE102008054118A1 (de) * | 2008-10-31 | 2010-05-06 | Henkel Ag & Co. Kgaa | Wirkstoffkombination zur Behandlung reifer Haut I |
RU2536266C2 (ru) * | 2009-04-13 | 2014-12-20 | Сулур Субраманиам ВАНАНГАМУДИ | Крем медицинского назначения, изготовленный с использованием фрамицетина сульфата и хитозана, и способ его изготовления |
WO2011004399A2 (en) | 2009-07-09 | 2011-01-13 | Manoj Vinoy Mojamdar | Liquid filmogenic chitosan skin for wound healing and a method for preparation thereof |
US9144434B1 (en) | 2010-09-29 | 2015-09-29 | Rodan & Fields, Llc | Methods and compositions for treating skin |
US8404743B2 (en) * | 2010-10-29 | 2013-03-26 | Mary Kay Inc. | Zinc oxide complexes |
US10639252B2 (en) | 2011-09-23 | 2020-05-05 | Allergan, Inc. | Compositions for skin exfoliation and use thereof |
JP5900978B2 (ja) * | 2012-10-31 | 2016-04-06 | 公立大学法人福岡県立大学 | 皮膚創傷部治癒用組成物及び同皮膚創傷部治癒用組成物の製造方法 |
-
2015
- 2015-07-28 US US14/811,264 patent/US9248160B1/en active Active
-
2016
- 2016-06-03 RU RU2016122026A patent/RU2640504C2/ru active
- 2016-06-07 JP JP2016113662A patent/JP6008457B1/ja not_active Expired - Fee Related
- 2016-06-16 EP EP16174860.3A patent/EP3124033A1/en not_active Withdrawn
- 2016-07-01 BR BR102016015576A patent/BR102016015576A2/pt not_active Application Discontinuation
- 2016-07-12 CA CA2935916A patent/CA2935916A1/en not_active Abandoned
- 2016-07-13 IL IL246763A patent/IL246763A/en active IP Right Grant
- 2016-07-22 CN CN201610585492.4A patent/CN106390093B/zh active Active
- 2016-07-28 MX MX2016009852A patent/MX353942B/es active IP Right Grant
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4572906A (en) * | 1983-11-21 | 1986-02-25 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government | Chitosan based wound dressing materials |
US5510102A (en) * | 1995-01-23 | 1996-04-23 | The Regents Of The University Of California | Plasma and polymer containing surgical hemostatic adhesives |
CN1419453A (zh) * | 2000-03-27 | 2003-05-21 | 奇尔特恩药物有限公司 | 药物凝胶组合物 |
CN1919209A (zh) * | 2006-07-10 | 2007-02-28 | 江西3L医用制品集团有限公司 | 一种用于愈合皮肤伤口的药物组合物 |
CN103110935A (zh) * | 2013-01-25 | 2013-05-22 | 江苏圣宝罗药业有限公司 | 皮肤局部用水解胶原蛋白脂质体及其制备方法 |
CN103405353A (zh) * | 2013-07-18 | 2013-11-27 | 石磊 | 一种皮肤外用贴膜及其密集渗透生产技术 |
CN103784372A (zh) * | 2014-02-19 | 2014-05-14 | 北京德喜天地科贸有限公司 | 一种含有壳聚糖的化妆品 |
Also Published As
Publication number | Publication date |
---|---|
RU2016122026A (ru) | 2017-12-07 |
JP2017031135A (ja) | 2017-02-09 |
US9248160B1 (en) | 2016-02-02 |
EP3124033A1 (en) | 2017-02-01 |
BR102016015576A2 (pt) | 2017-01-31 |
MX353942B (es) | 2018-02-07 |
RU2640504C2 (ru) | 2018-01-09 |
CA2935916A1 (en) | 2016-10-21 |
CN106390093A (zh) | 2017-02-15 |
MX2016009852A (es) | 2017-02-20 |
IL246763A (en) | 2017-01-31 |
JP6008457B1 (ja) | 2016-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106390093B (zh) | 操作后的皮肤护理系统、组合物及其使用方法 | |
CA2907495C (en) | Antioxidant compositions and methods of using the same | |
CA2749750C (en) | Skin care compositions and methods of use thereof | |
CN108883048A (zh) | 用于侵入性和非侵入性程序性护肤的组合物和方法 | |
MXPA04000002A (es) | Agente con un contenido de gasa (aceite), que contiene un extracto de cebolla su preparacion y su utilizacion para el cuidado, la prevencion o el tratamiento de un tejido cutaneo danado, en particular de cicatrices. | |
TW200412992A (en) | Compositions containing peptide copper complexes and phytochemical compounds, and methods related thereto | |
US20200000699A1 (en) | Bioactive compositions and methods for treating skin | |
JP4685375B2 (ja) | 皮膚外用剤 | |
JP2005060234A (ja) | 皮膚外用剤 | |
CN107670027A (zh) | 治疗皮肤病况的组合物和方法 | |
WO2009042402A2 (en) | Composition and method for treating rosacea | |
JP2007332078A (ja) | オゾン溶存グリセリン溶液を含む化粧料、医薬部外品、医薬(医薬品)等の外用剤 | |
CN109453088B (zh) | 美白紧致霜及其制备方法和酪氨酸酶抑制剂 | |
JP2001072571A (ja) | 皮膚外用剤 | |
JP2009001575A (ja) | オゾン溶存グリセリン溶液を含む化粧料、医薬部外品、医薬(医薬品)等の外用剤 | |
EP2116237A1 (en) | Compositions for treating rosacea comprising chitosan and a dicarboxylic acid | |
CA3099843A1 (en) | Sterile topical saline putrescine formulation and uses thereof | |
JP3940633B2 (ja) | 皮膚外用剤 | |
KR102678663B1 (ko) | 히알루론산 또는 그의 염을 유효성분으로 포함하는 조성물 및 이의 제조 방법 | |
JP2007077101A (ja) | 皮膚外用剤 | |
JP2003335628A (ja) | 皮膚外用剤 | |
KR20120069198A (ko) | 5-아미노레블린산 및 비타민씨 복합체를 함유하는 화장품 조성물 | |
JP2003300853A (ja) | 皮膚外用剤組成物 | |
US20240065961A1 (en) | Composition for caring for kertatin materials | |
JP2010215532A (ja) | コラーゲンゲル収縮促進剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1233528 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant |